Expression Analysis of Macrophages That Facilitate Tumor Invasion Supports a Role for Wnt-Signaling in Mediating Their Activity in Primary Mammary Tumors This information is current as of October 2, 2021. Laureen S. Ojalvo, Charles A. Whittaker, John S. Condeelis and Jeffrey W. Pollard J Immunol 2010; 184:702-712; Prepublished online 16 December 2009;

doi: 10.4049/jimmunol.0902360 Downloaded from http://www.jimmunol.org/content/184/2/702

Supplementary http://www.jimmunol.org/content/suppl/2009/12/15/jimmunol.090236 Material 0.DC1 http://www.jimmunol.org/ References This article cites 69 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/184/2/702.full#ref-list-1

Why The JI? Submit online.

• Rapid Reviews! 30 days* from submission to initial decision by guest on October 2, 2021

• No Triage! Every submission reviewed by practicing scientists

• Fast Publication! 4 weeks from acceptance to publication

*average

Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology

Gene Expression Analysis of Macrophages That Facilitate Tumor Invasion Supports a Role for Wnt-Signaling in Mediating Their Activity in Primary Mammary Tumors

Laureen S. Ojalvo,* Charles A. Whittaker,† John S. Condeelis,‡ and Jeffrey W. Pollard*

The tumor microenvironment modifies the malignancy of tumors. In solid tumors, this environment is populated by many macro- phages that, in genetic studies that depleted these cells from mouse models of breast cancer, were shown to promote tumor pro- gression to malignancy and increase metastatic potential. Mechanistic studies showed that these tumor-promoting effects of macrophages are through the stimulation of tumor cell migration, invasion, intravasation, and enhancement of angiogenesis. Using an in vivo invasion assay, it was demonstrated that invasive carcinoma cells are a unique subpopulation of tumor cells whose invasion and chemotaxis is dependent on the comigration of tumor-associated macrophages (TAMs) with obligate reciprocal signaling through an epidermal growth factor–CSF-1 paracrine loop. In this study, these invasion-promoting macrophages were isolated Downloaded from and subjected to analysis of their transcriptome in comparison with TAMs isolated indiscriminately to function using established macrophage markers. Unsupervised analysis of transcript patterns showed that the invasion-associated TAMs represent a unique subpopulation of TAMs that, by criteria, have gene expression patterns related to tissue and organ development. Gene set enrichment analysis showed that these macrophages are also specifically enriched for molecules involved in Wnt- signaling. Previously, it was shown that macrophage-derived Wnt molecules promote vascular remodeling and that tumor cells are highly motile and intravasate around perivascular TAM clusters. Taken together, we conjecture that invasive TAMs link http://www.jimmunol.org/ angiogenesis and tumor invasion and that Wnt-signaling plays a role in mediating their activity. The Journal of Immunology, 2010, 184: 702–712.

umor-associated macrophages (TAM) have been shown to Within the primary tumor microenvironment, at least two perform a number of different roles in the tumor micro- mechanisms are proposed by which TAMs facilitate tumor me- T environment to facilitate tumor progression (1–4). For tastasis. The first relates to the demonstrated ability of TAMs to example, in breast cancer an increased density of TAMs has secrete within the tumor microenvironment, such as correlated with poor prognosis including increased lymph node urokinase plasminogen activator (10) (uPA), cathepsins B and D by guest on October 2, 2021 involvement and decreased survival (5–7). In previous work in the (11, 12), and matrix metallopeptidases 2 and 9 (13). It is believed polyoma middle T (PyMT) mouse model of human breast cancer (8) that these TAM-derived digest the tumor basement genetic depletion of the key macrophage growth factor, CSF-1 using membrane, facilitating tumor cell escape. Indeed, there are in- the mice homozygous for the Csf1op null allele resulted in signifi- creased TAM numbers overlying sites of basement membrane cantly reduced TAM density. In these animals, a significant delay in breakdown in PyMT tumors (8). Moreover, there is enrichment of tumor progression to metastatic disease was observed, indicating numerous other extracellular proteases in the tumor stroma of that TAMs are required for efficient tumor metastasis (9). PyMT animals (14), coinciding with the localization of most TAMs in the tumor microenvironment (5, 15). A second mechanism by which TAMs facilitate tumor metastasis *Department of Developmental and Molecular Biology and ‡Department of Anatomy is through directly enhancing an early stage of the metastatic and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461; and cascade (16): carcinoma cell invasion. In vitro evidence demon- †David H. Koch Institute for Integrative Cancer Research, Bioinformatics and Com- puting Core Facility, Massachusetts Institute of Technology, Cambridge, MA 02142 strated that macrophage production and release of the Wnt- Wnt5a can stimulate the noncanonical planar cell polarity Wnt Received for publication July 21, 2009. Accepted for publication November 2, 2009. signaling pathway in carcinoma cells to promote invasion (17). In This research was supported by National Institutes of Health Grants CA131270 (J.W.P), CA100324 (J.S.C. and J.W.P), and CA126511 (J.S.C.); the Einstein addition, an in vivo invasion assay (15, 18) similarly showed that Cancer Center Grant P30 133330 (J.W.P., J.S.C.); and the Massachusetts Institute TAMs promote carcinoma cell motility and invasion, but through of Technology Cancer Center Grant P30-CA14051 (C.A.W.). L.S.O. was sup- a different mechanism that involves a paracrine signaling loop ported by the Medical Sciences Training Grant T32 GM 07288. J.W.P. is the Louis Goldstein Swan Chair in Women’s Cancer Research. between tumor cells and TAMs. Address correspondence and reprint requests to Dr. Jeffrey W. Pollard, Albert Einstein In the in vivo invasion assay, a growth factor or chemokine was College of Medicine, Department of Developmental and Molecular Biology, 1300 Mor- held within a 33-gauge microneedle containing Matrigel (BD ris Park Avenue Bronx, NY 10461. E-mail address: [email protected] Biosciences, San Jose, CA) and then positioned and stabilized The online version of this article contains supplemental material. within the primary tumor to collect responsive cells (18). It was Abbreviations used in this paper: AU, approximately unbiased; EGF, epidermal noted that whether the tumor cell chemokine epidermal growth growth factor; EGFP, enhanced GFP; FDR, false discovery rate; GSEA, gene set enrichment analysis; GT, general tumor-associated macrophage; IPA, Ingenuity Path- factor (EGF) or the macrophage chemokine CSF-1 was placed into ways Knowledge Base; PyMT, polyoma middle T; QRT-PCR, quantitative real-time the needles, both tumor cells and macrophages migrated in re- polymerase chain reaction; SAM, significance analysis of microarray; SM, splenic sponse (18). Moreover, pharmacologic or Ab functional inhibition macrophage; TAM, tumor-associated macrophage; VEC, vascular endothelial cell. of EGF/EGFR or CSF-1/CSF-1R signaling halted the movement of Copyright Ó 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00 both cell types (15, 19, 20). Further experiments confirming the www.jimmunol.org/cgi/doi/10.4049/jimmunol.0902360 The Journal of Immunology 703 results of the in vivo invasion assay demonstrated that significantly lection. Matrigel was added to 10% total volume (needle mixture). This fewer cells were collected in Csf1op/op animals (21), but cell mixture was then filled into six 33-gauge microneedles and kept at 4˚C numbers increased when CSF-1 was transgenically restored to the until the animal was prepared. A mouse with two solid tumors of ∼2 cm diameter was anesthetized mammary fat pad. Furthermore, preinjection of wild type tumors using isoflurane, and a small flap of skin was removed to expose the tumor. with CSF-1 significantly increases collected cell numbers (19). A micromanipulator connected to a needle holder (consisting of three 25- These results are in agreement with human breast cancer studies in gauge needles) was used to stably guide the insertion of three guide wires ∼ 2 which increased levels of circulating CSF-1 (22) and/or increased 2 5 mm into the surface of the tumors. Two micromanipulators were used per animal in separate tumors. Gently, the guide wires were removed tumor CSF-1R staining (23) correlate with poor prognosis and the and replaced with the filled collection needles one by one. The animal was observed expression of EGF by TAMs in breast cancer (24). kept under monitored anesthesia for 4 h and sacrificed by cervical dislo- Isolation and expression profiling of invasive carcinoma cells cation at termination of collection. demonstrated that these are a unique subpopulation of tumor cells Prior to sacrifice, the six collection needles were removed and the ∼ m (25, 26) that are highly motile, but less proliferative and apoptotic contents extruded using 100 l per needle of Leibowitz’s L-15 media and 10% BSA into an RNase-free 1.5 ml Eppendorf tube. Five percent total compared with the general carcinoma cell population (26, 27). volume was stained by DAPI for cell count. Ten microliters CD11b (Mac- Overall, these invasive cells have a survival advantage and in- 1) magnetic beads (Miltenyi-Biotec, Gladbach, Germany) were added to creased resistance to chemotherapeutic agents (28). Although the remaining volume and incubated at 4˚C with gentle agitation for 30 these studies were originally performed in tumor xenografts, the min. The sample was next placed onto a magnetic block for 30 min. and the remaining invasive carcinoma cells in the supernatant were removed. results are conserved in the transgenic PyMT animals (29). Two hundred microliters guanidine thiocyanate containing Buffer RLT We hypothesized that, similar to the invasive carcinoma cells, (Qiagen, Valencia, CA) was added to remaining beads and then incubated invasive TAMs are a unique subpopulation of TAMs found at sites over ice for 10 m. Beads were centrifuged and the supernatant containing of tumor invasion. We therefore aimed to collect and compare these RNA was transferred into an RNAse-free 1.5 ml Eppendorf tube. RNA Downloaded from cells to general TAMs (GTs) collected indiscriminately to specific isolation was performed on a cohort of four animals, resulting in RNA from ∼6000 invasive TAMs per final array sample. function, using cell markers and flow cytometry. The studies herein identify a gene expression signature for invasive TAMs and provide RNA extraction, amplification, and cDNA preparation the first example of an isolated subpopulation of TAMs. These invasive cells are compelling therapeutic targets because they Total RNA was extracted from flow-sorted GTs and in vivo invasion assay

isolated invasive TAMs using RNeasy Micro Kits (Qiagen) according to the http://www.jimmunol.org/ represent a population of cells caught at an early stage of me- manufacturer’s instruction. Amplification-grade DNase 1 treatment was tastasis. Considering the invasive carcinoma cell requirement of performed on the RNA elution column to remove potential genomic DNA comigrating TAMs, targeting these nongenomically transformed— contamination. Approximate yields were 150 ng. Quality was determined and therefore less therapy resistant—host cells could provide using a nanobiosizing assay (Agilent Bioanalyzer; Agilent Technologies, a novel opportunity for therapeutic benefits. Palo Alto, CA). Approximately 100 ng RNA from samples was resuspended into 11 ml RNase/DNase-free water, and a single round of linear amplification was Materials and Methods performed by the in vitro transcription T7 promoter method as outlined by Mice the manufacturer’s protocol (Ambion’s Message Amp T7 Kit; Ambion, Austin, TX). For microarray samples, a second round of linear amplifi- All procedures involving mice were conducted in accordance with National cation was performed with 200 ng first round amplified material. At all by guest on October 2, 2021 Institutes of Health regulations concerning the use and care of experimental steps, yield and quality were established using spectrophotometry and an animals. The study of mice was approved by the Albert Einstein College of Agilent Bioanalyzer. Medicine animal use committee. The FVB/N-Tg(MMTV-PyVmT)Mul For samples to be used for microarray hybridization, Superscript III (PyMT) transgenic mice were provided by Dr. W.J. Muller (McGill Uni- (Invitrogen) reverse transcriptase was used to prepare 5 mg cDNA from versity, Montreal, Quebec, Canada) and have been described previously (8, amplified RNA. Random primers (Invitrogen) were used to prime the re- 30). Tg(Csf1r-Gfp)Hume (MacGreen) mice have also been described action. Second-strand cDNA synthesis was performed using Escherichia previously (31). Male PyMT mice on an FVB background were bred to coli DNA (Invitrogen), E. coli DNA Polymerase 1 (Invitrogen) and homozygous MacGreen female mice on a mixed background to generate T4 DNA Polymerase (Invitrogen). RNase H (Invitrogen) treatment was PyMT mice that produce tumors with GFP-labeled macrophages. All additionally performed. The reaction was stopped with 0.5 M EDTA and genotyping was done by PCR. Tumors were allowed to grow until 14–16 purified using a PCR purification kit (Qiagen) following the manu- wk to ensure late-stage carcinomas for TAM isolation by flow cytometry or facturer’s protocol. Samples were resuspended to ∼200 ng/ml. in vivo invasion assay. Collection of general TAMs (flow cytometry) Gene expression arrays Five micrograms of double-stranded cDNA from each invasive TAM and PyMT female mice with late-stage tumors of ∼2 cm diameter were injected GT sample was used for gene expression array processing. The expression in the lateral tail-vein with 200 ml 10 mg/ml 70 kDa dextran conjugated to array chip used contained 385,000 60-mer probes representing 42,586 the Texas Red fluorphore (Invitrogen, Eugene, Oregon) resuspended in (average nine probes per target; NimbleGen, Reykjavik, Iceland). A total of PBS. Two hours postinjection, animals were anesthetized with isofluorane five independent samples for each macrophage population were prepared. and perfused intracardiacally with ice cold PBS. Following sacrifice, all At NimbleGen, quality and yield were verified before DNA end-labeling, subsequent steps were performed at 4˚C. Tumors were minced and filtered hybridization, and scanning. Raw data files for each sample were nor- four times through graded nylon filters, centrifuged at 1200 RPM for 5 min, malized, background-corrected, and saved to logarithmic scale using a ro- and resuspended in erythrocyte lysis buffer (Beckman-Coulter, Marseille, bust multi-array analysis (32) as implemented by NimbleScan software, France). Cells were washed three times in nuclease-free PBS containing 2% version 2.2.33 (Nimblegen, Reykjavik, Iceland). Raw and normalized data BSA and incubated with the macrophage-specific Alexa-fluor 488 conju- available at the National Center for Biotechnology Information Gene gated F4/80 monoclonal Ab (Invitrogen, Carlsbad, CA). Dextran/F4/80 Expression Omnibus (www.ncbi.nlm.nih.gov/geo/), series record double-positive cells were sorted on a DakoCytomation MoFlo High-Speed GSE18295. Normalized data were analyzed and presented using R project Cell Sorter (DakoCytomation, Fort Collins, Colorado) at 23 pounds per (33, 34). Several packages developed for R through Bioconductor (35)—an square inch. into PBS + 2% BSA. Dextran/Csf1r-enhanced GFP (EGFP) open-source, open-development software project—were used for array double positive cells were isolated similarly as previously described (4). analysis. These packages include limma (36), marray, siggenes and Collection of invasive TAMs (in vivo invasion assay) RColorBrewer. Significance analysis of microarray (SAM) (37) was im- plemented for stringent gene selection criteria using the siggenes package. The collection of invasive cells via the in vivo invasion assay was originally A d value of 3.859 called 1457 significantly regulated transcripts with designed, validated, and described by Wyckoff et al. (18) and Wang et al. a false discovery rate (FDR) of 1% when comparing invasive TAM to GT. (25). A solution of 25 nM purified EGF and 0.01 mM EDTA (pH 7.4) in Five biologic repeats were prepared for gene expression arrays when Leibowitz’s L-15 media and 10% BSA was freshly made the day of col- comparing F4/80+/dextran+ FVB background TAMs to Csf1r-EGFP+/ 704 GENE EXPRESSION ANALYSIS OF INVASIVE TAMs dextran+ mixed background TAMs as described above. By SAM, a d value of needle control experiments, gene expression was reported as normalized to 1.4 called 41 significantly regulated transcripts with a 10% FDR. the housekeeping gene. All transcripts assayed by the microarrays were subjected to hierarchical clustering, and a sample dendrogram was produced using the R package Cultured flow cytometry–sorted macrophages pvclust (38). The required R commands are included in the text file “TAMpvclust.r” (http://tinyurl.com/yg3l8gr) and the input data are the file TAMs from PyMT females and splenic macrophages from non–tumor- “TAM.txt” (http://tinyurl.com/yg5j2qn). bearing littermate controls were isolated as previously described (4). Re- sulting cells were seeded onto bacterial plastic plates and allowed to ad- Bioinformatics here for 12 h. Cells were washed and the RNA was extracted using the RNeasy Micro kit (Qiagen) per the manufacturer’s protocol. RNA was The Ingenuity Pathways Knowledge Base (IPA) version 6.3 (www. quantitated before semiquantitative PCR for Wnt7b expression and then ingenuity.com/products/pathways_analysis.html) was used to identify en- normalized to the housekeeping gene GAPDH. riched cellular and molecular functions and canonical pathways among differentially regulated transcripts. p Values were calculated through IPA 6.3 using a right-tailed Fisher exact test and related to the likelihood of en- Results richment of specific function within a queried gene-set. Oncomine (www. Invasive TAMs collected via the in vivo invasion assay are a oncomine.org) was used to mine human breast cancer microarray data as previously described (39, 40). unique subpopulation of TAM Gene set enrichment analysis (GSEA) (www.broad.mit.edu/gsea/) was Invasive TAMs were isolated from PyMT animals on the FVB used to identify KEGG pathways upregulated in invasive TAMs. KEGG background with late stage tumors as previously described (18, 25, gene sets containing between 15 and 500 genes were considered, and sta- tistical significance was assessed using 5000 gene set permutations. Ad- 26). In brief, 33-gauge microneedles containing a mixture in- ditional details about the GSEA run can be found here: http://tinyurl.com/ cluding 25 nM EGF and the matrix, Matrigel, were placed into the yh2rzed; the files needed to recreate the analysis are here: http://tinyurl. primary tumors of anesthetized animals. Over a 4-h collection Downloaded from com/ybe4dc5. ∼1000 carcinoma cells and macrophages migrate into a single needle in an ∼3:1 ratio (26). Six needles were used per animal, Quantitative real time PCR yielding ∼1500 invasive TAMs. Positive selection for invasive Four subsequent biologic repeats of each GT and invasive TAM sample that TAMs was performed using CD11b (Mac-1:integrin aM subunit) had been single-round amplified were used for quantitative real-time magnetic beads to separate TAMs from the invasive carcinoma polymerase chain reaction (QRT-PCR). Needle control bone marrow cells as previously described (25). To obtain sufficient material for http://www.jimmunol.org/ macrophage experiments (described below) did not require amplification. Superscript III (Invitrogen) reverse transcriptase was used to prepare 200 ng efficient RNA isolation and amplification for gene expression ar- cDNA from RNA or amplified RNA. Random nonamers (a gift from Dr. ray, invasive TAMs from four separate animals were pooled for Sumanta Goswami, Yeshiva University, New York, NY) were used to prime each sample. Five of these biologic replicates were obtained and the reaction. Relative transcript abundance was detected by SybrGreen compared by microarray with five biologic replicates of GTs, (Applied Biosystems, Foster City, CA) on the ABI 7900HT thermal cycler using gene-specific primers. Gene expression was normalized to the which were isolated by flow cytometry based on their expression of housekeeping gene, cyclophilin A (Ppia), and expressed values in invasive the macrophage-specific marker F4/80 and their ability to macro- TAMs relative to GTs were determined using the DDCT method (41). In pinocytose fluorochrome conjugated 70 kDa dextran (Fig. 1A). by guest on October 2, 2021

FIGURE 1. Isolation of a functionally defined subpopulation of invasive TAMs for gene expression analysis. A, Schematic of array experimental protocol comparing gene expression profile of invasive TAMs to GTs (26). B, Volcano plot illustrating fold change (log base 2) compared with p value (2log base 10) between invasive TAMs and GTs. Horizontal bar at y  1.303 represents a significance level of p = 0.05 significance level. C, SAM for d 3.859, FDR 1%. The Journal of Immunology 705

These sorted cells are uniformly CD11b positive and Gr1 negative, tamination of carcinoma cells present in the invasive TAM sample, defining them further as macrophages (4, 42). which has been demonstrated previously to be ∼10% (25), and Previously, it has been shown that TAMs are not compromised in was unchanged in our hands (data not shown). To assess whether their ability to secrete EGF or migrate into microneedles following tumor cell contamination was significant in the data set, the pre- ingestion of 70 kDa dextran (15), and that invasive TAMs uni- viously published invasive carcinoma cell signature from PyMT formly express F4/80 (19). However, in the absence of transgenic tumors (29) was compared with that for the invasive TAM. Of the labeling, F4/80 and dextran phagocytosis are minimally needed to 901 differentially regulated transcripts (absolute fold change .2) isolate a pure population of TAMs from the heterogeneous tumor in invasive carcinoma cells, 55 were also represented in the 1457 microenvironment (4). Therefore, although commercially produced differentially regulated transcripts of the invasive TAMs. Only 17 and validated CD11b magnetic beads were sufficient for separating transcripts were differentially regulated in the same direction (i.e., the two invasive cell populations that migrate into the needle, more up in both samples or down in both samples). Of the 901 genes from stringent criteria were required for flow cytometrically obtaining the invasive carcinoma cell study, 188 were not able to be annotated the GT population. Of note, by defining markers for macrophages, because of expired annotations, and therefore may have been these two populations are identical; therefore, microarrays were missed. However, overall we found no evidence of significant used to determine variance in gene expression between all TAMs contamination of carcinoma cell transcripts in our samples. and the functionally defined invasive subpopulation. Although no specific confounder was identified that caused the A volcano plot illustrates the large number of transcript abun- differences between general and invasive TAMs, in our data analysis dance differences between the invasive TAM and GT populations. we used unsupervised analytical techniques for broad general- 4687 genes were identified as downregulated (Log2Ratio ,21; p , izations of invasive TAM physiological functions in combination Downloaded from 0.05), and 3294 genes were upregulated (Log2Ratio . 1; p , 0.05; with carefully supervised analyses to establish that sufficient pre- Fig. 1B). To obtain a more stringently selected population of dif- cedent exists to ascribe specific results to invasive TAM activity. ferentially regulated transcripts, SAM (37) was used with a d value Consistent with the volcano plot and SAM analyses, hierarchical of 3.859, corresponding to a 1% FDR. This criterion resulted in clustering (43) of all transcripts assayed on the gene expression 1457 genes called as significantly differentially regulated (Fig. 1C). chip demonstrates clear separation between the invasive TAM and An early concern in the analysis of the invasive TAM micro- GT samples (Fig. 2). Hierarchical clustering and a sample den- arrays had been the large number of transcripts called as differ- drogram was produced using the R package pvclust (38). The ap- http://www.jimmunol.org/ entially regulated. Previous work comparing the gene expression proximately unbiased scores give an indication of clade reliability. profiles of macrophages from two separate tissues (tumor and Clades supported by scores near 100 can be considered reliable. spleen) yielded 460 differentially regulated genes by SAM using Interestingly, the GT samples from the pure FVB mice used in a standard FDR of 10% (4). In this study, 1457 transcripts were this study did not separate from the TAM samples sorted by flow called with an FDR of 1% when comparing macrophages isolated cytometry from MacGreen mice, a mixed strain. The MacGreen from the same tissue. Therefore, to proceed with the analysis it animals express EGFP via the colony stimulating factor 1 was first necessary to explore the arrays to validate their utility. (Csf1r) promoter, in granulocytes, monocytes and macrophages Results summarized in Supplemental Fig. 1 indicate that all (4, 31, 44). Previously we demonstrated that a pure population of by guest on October 2, 2021 samples were successfully labeled, hybridized, scanned, and TAMs can be isolated based on EGFP expression (myeloid line- globally reproducible. Excess differences between GTs and in- age) and Texas Red dextran uptake (macropinocytic ability) from vasive TAMs could also be due to the increased irreducible con- these tumor-bearing animals (4). This is consistent with the DNA

FIGURE 2. Invasive TAMs are a unique subpopulation of TAMs Unsupervised clustering of data from several macrophage populations shows that invasive TAMs group together in a clade with strong statistical support. A total of 18 macrophage samples were used including the five invasive TAM samples (Invasive) and five GT samples from the FVB mouse strain used in this study, and the four TAM and 4 splenic macrophage (SM) samples from mice on a mixed background, as previously published (4). Approximately unbiased (AU) scores are listed below individual pairs. Values close to 100 indicate a reliable clade. Larger heights on the vertical axis are indicative of a greater distance between clades. 706 GENE EXPRESSION ANALYSIS OF INVASIVE TAMs microarray comparison of both these samples that demonstrated the enriched functional categories relating to physiologic system only a small number of differences between the samples, despite and development when comparing those regulated transcripts strain differences and methods of isolation. These hierarchical that are upregulated or downregulated. Embryonic development clustering data are consistent with microarray comparison of these and tissue development were the two functions determined to be samples, demonstrating minimal changes despite differences in most enriched in invasive TAMs. Previously, TAMs generically strain and markers for isolation. It further confirms that GTs are have been shown to have an expression signature similar to that of distinct compared with splenic macrophages. It is now also shown macrophages in developing embryos (4, 45). These results suggest that the invasive TAM subpopulation is unique to each. that invasive TAMs are a TAM subpopulation that is expressly en- The final list of 1457 identified differentially regulated tran- gaged in tissue trophic functions most similarly to embryonic scripts is listed in Supplemental Table I. QRT-PCR was used to phagocytes. confirm the results from the gene expression arrays, and all tran- To further explore the dataset, GSEA (46) was used to identify scripts tested were validated in their relative expression pattern by groups of functionally related genes with expression patterns that this assay (Fig. 3). mRNA transcripts of decreased abundance in correlate with the invasive TAM phenotype. The dataset was the invasive TAMs include the Csf1r, the src-family kinase Lyn, collapsed to a single expression value per HUGO gene symbol, so the proinflammatory cytokine IL-18, a macrophage scavenger that the probe with the highest average expression value across all receptor (Msr1), and two metalloproteases (Adam8 and Mmp14). the samples was selected as the representative for that gene in the Transcripts more abundantly expressed in invasive TAMs include dataset. Genes were ranked based on differential expression be- a serine (Mtsp1), a proangiogenic molecule (Ccn1/ tween invasive TAMs and GTs with genes high in invasive TAMs Cyr61) and a member of the Wnt-family of ligands, Wnt5b. No- at the top of the list and those high in GTs at the bottom. The tably, a second Wnt-family ligand, Wnt7b, was also identified as GSEA method was then used to examine the distribution of the Downloaded from significantly increased in invasive TAMs; however, the baseline 148 functionally related human KEGG pathway gene sets (47) transcript abundance in GTs was not sufficient for detection by within the ranked gene list to gain an appreciation for functional QRT-PCR and could not be tested for comparison. However, motifs mediating invasive TAM activity. Eleven gene sets were semiquantitative RT-PCR was used to validate increased Wnt7b enriched in the invasive TAM phenotype using a 25% false dis- expression (Fig. 4E). covery rate cut-off (Fig. 4A, Table II). GSEA leading edge anal- ysis was then performed to compare the sets of genes responsible http://www.jimmunol.org/ Gene expression pattern of invasive TAMs for the enrichment observations. Two clusters of relationship were Using the Ingenuity Pathway Analysis system (IPA 6.3), differ- observed (Fig. 4A). The first contains the cell communication gene entially regulated transcripts were analyzed for physiological set (HSA01430) and the ECM receptor interaction gene set functions and corresponding significance. To gain an appreciation (HSA04512) and is driven by a group of laminin, collagen, and for tissue trophic functions of this TAM population, Table I ranks thrombospondin genes (http://tinyurl.com/yg3dhrf). The second set by guest on October 2, 2021

FIGURE 3. QRT-PCR validates gene expression array data for downregulated (A) and upregulated (B) transcripts. Invasive TAMs (black bars) and GTs (gray bars) normalized to expression of housekeeping gene cyclophilin A (Ppia). The Journal of Immunology 707

FIGURE 4. KEGG pathways enriched in invasive TAMs are related through Wnts. A, Set-to-set diagram, created through performing a leading edge analysis using GSEA, indicates the overlap between signifi- cantly enriched KEGG pathways listed in Table II. Dark green cells indicate that the gene sets have leading edge genes in common, whereas a white cell indicates no leading edge gene overlap. Four sets demonstrate overlap (red arrows). B, Venn diagram of overlapping molecules between enriched KEGG pathways. Notably, 10 molecules are common to all four pathways including: Wnts 1, 3, 4, 5B, 6, 7B, 9A, 9B, 10A and 16. Boxes shaded using diagonal lines

have no overlap between pathways. Official human Downloaded from KEGG pathway signifiers are listed. http://www.jimmunol.org/

consists of four gene sets: basal cell carcinoma (HSA05217), ment are depicted with the associated expression normograms to Hedgehog signaling pathway (HAS04340), Wnt signaling pathway demonstrate the consistency between samples (Fig. 5B). (HSA04310), and melanogenesis (HAS04916; Fig. 4B). This re- lationship is driven by a group 10 Wnt family members that are The Wnt-signaling pathway has a role in TAM activity present in all four of these gene sets (WNT 1, 4, 5, 5B, 6, 7B, 9A, 9B,

Returning to the IPA, graphing the log2ratio for every Wnt ligand by guest on October 2, 2021 10 and 16; http://tinyurl.com/yg3dhrf). This Wnt-containing set is demonstrates that all but Wnt8b were increased in invasive TAMs of particular interest because of the recognized role of the Wnt- (Fig. 6A). However, as previously mentioned, only Wnt5b and signaling pathway in development and its identified role in Wnt7b were identified by stringent criteria (SAM) as in- macrophage function (17, 48, 49). Besides the Wnt-ligands, dependently statistically significant. Those significant molecules several frizzled receptors and molecules that modulate Wnt-sig- called by SAM were superimposed on the Wnt pathway, and naling were also present in these enriched gene sets, pointing similar to the GSEA results, other molecules related to Wnt ac- toward a larger role for macrophage-mediated Wnt activity in the tivity were represented in this gene set (Fig. 6B). Wnt5b and tumor microenvironment. Using GSEA, the genes associated with Wnt7b were reproducible between gene expression chips (Fig. a role in the Wnt pathway were graphed (Fig. 5A) (46). The en- 6C). Wnt5b expression was validated by QRT-PCR in Fig. 3. richment score of the Wnt-signaling pathway is 0.299 and the Wnt7b is of very low transcript abundance and therefore nested nominal p value is 0.021 (Table II). Of the 140 pathway-affiliated semiquantitative RT-PCR, a two-step PCR protocol, is required for genes, there are groups of genes positively (red) and negatively detection. Fig. 6D illustrates that Wnt7b is not produced in splenic (blue) correlated with invasive TAM expression. Those positively macrophages (Sp Macs), but is slightly increased in GTs and correlated genes that most-contributed to Wnt pathway enrich- highly enriched in invasive TAMs (NC TAMs).

Table I. Categories relating to physiologic system development and function enriched in invasive TAMs

Rank Category p Value Upregulated 1 Embryonic development 2.87 3 1024 – 4.14 3 1022 2 Tissue development 2.87 3 1024 – 4.14 3 1022 3 Tissue morphology 2.87 3 1024 – 4.14 3 1022 4 Nervous system development and function 1.21 3 1023 – 4.14 3 1022 5 Immune response 1.29 3 1023 – 4.14 3 1022 Downregulated 1 Immune response 2.18 3 10210– 2.04 3 1023 2 Immune and lymphatic system development and function 5.08 3 1029 – 2.19 3 1023 3 Hematologic system development and function 8.02 3 1029 – 2.19 3 1023 4 Tissue development 2.36 3 1027 – 2.00 3 1023 5 Reproductive system development and function 7.38 3 1027 – 7.38 3 1027 708 GENE EXPRESSION ANALYSIS OF INVASIVE TAMs

Table II. KEGG gene sets enriched in invasive TAMs and associated statistics

Gene Enrichment Normalized Nominal FDR Rank Gene Set Set Size Score Enrichment Score p Value q Value at Max HSA01430_CELL_COMMUNICATION 121 0.59563637 2.6974535 0 0 3511 HSA05217_BASAL_CELL_CARCINOMA 55 0.5553169 2.1564224 0 4.06 3 1024 4580 HSA04512_ECM_RECEPTOR_INTERACTION 83 0.45781794 1.9435273 0 0.00513476 2211 HSA04530_TIGHT_JUNCTION 124 0.39952913 1.808554 0 0.0177126 3194 HSA03010_RIBOSOME 61 0.44803682 1.7929574 8.62 3 1024 0.01682182 6356 HSA04340_HEDGEHOG_SIGNALING_PATHWAY 54 0.44944367 1.7346396 8.31 3 1024 0.02487251 5313 HSA04950_MATURITY_ONSET_DIABETES_OF_THE_YOUNG 25 0.4811138 1.5646982 0.0249273 0.08812157 4153 HSA04742_TASTE_TRANSDUCTION 39 0.4193784 1.5260606 0.02017655 0.10253292 3603 HSA04360_AXON_GUIDANCE 124 0.31950954 1.4521579 0.0087222 0.15447515 2581 HSA04310_WNT_SIGNALING_PATHWAY 140 0.29928747 1.3827081 0.02131439 0.22107984 3271 HSA04916_MELANOGENESIS 96 0.31248757 1.3567276 0.03821103 0.23827241 2987

Because Wnt7b is a confirmed macrophage gene product (48, used to analyze previously published human breast cancer mi- 49), it was selected for more stringent confirmation of expression croarray studies for its expression (Fig. 6F). Oncomine compiles in TAMs, which has not previously been demonstrated. Consid- and organizes human tumor microarray studies, allowing the data ering there is a known contamination of invasive carcinoma cells to be analyzed by independent researchers. In these prior studies, Downloaded from in the invasive TAM preparations (25), it was desired to attribute tumor samples are generally from whole-tissue biopsies; there- the expression of Wnt7b to the TAMs directly. Wnt7b was in- fore, a heterogeneous assortment of cell types from the tumor dicated to be enriched in GTs, and although GTs show decreased microenvironment can be carefully assessed as previously dem- expression compared with invasive TAMs, we aimed to determine onstrated in follicular lymphoma (51) and human breast cancer whether Wnt7b expression could be detected in a pure population (52). In our screening of the database, increased expression of of GTs. It has been previously established that using a protocol WNT7B was found to be significantly correlated with positive exploiting the adhesive property of macrophages, a pure population lymph node metastasis (53, 54). Although this analysis inter- http://www.jimmunol.org/ of TAMs can be isolated (50). Dextran+ Csf1r-EGFP+ splenic rogates the expression of every cell present in the tumor biopsy macrophages and TAMs were sorted by flow cytometry and plated and not TAMS alone, when analyzed in conjunction with the onto bacterial plastic. After 12 h incubation, macrophages were other data, it provides support that this increased WNT7B ex- washed and RNA was extracted. Following semiquantitative RT- pression in advanced disease is due to the increased expression in PCR, Wnt7b expression was present only in the TAM population present TAMs. (Fig. 6E). It is noted that this method is not specific for invasive TAMs whose paucity precludes this type of analysis; however, by

establishing that Wnt7b was present in a pure population of TAMs, Discussion by guest on October 2, 2021 the microarray data already presented suggest that this expression As an early step in tumor metastasis, targeting carcinoma cell would be enriched in invasive TAMs. motility and invasion within the primary tumor microenvironment Lastly, to ascertain the significance of Wnt7b expression in presents a unique opportunity to impede tumor progression. Pre- human breast cancer, Oncomine (www.oncomine.org) (39) was vious clinical data have indicated that high density of TAMs within

FIGURE 5. GSEA analysis for Wnt-signaling pathway and positively enriched associated molecules. A, Distribution of the 142 Wnt-signaling pathway molecules amid the total ranked list of all transcripts analyzed by GSEA (46). Enrichment score of the pathway of 0.299 is identified by determining the peak of positively correlated transcripts. B, Normogram for the core enriched Wnt-signaling pathway related molecules in the array dataset. Increased expression (red), decreased expression (blue). The Journal of Immunology 709

FIGURE 6. Wnt7b in TAMs and human breast cancer. A, Expression pattern for all Wnt ligands queried by Nimblegen gene expression arrays. Most Wnt ligands were found to be increased (red) in invasive TAMs compared with general TAMs, except for Wnt8b which was decreased

(green). Asterisks indicate Wnt5b and Wnt7b that Downloaded from were called as significantly differentially regu- lated. B, Generalized representation of relative abundance of molecules driving Wnt-signaling in invasive TAMs. Double outlined molecules (Frizzled, LRP1/5/6, DKK, and WNT) contain multiple members that are not individually de- picted. Shading represents the trend for the entire http://www.jimmunol.org/ group (e.g., note expression of individual Wnt li- gands in Aversus total WNTexpression). Diagram generated using IPA 6.3. C, Normalized array expression intensities (log base 2) for Wnt5b and Wnt7b for each biologic replicate depict re- producibility between samples. The line indicates average expression for each set of experiments. D, Semiquantitative PCR for Wnt7b expression in splenic macrophages (Sp Macs), GTs (TAMs) and by guest on October 2, 2021 invasive, needle-collected TAMs (NC TAMs). E, Representative semiquantitative PCR for Wnt7b in splenic macrophages (Sp Macs) and TAMs following flow cytometric sorting and 12-h cul- ture to ensure pure macrophage populations. F, Higher expression of Wnt7b in human breast cancer correlates with advanced disease. Two separate studies were mined using Oncomine (39) and indicate that breast cancer metastatis to lymph nodes has significantly higher WNT7B expression.

a tumor microenvironment correlates with poor prognosis (55). function by flow cytometry using the macrophage known macro- Furthermore, recent experimental data has provided compelling pinocytic capacity and cell-surface expression of F4/80 as mark- evidence indicating TAMs in the direct facilitation of tumor in- ers. It has previously been shown that phagocytosis of dextran vasion (15, 19, 20). The studies herein describe the in vivo does not compromise a macrophage’s motility or its ability to functional isolation of a subpopulation of TAMs caught in the act secrete EGF in response to CSF-1 (15). Furthermore, it has pre- of promoting carcinoma cell motility; their gene expression pro- viously been shown that invasive TAMs are a uniform population file, compared with a GT population, isolated indiscriminately to that express F4/80 and are macropinocytic (15, 19). Therefore, 710 GENE EXPRESSION ANALYSIS OF INVASIVE TAMs these experiments are specific for comparing the gene expression velopment (1, 60), and especially during mammary gland de- of those TAMs actively promoting tumor cell invasion versus the velopment (21, 61, 62). TAMs may be recapitulating a number of vast majority of TAMs that are not. these tissue trophic functions executed during development to Previously, gene expression studies of invasive tumor cells promote tumor progression (63, 64). The annotation of tran- collected through the in vivo invasion assay have yielded mech- scriptional profiles to function was further explored using GSEA anistic insight into the cell biology–namely motility (26, 27, 29, (46), an analytical method that examines the distribution of 56) and viability (28)–of this subpopulation of tumor cells. Con- functionally related genes in an ordered gene expression dataset sidering an inherent requirement for TAMs, we hypothesized that without the selection of upregulated or downregulated genes. This gene expression studies of invasive TAMs would also provide method was used to examine the KEGG pathways that are present useful insight into the physiology of TAM promotion of tumor in and enriched in the invasive TAM dataset. Notably, the progression. The invasive TAM arrays indicated a considerable Wnt-signaling pathway, a pathway critical to normal tissue de- number of transcripts as differentially regulated, despite use of velopment was identified as highly enriched (Fig. 4, Table II). highly stringent gene selection criteria. Therefore, we interrogated Although a KEGG pathway does not exist specifically for breast possible artifactual explanations that could account for these dif- cancer, it was noted that the invasive TAM gene set was enriched ferences. In-depth examination of the array data failed to identify for molecules frequently overexpressed in human basal cell car- consistent biases or deviations from the norm; therefore, technical cinoma (Fig. 4B). Except for Wnt-signaling being a common artifacts could not account for why so many genes were differ- denominator, the significance of this association is unclear. entially regulated (Supplemental Fig. 1). Moreover, QRT-PCR on However, through population studies it is known that the diagnosis subsequent biologic repeats confirmed all tested results from the of numerous skin cancers, including basal cell carcinoma, confers gene expression arrays (Fig. 3). We were also concerned that the an increased relative risk of the development of breast cancer (65, Downloaded from large number of differences would be due to an irreducible con- 66). Moreover, in human basal cell carcinoma, increased TAM tamination of carcinoma cells, but significant overlap in expres- density correlates with increased depth of invasion and micro- sion data was not found when the results were compared with vessel density (67). This finding suggests that perhaps the KEGG invasive carcinoma cell expression data. Taken together, these gene set attributed to basal cell carcinoma derives in part from the results indicate that this invasive macrophage population has TAMs present within the tumor micronenvironment. a unique transcriptome significantly different from the GT pop- We were compelled to further study the significant over-expression http://www.jimmunol.org/ ulation. Useful data can be extracted from the microarray data; of Wnt7b in TAMs because of its known production by macrophages however, given that some of these differences may be caused by (48, 49) and the known role of Wnt signaling in development (68, 69) the experimental perturbation required to collect these cells, and cancer (70). The Wnt7b ligand is a notoriously low-abundant caution must be exercised and mechanistic experiments will be transcript, and it was necessary to use nested primers for semi- needed to confirm that the results are physiologically relevant. quantitative PCR to detect message (48). Genetic tools to transgeni- IPA 6.3 was used to embark on a bioinformatic analysis of the cally label cells producing Wnt7b, described instudies of macrophage enriched functional categories within the stringently identified 1457 contribution to vascular remodeling of hyaloid vessels in the de- transcripts called as differentially regulated by SAM. Physiologic veloping mouse eye (48), will be useful in future tumor studies al- by guest on October 2, 2021 system development and function categories were ranked by sig- though conclusive studies may be hampered when transitioning these nificance of enrichment for clues as to how this invasive TAM models from the relatively hypocellular developing mouse eye to the population was affecting the tumor microenvironment (Table I). It hypercellular tumor microenvironment. Therefore, although our gene was anticipated that, similar to invasive carcinoma cells (25), in- expression studies originally identified Wnt7b as being increased in vasive TAMs would distinctly demonstrate enrichment in mole- invasive TAMs compared with GTs, we aimed to provide evidence cules involved in the paracrine loop required for tumor cell that in general, TAMs express Wnt7b. migration and invasion–EGF and CSF-1R in macrophages (19)– Semiquantitative PCR confirmed that Wnt7b is minimally and those mediating macrophage motility to be specifically en- enriched in TAMs and further enriched in invasive TAMs (Fig. 6D). riched in invasive TAMs. In fact, the opposite was found wherein We considered that if carcinoma cells produced the majority of Csf1r transcript expression, whose biochemical function is critical Wnt7b, a profile similar to that seen in Fig. 6D would be produced, to the paracrine loop expression, was diminished, as were mole- because flow cytometric sorting generally isolates a 97–99% pure cules critical to normal macrophage migration (Fig. 3). Unlike tu- population on postsort, whereas cell separation following the in mor cells, macrophages are nongenomically transformed immune vivo invasion assay yields a slightly higher contamination (25). cells in which exquisite transcriptional, translational, and post- Therefore, a second validated (50) macrophage isolation step translational control is maintained to prevent a shift in balance of following flow cytometry was used to more purely study the immune activity to an overly exaggerated inflammatory response. Wnt7b expression in adherent TAMs. After isolation of TAMs and Therefore, although the results were not anticipated, we do not splenic macrophages by flow cytometry, they were allowed to suggest that they conflict with the established requirement adhere to petri dishes. RNA was subsequently extracted from both for these molecules in the paracrine loop and macrophage motility. pure macrophage populations and Wnt7b expression was only The CSF-1R, while not only being on the cell surface, is maintained detected in TAMs. in a large cryptic intracellular pool from where it can be rapidly As mentioned above, in the developing mouse eye, macrophages mobilized to the cell surface (57). Furthermore, it has recently been direct vascular remodeling of hyaloid vessels by producing Wnt7b shown that Csf1r expression is decreased in macrophages following (48, 49). Interestingly, recent work (49) has proposed a mecha- stimulation by lipopolysaccharide (58, 59), and it is feasible that nism in this model whereby macrophages produce Wnt7b that other molecules communicating between TAMs and tumor cells stimulates the canonical Wnt signaling pathway in vascular en- during their active comigration may produce a similar effect. dothelial cells (VECs), which express Wnt coreceptors Lrp5 and Conversely, embryonic and tissue development were enriched Frizzled, in a paracrine fashion. This signaling cascade eventually ontologic designations of genes overexpressed in invasive TAMs. results in the stabilization of b-catenin and VEC entry into cell This finding was interesting, considering that macrophages are well cycle. Furthermore, in the developing mouse eye, angiopoietin-2 known to have essential tissue trophic functions during de- production by vessel-related pericytes provides an apoptotic signal The Journal of Immunology 711 to VECs, leading to their death and overall vascular remodeling. 12. Wolf, M., I. Clark-Lewis, C. Buri, H. Langen, M. Lis, and L. Mazzucchelli. This would suggest that in the absence of an apoptotic signal to 2003. Cathepsin D specifically cleaves the chemokines macrophage in- flammatory protein-1 a, macrophage inflammatory protein-1 b, and SLC that are VECs, this model could provide a mechanism for macrophage expressed in human breast cancer. Am. J. Pathol. 162: 1183–1190. stimulation of VEC proliferation, such as in tumor angiogenesis. 13. Hagemann, T., S. C. Robinson, M. Schulz, L. Tru¨mper, F. R. Balkwill, and Perivascular TAM clusters are indicated to most efficiently pro- C. Binder. 2004. Enhanced invasiveness of breast cancer cell lines upon co- cultivation with macrophages is due to TNF-a dependent up-regulation of matrix mote carcinoma cell motility in an EGF/CSF-1 paracrine loop de- metalloproteases. Carcinogenesis 25: 1543–1549. pendent manner in PyMT mammary tumors. Consequently, these 14. Pedersen, T. X., C. J. Pennington, K. Almholt, I. J. Christensen, B. S. Nielsen, perivascular TAM clusters have been proposed to be an invasive hot- D. R. Edwards, J. Rømer, K. Danø, and M. Johnsen. 2005. Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected spot (15). In human breast cancer tissue sections, triple staining for mouse breast carcinomas. Carcinogenesis 26: 1233–1240. juxtaposed clusters of macrophages, vascular endothelial cells, and 15. Wyckoff, J. B., Y. Wang, E. Y. Lin, J. F. Li, S. Goswami, E. R. Stanley, a specific protein marker found in invasive carcinoma cells indicated J. E. Segall, J. W. Pollard, and J. Condeelis. 2007. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. that more of these clusters correlated with human metastatic disease 67: 2649–2656. (71). We propose that these macrophages located along the tumor 16. Fidler, I. J. 2003. The pathogenesis of cancer metastasis: the ‘seed and soil’ vasculature and associated with invasive tumor cells are the invasive hypothesis revisited. Nat. Rev. Cancer 3: 453–458. 17. Pukrop, T., F. Klemm, T. Hagemann, D. Gradl, M. Schulz, S. Siemes, TAM subpopulation and that these TAMs function, in part, through L. Tru¨mper, and C. Binder. 2006. Wnt 5a signaling is critical for macrophage- modulating Wnt-signaling in the local microenvironment. It would induced invasion of breast cancer cell lines. Proc. Natl. Acad. Sci. USA 103: not be insignificant that TAM-derived Wnt7b may also have a role in 5454–5459. 18. Wyckoff, J. B., J. E. Segall, and J. S. Condeelis. 2000. The collection of the vasculogenesis, as seen in the developing eye (48, 49) because there motile population of cells from a living tumor. Cancer Res. 60: 5401–5404. is considerable evidence of extensive angiogenesis at the sites of 19. Wyckoff, J., W. Wang, E. Y. Lin, Y. Wang, F. Pixley, E. R. Stanley, T. Graf, leukocytic invasion in human breast tumors (6). Furthermore, it is J. W. Pollard, J. Segall, and J. Condeelis. 2004. A paracrine loop between tumor Downloaded from cells and macrophages is required for tumor cell migration in mammary tumors. believed that these angiogenic beds are also the sites of tumor cell Cancer Res. 64: 7022–7029. invasion (3, 63). Our results linking Wnt7b and tumor cell invasion 20. Goswami, S., E. Sahai, J. B. Wyckoff, M. Cammer, D. Cox, F. J. Pixley, are consistent with this hypothesis. Not insignificantly, human E. R. Stanley, J. E. Segall, and J. S. Condeelis. 2005. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal breast tumors that have higher expression levels of WNT7B are as- growth factor paracrine loop. Cancer Res. 65: 5278–5283. sociated with advanced disease as defined by tumor-positive lymph 21. Lin, E. Y., V. Gouon-Evans, A. V. Nguyen, and J. W. Pollard. 2002. The mac- nodes (Fig. 6F). rophage growth factor CSF-1 in mammary gland development and tumor pro- http://www.jimmunol.org/ gression. J. Mammary Gland Biol. Neoplasia 7: 147–162. This article describes the gene expression signature of a unique 22. Kacinski, B. M. 1995. CSF-1 and its receptor in ovarian, endometrial and breast invasive TAM subpopulation that putatively has roles in tumor cancer. Ann. Med. 27: 79–85. progression through promotion of tumor metastasis and angio- 23. Scholl, S. M., C. Pallud, F. Beuvon, K. Hacene, E. R. Stanley, L. Rohrschneider, R. Tang, P. Pouillart, and R. Lidereau. 1994. Anti-colony-stimulating factor-1 genesis, with the role of Wnt signaling as a common denominator antibody staining in primary breast adenocarcinomas correlates with marked via TAM-derived Wnt7b. Moreover, we submit that with careful inflammatory cell infiltrates and prognosis. J. Natl. Cancer Inst. 86: 120–126. mining, the results from the gene expression arrays described in this 24. O’Sullivan, C., C. E. Lewis, A. L. Harris, and J. O. McGee. 1993. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. study will provide a useful tool for further insight into mechanisms Lancet 342: 148–149. of TAM promotion of tumor progression. 25. Wang, W., J. B. Wyckoff, Y. Wang, E. P. Bottinger, J. E. Segall, and J. S. Condeelis. 2003. Gene expression analysis on small numbers of invasive by guest on October 2, 2021 cells collected by chemotaxis from primary mammary tumors of the mouse. Disclosures BMC Biotechnol. 3: 13. The authors have no financial conflicts of interest. 26. Wang, W., S. Goswami, K. Lapidus, A. L. Wells, J. B. Wyckoff, E. Sahai, R. H. Singer, J. E. Segall, and J. S. Condeelis. 2004. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mam- mary tumors. Cancer Res. 64: 8585–8594. References 27. Wang, W., G. Mouneimne, M. Sidani, J. Wyckoff, X. Chen, A. Makris, S. Goswami, A. R. Bresnick, and J. S. Condeelis. 2006. The activity status of Nat. Rev. 1. Pollard, J. W. 2009. Trophic macrophages in development and disease. cofilin is directly related to invasion, intravasation, and metastasis of mammary Immunol. 9: 259–270. tumors. J. Cell Biol. 173: 395–404. 2. Joyce, J. A., and J. W. Pollard. 2009. Microenvironmental regulation of metas- 28. Goswami, S., W. Wang, J. B. Wyckoff, and J. S. Condeelis. 2004. Breast cancer tasis. Nat. Rev. Cancer 9: 239–252. cells isolated by chemotaxis from primary tumors show increased survival and 3. Pollard, J. W. 2004. Tumour-educated macrophages promote tumour progression resistance to chemotherapy. Cancer Res. 64: 7664–7667. and metastasis. Nat. Rev. Cancer 4: 71–78. 29. Wang, W., J. B. Wyckoff, S. Goswami, Y. Wang, M. Sidani, J. E. Segall, and 4. Ojalvo, L. S., W. King, D. Cox, and J. W. Pollard. 2009. High-density gene J. S. Condeelis. 2007. Coordinated regulation of pathways for enhanced cell expression analysis of tumor-associated macrophages from mouse mammary Cancer tumors. Am. J. Pathol. 174: 1048–1064. motility and chemotaxis is conserved in rat and mouse mammary tumors. 5. Lewis, C. E., and J. W. Pollard. 2006. Distinct role of macrophages in different Res. 67: 3505–3511. tumor microenvironments. Cancer Res. 66: 605–612. 30. Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors 6. Leek, R. D., R. J. Landers, A. L. Harris, and C. E. Lewis. 1999. Necrosis cor- by expression of polyomavirus middle T oncogene: a transgenic mouse model relates with high vascular density and focal macrophage infiltration in invasive for metastatic disease. Mol. Cell. Biol. 12: 954–961. carcinoma of the breast. Br. J. Cancer 79: 991–995. 31. Sasmono, R. T., D. Oceandy, J. W. Pollard, W. Tong, P. Pavli, B. J. Wainwright, 7. Tsutsui, S., K. Yasuda, K. Suzuki, K. Tahara, H. Higashi, and S. Era. 2005. Mac- M. C. Ostrowski, S. R. Himes, and D. A. Hume. 2003. A macrophage colony- rophage infiltration and its prognostic implications in breast cancer: the relation- stimulating factor receptor-green fluorescent protein transgene is expressed ship with VEGF expression and microvessel density. Oncol. Rep. 14: 425–431. throughout the mononuclear phagocyte system of the mouse. Blood 101: 1155– 8. Lin, E. Y., J. G. Jones, P. Li, L. Zhu, K. D. Whitney, W. J. Muller, and 1163. J. W. Pollard. 2003. Progression to malignancy in the polyoma middle T onco- 32. Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, protein mouse breast cancer model provides a reliable model for human diseases. U. Scherf, and T. P. Speed. 2003. Exploration, normalization, and summaries of Am. J. Pathol. 163: 2113–2126. high density oligonucleotide array probe level data. Biostatistics 4: 249–264. 9. Lin, E. Y., A. V. Nguyen, R. G. Russell, and J. W. Pollard. 2001. Colony- 33. R Development Core Team, 2009. R: A language and environment for statistical stimulating factor 1 promotes progression of mammary tumors to malignancy. computing. R Foundation for Statistical Computing, Vienna, Austria. J. Exp. Med. 193: 727–740. 34. Ihaka, R., and R. Gentleman. 1996. R: A Language for Data Analysis and 10. Hildenbrand, R., G. Wolf, B. Bo¨hme, U. Bleyl, and A. Steinborn. 1999. Uro- Graphics. J. Comput. Graph. Statist. 5: 299–314. kinase plasminogen activator receptor (CD87) expression of tumor-associated 35. Gentleman, R. C., V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, macrophages in ductal carcinoma in situ, breast cancer, and resident macro- B. Ellis, L. Gautier, Y. Ge, J. Gentry, et al. 2004. Bioconductor: open software phages of normal breast tissue. J. Leukoc. Biol. 66: 40–49. development for computational biology and bioinformatics. Genome Biol. 5: R80. 11. Vasiljeva, O., A. Papazoglou, A. Kru¨ger, H. Brodoefel, M. Korovin, J. Deussing, 36. Smyth, G. K. 2005. Limma: linear models for microarray data. In Bioinformatics N. Augustin, B. S. Nielsen, K. Almholt, M. Bogyo, et al. 2006. Tumor cell- and Computational Biology Solutions using R and Bioconductor.V.C.R. derived and macrophage-derived cathepsin B promotes progression and lung Gentleman, S. Dudoit, R. Irizarry, and W. Huber, eds. Springer, New York, pp. metastasis of mammary cancer. Cancer Res. 66: 5242–5250. 397–420. 712 GENE EXPRESSION ANALYSIS OF INVASIVE TAMs

37. Tusher, V. G., R. Tibshirani, and G. Chu. 2001. Significance analysis of mi- 53. Miller, L. D., J. Smeds, J. George, V. B. Vega, L. Vergara, A. Ploner, Y. Pawitan, croarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. P. Hall, S. Klaar, E. T. Liu, and J. Bergh. 2005. An expression signature for p53 98: 5116–5121. status in human breast cancer predicts mutation status, transcriptional effects, 38. Suzuki, R., and H. Shimodaira. 2006. Pvclust: an R package for assessing the and patient survival. Proc. Natl. Acad. Sci. U.S.A. 102: 13550–13555. uncertainty in hierarchical clustering. Bioinformatics 22: 1540–1542. 54. Ivshina, A. V., J. George, O. Senko, B. Mow, T. C. Putti, J. Smeds, T. Lindahl, 39. Rhodes, D. R., S. Kalyana-Sundaram, V. Mahavisno, R. Varambally, J. Yu, Y. Pawitan, P. Hall, H. Nordgren, et al. 2006. Genetic reclassification of histo- B. B. Briggs, T. R. Barrette, M. J. Anstet, C. Kincead-Beal, P. Kulkarni, et al. logic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66: 2007. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 10292–10301. cancer gene expression profiles. Neoplasia 9: 166–180. 55. Bingle, L., N. J. Brown, and C. E. Lewis. 2002. The role of tumour-associated 40. Rhodes, D. R., J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, macrophages in tumour progression: implications for new anticancer therapies. T. Barrette, A. Pandey, and A. M. Chinnaiyan. 2004. ONCOMINE: a cancer J. Pathol. 196: 254–265. microarray database and integrated data-mining platform. Neoplasia 6: 1–6. 56. Lapidus, K., J. Wyckoff, G. Mouneimne, M. Lorenz, L. Soon, J. S. Condeelis, 41. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression and R. H. Singer. 2007. ZBP1 enhances cell polarity and reduces chemotaxis. DD data using real-time quantitative PCR and the 2(- C(T)) Method. Methods 25: J. Cell Sci. 120: 3173–3178. 402–408. 57. Guilbert, L. J., and E. R. Stanley. 1986. The interaction of 125I-colony-stimulating 42. Qian, B., Y. Deng, J. H. Im, R. J. Muschel, Y. Zou, J. Li, R. A. Lang, and factor-1 with bone marrow-derived macrophages. J. Biol. Chem. 261: 4024–4032. J. W. Pollard. 2009. A distinct macrophage population mediates metastatic breast 58. Bonifer, C., and D. A. Hume. 2008. The transcriptional regulation of the Colony- cancer cell extravasation, establishment and growth. PLoS One 4: e6562. Stimulating Factor 1 Receptor (csf1r) gene during hematopoiesis. Front. Biosci. 43. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster 13: 549–560. analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. 59. Sester, D. P., A. Trieu, K. Brion, K. Schroder, T. Ravasi, J. A. Robinson, U.S.A. 95: 14863–14868. R. C. McDonald, V. Ripoll, C. A. Wells, H. Suzuki, et al. 2005. LPS regulates 44. Sasmono, R. T., A. Ehrnsperger, S. L. Cronau, T. Ravasi, R. Kandane, a set of genes in primary murine macrophages by antagonising CSF-1 action. M. J. Hickey, A. D. Cook, S. R. Himes, J. A. Hamilton, and D. A. Hume. 2007. Immunobiology 210: 97–107. Mouse neutrophilic granulocytes express mRNA encoding the macrophage 60. Rae, F., K. Woods, T. Sasmono, N. Campanale, D. Taylor, D. A. Ovchinnikov, colony-stimulating factor receptor (CSF-1R) as well as many other macrophage- S. M. Grimmond, D. A. Hume, S. D. Ricardo, and M. H. Little. 2007. Char- specific transcripts and can transdifferentiate into macrophages in vitro in re-

acterisation and trophic functions of murine embryonic macrophages based upon Downloaded from sponse to CSF-1. J. Leukoc. Biol. 82: 111–123. the use of a Csf1r-EGFP transgene reporter. Dev. Biol. 308: 232–246. 45. Pucci, F., M. A. Venneri, D. Biziato, A. Nonis, D. Moi, A. Sica, C. Di Serio, 61. Gouon-Evans, V., E. Y. Lin, and J. W. Pollard. 2002. Requirement of macro- L. Naldini, and M. De Palma. 2009. A distinguishing gene signature shared by phages and eosinophils and their cytokines/chemokines for mammary gland tumor-infiltrating Tie2-expressing monocytes (TEMs), blood “resident” mono- development. Breast Cancer Res. 4: 155–164. cytes and embryonic macrophages suggests common functions and develop- 62. Gouon-Evans, V., M. E. Rothenberg, and J. W. Pollard. 2000. Postnatal mam- mental relationships. Blood. 114: 901–914. mary gland development requires macrophages and eosinophils. Development 46. Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and 127: 2269–2282. 63. Condeelis, J., and J. W. Pollard. 2006. Macrophages: obligate partners for tumor J. P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-based approach http://www.jimmunol.org/ for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. cell migration, invasion, and metastasis. Cell 124: 263–266. 102: 15545–15550. 64. Ingman, W. V., J. Wyckoff, V. Gouon-Evans, J. Condeelis, and J. W. Pollard. 47. Kanehisa, M., S. Goto, M. Hattori, K. F. Aoki-Kinoshita, M. Itoh, S. Kawashima, 2006. Macrophages promote collagen fibrillogenesis around terminal end buds T. Katayama, M. Araki, and M. Hirakawa. 2006. From genomics to chemical of the developing mammary gland. Dev. Dyn. 235: 3222–3229. genomics: new developments in KEGG. Nucleic Acids Res. 34(Database issue): 65. Frisch, M., H. Hjalgrim, J. H. Olsen, and M. Melbye. 1996. Risk for subsequent D354–D357. cancer after diagnosis of basal-cell carcinoma. A population-based, epidemio- 48. Lobov, I. B., S. Rao, T. J. Carroll, J. E. Vallance, M. Ito, J. K. Ondr, S. Kurup, logic study. Ann. Intern. Med. 125: 815–821. D. A. Glass, M. S. Patel, W. Shu, et al. 2005. WNT7b mediates macrophage- 66. Soerjomataram, I., W. J. Louwman, V. E. Lemmens, J. W. Coebergh, and E. de induced programmed cell death in patterning of the vasculature. Nature 437: Vries. 2008. Are patients with skin cancer at lower risk of developing colorectal 417–421. or breast cancer? Am. J. Epidemiol. 167: 1421–1429. 49. Rao, S., I. B. Lobov, J. E. Vallance, K. Tsujikawa, I. Shiojima, S. Akunuru, 67. Tjiu, J. W., J. S. Chen, C. T. Shun, S. J. Lin, Y. H. Liao, C. Y. Chu, T. F. Tsai,

K. Walsh, L. E. Benjamin, and R. A. Lang. 2007. Obligatory participation of H. C. Chiu, Y. S. Dai, H. Inoue, et al. 2009. Tumor-associated macrophage- by guest on October 2, 2021 macrophages in an angiopoietin 2-mediated cell death switch. Development 134: induced invasion and angiogenesis of human basal cell carcinoma cells by cy- 4449–4458. clooxygenase-2 induction. J. Invest. Dermatol. 129: 1016–1025. 50. Biswas, S. K., L. Gangi, S. Paul, T. Schioppa, A. Saccani, M. Sironi, B. Bottazzi, 68. Moon, R. T., J. D. Brown, and M. Torres. 1997. WNTs modulate cell fate and A. Doni, B. Vincenzo, F. Pasqualini, et al. 2006. A distinct and unique tran- behavior during vertebrate development. Trends Genet. 13: 157–162. scriptional program expressed by tumor-associated macrophages (defective NF- 69. Schwab, K. R., L. T. Patterson, H. A. Hartman, N. Song, R. A. Lang, X. Lin, and kappaB and enhanced IRF-3/STAT1 activation). Blood 107: 2112–2122. S. S. Potter. 2007. Pygo1 and Pygo2 roles in Wnt signaling in mammalian kidney 51. Dave, S. S., G. Wright, B. Tan, A. Rosenwald, R. D. Gascoyne, W. C. Chan, development. BMC Biol. 5: 15. R. I. Fisher, R. M. Braziel, L. M. Rimsza, T. M. Grogan, et al. 2004. Prediction 70. Logan, C. Y., and R. Nusse. 2004. The Wnt signaling pathway in development of survival in follicular lymphoma based on molecular features of tumor- and disease. Annu. Rev. Cell Dev. Biol. 20: 781–810. infiltrating immune cells. N. Engl. J. Med. 351: 2159–2169. 71. Robinson, B. D., G. L. Sica, Y. F. Liu, T. E. Rohan, F. B. Gertler, J. S. Condeelis, 52. Perou, C. M., T. Sørlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, and J. G. Jones. 2009. Tumor microenvironment of metastasis in human breast J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, et al. 2000. Molecular carcinoma: a potential prognostic marker linked to hematogenous dissemination. portraits of human breast tumours. Nature 406: 747–752. Clin. Cancer Res. 15: 2433–2441. Supplementary Figure: Analysis of invasive array validity

(A) Pair-wise plots comparing log base 2 expression for each General TAM sample compared to one another (left) and each Invasive TAM sample compared to one another (right). Linear-regression line plotted for each comparison, respective correlation coefficients in bottom left boxes for each group. (B) Density histograms for each general TAM sample (left) and invasive TAM sample (right. (C) Chip image for each conducted array comparing invasive TAM (Cy3/green) to general TAM (Cy5/red). Inlaid 3.5x magnification of central control spots. Note overall uniform distribution of experimental probes and coloration of control probes. (D) Composite pair-wise plot comparing overall log base 2 expression of invasive TAMs to general TAMs. Regression line depicted, r=0.916. (E) MA plot indicating log ratio of general TAMs and invasive TAMs (M) to fluorescence intensity. (F) Generated SAM plots depicting relation of delta value to FDR (left) and delta value to number of called significant transcripts (right). Delta value of 3.859, used for further study, corresponds to 1% FDR and 1457 called significantly regulated genes.

Supplementary Table: Invasive TAM expression table for significantly (FDR=1%) called transcripts

Log2Rati Genbank Gene Name o T-test NM_011823 G PROTEIN-COUPLED RECEPTOR 34 -4.77242 0.001276 AK021044 G PROTEIN-COUPLED RECEPTOR 34 -4.63118 0.000759 AK079897 MANNOSE RECEPTOR, C TYPE 1 -4.6004 0.000411 X17501 CD48 ANTIGEN -4.41636 0.001023 NM_008152 G-PROTEIN COUPLED RECEPTOR 65 -4.31912 0.002659 NM_011539 THROMBOXANE A SYNTHASE 1, PLATELET -4.25924 0.000566 L20331 ADENOSINE A3 RECEPTOR -4.25628 0.000189 , GROUP VII (PLATELET-ACTIVATING NM_013737 FACTOR ACETYLHYDROLASE, PLASMA) -4.23988 0.000168 AF055908 MULTIDRUG RESISTANT PROTEIN -4.2237 0.000251 AY255553 G PROTEIN-COUPLED RECEPTOR 141 -4.18974 0.001821 AK032259 RING FINGER PROTEIN 180 -4.17832 0.00026 M14277 FC RECEPTOR, IGG, LOW AFFINITY IIB -4.1651 0.000836 NM_027571 PURINERGIC RECEPTOR P2Y, G-PROTEIN COUPLED 12 -4.1343 0.002686 NM_009983 CATHEPSIN D -4.0946 0.000828 NM_153197 C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER A3 -4.0801 0.003056 EGF-LIKE MODULE CONTAINING, MUCIN-LIKE, HORMONE NM_010130 RECEPTOR-LIKE SEQUENCE 1 -4.06538 0.003401 NM_009917 CHEMOKINE (C-C MOTIF) RECEPTOR 5 -4.04278 0.001088 NM_008855 PROTEIN KINASE C, BETA 1 -4.01864 0.003217 L20315 MACROPHAGE EXPRESSED GENE 1 -4.00828 0.000669 SOLUTE CARRIER FAMILY 37 (GLYCEROL-3-PHOSPHATE BC022752 TRANSPORTER), MEMBER 2 -3.9758 0.000535 AY255606 EPSTEIN-BARR VIRUS INDUCED GENE 2 -3.97454 0.00142 NM_009370 TRANSFORMING GROWTH FACTOR, BETA RECEPTOR I -3.95734 0.001766 NM_009890 CHOLESTEROL 25-HYDROXYLASE -3.95148 0.00047 NM_029394 SORTING NEXING 24 -3.94424 0.001351 AY392766 LEUKOCYTE-ASSOCIATED IG-LIKE RECEPTOR 1 -3.9176 0.004806 BC049256 MACROPHAGE EXPRESSED GENE 1 -3.91756 0.000854 BC005430 MANNOSIDASE 2, ALPHA B1 -3.91296 0.002637 NM_028749 N-ACETYLNEURAMINATE PYRUVATE -3.90154 0.000653 Y18463 CATHEPSIN B -3.901 0.000343 AK077187 COMPLEMENT COMPONENT FACTOR H -3.8873 0.003278 BC055753 SESTRIN 1 -3.88472 0.001999 BC004724 FIBRONECTIN 1 -3.88044 0.000182 NM_010422 HEXOSAMINIDASE B -3.8677 0.001562 NM_011055 PHOSPHODIESTERASE 3B, CGMP-INHIBITED -3.86056 0.000178 BC025535 FC RECEPTOR, IGG, HIGH AFFINITY I -3.85636 0.003171 AY392765 LEUKOCYTE-ASSOCIATED IG-LIKE RECEPTOR 1 -3.85634 0.005862 NM_025961 GLYCINE AMIDINOTRANSFERASE (L-ARGININE:GLYCINE -3.84622 0.001201 AMIDINOTRANSFERASE) NM_177715 EXPRESSED SEQUENCE AW538430 -3.84566 0.000531 BC051976 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, O -3.84196 0.00074 FASCICULATION AND ELONGATION PROTEIN ZETA 2 (ZYGIN NM_199448 II) -3.82086 0.000188 NM_031195 MACROPHAGE SCAVENGER RECEPTOR 1 -3.80244 0.000273 NM_007807 CYTOCHROME B-245, BETA POLYPEPTIDE -3.78824 0.001343 M65027 GLYCOPROTEIN 49 A -3.78426 0.000513 NM_010421 HEXOSAMINIDASE A -3.77754 0.001938 NM_011175 LEGUMAIN -3.7472 0.000771 NM_011693 VASCULAR CELL ADHESION MOLECULE 1 -3.74268 0.003425 NM_007406 ADENYLATE CYCLASE 7 -3.7408 0.000139 NM_010368 BETA-GLUCURONIDASE STRUCTURAL -3.7372 0.000376 NM_133792 LYSOPHOSPHOLIPASE 3 -3.73584 0.003541 AY392766 LEUKOCYTE-ASSOCIATED IG-LIKE RECEPTOR 1 -3.72844 0.006978 AF135166 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, O -3.72086 0.001921 NM_009155 SELENOPROTEIN P, PLASMA, 1 -3.71102 0.0016 NM_021476 CYSTEINYL RECEPTOR 1 -3.71014 0.001904 NM_010233 FIBRONECTIN 1 -3.70932 0.000519 BC025521 FIBRONECTIN 1 -3.70726 0.000336 AK011113 PLEXIN C1 -3.70392 0.000479 SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT NM_013612 METAL ION TRANSPORTERS), MEMBER 1 -3.68992 0.001557 ATP-BINDING CASSETTE, SUB-FAMILY C (CFTR/MRP), AK006128 MEMBER 3 -3.6877 0.001719 NM_021334 INTEGRIN ALPHA X -3.68648 0.002032 AY155439 RING FINGER PROTEIN 149 -3.67818 0.000439 BC063258 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, O -3.67758 0.001221 BC021937 ALDO-KETO REDUCTASE FAMILY 1, MEMBER C12 -3.675 0.001332 NM_008175 GRANULIN -3.66208 9.53E-05 NM_183031 EPSTEIN-BARR VIRUS INDUCED GENE 2 -3.65542 0.000382 AK043664 LEUKOCYTE-ASSOCIATED IG-LIKE RECEPTOR 1 -3.65306 0.008084 BC003782 PHOSPHOLIPID TRANSFER PROTEIN -3.64044 0.000477 AK122312 ZINC FINGER HOMEOBOX 1B -3.62944 0.001025 BC018363 SERUM/GLUCOCORTICOID REGULATED KINASE 3 -3.62738 0.000616 NM_013454 ATP-BINDING CASSETTE, SUB-FAMILY A (ABC1), MEMBER 1 -3.61892 0.002213 NM_138672 STABILIN 1 -3.61268 0.002108 AF440787 INTERLEUKIN 10 RECEPTOR, BETA -3.6007 0.000293 AK036697 C-TYPE LECTIN DOMAIN FAMILY 5, MEMBER A -3.59832 0.003029 NM_146037 POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 13 -3.59828 0.000131 U37465 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, O -3.5974 0.001414 AB109560 TRANSMEMBRANE 7 SUPERFAMILY MEMBER 4 -3.59264 0.003174 NM_145133 TRAF2 BINDING PROTEIN -3.58976 0.000766 AK083832 I -3.58856 0.000648 AK018744 GRANULIN -3.5858 0.000247 NM_008147 GLYCOPROTEIN 49 A -3.58546 0.000393 NM_030707 MACROPHAGE SCAVENGER RECEPTOR 2 -3.585 0.006898 AK129416 CERAMIDE KINASE -3.58188 0.001263 X14951 INTEGRIN BETA 2 -3.5817 0.000956 NM_026436 TRANSMEMBRANE PROTEIN 86A -3.56978 0.000736 HEPATOMA-DERIVED GROWTH FACTOR, RELATED PROTEIN AK045542 3 -3.56716 0.001002 NM_023044 SOLUTE CARRIER FAMILY 15, MEMBER 3 -3.56158 0.002503 BC043054 COLONY STIMULATING FACTOR 1 RECEPTOR -3.55078 0.010011 PHOSPHOINOSITIDE-3-KINASE, CATALYTIC, GAMMA NM_020272 POLYPEPTIDE -3.54562 0.001295 S70805 ACID PHOSPHATASE 5, TARTRATE RESISTANT -3.54076 2.65E-05 MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, NM_026835 MEMBER 6D -3.5323 0.002181 NM_028808 PURINERGIC RECEPTOR P2Y, G-PROTEIN COUPLED 13 -3.53072 0.006662 BC031166 STABILIN 1 -3.52896 0.002313 NM_178881 -3.51796 0.000948 NM_145475 CERAMIDE KINASE -3.5166 0.00188 NM_010864 MYOSIN VA -3.51434 0.001617 NM_008533 CD180 ANTIGEN -3.50518 0.000596 NM_008625 MANNOSE RECEPTOR, C TYPE 1 -3.50458 0.000928 NM_133969 KALLIKREIN B, PLASMA 1 -3.502 0.001023 NM_015753 ZINC FINGER HOMEOBOX 1B -3.49978 0.00107 BC048553 ACID PHOSPHATASE 1, SOLUBLE -3.4997 0.001394 BC019611 LYSOZYME -3.49382 0.002176 NM_031198 TRANSCRIPTION FACTOR EC -3.48924 0.001054 NM_017372 LYSOZYME -3.48752 0.002744 LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY NM_013532 B, MEMBER 4 -3.48342 0.000844 AK081134 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 -3.47876 0.001548 NM_008512 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 -3.47534 0.002824 SOLUTE CARRIER FAMILY 39 (IRON-REGULATED NM_016917 TRANSPORTER), MEMBER 1 -3.46748 0.000694 BC058230 AXL RECEPTOR TYROSINE KINASE -3.4669 0.001191 AK020363 C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER A2 -3.4607 0.00315 AF307855 ARP3 ACTIN-RELATED PROTEIN 3 HOMOLOG (YEAST) -3.45678 0.001578 MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, AK046559 MEMBER 7 -3.44228 0.000266 L10627 BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE -3.44104 0.000475 BC043675 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 -3.43688 0.001905 NM_023149 CNDP 2 (METALLOPEPTIDASE M20 FAMILY) -3.42766 0.000748 AK078473 TRANSMEMBRANE PROTEIN 119 -3.4257 0.00075 AK084431 TRANSFORMING GROWTH FACTOR, BETA INDUCED -3.42542 0.002895 BC038070 FC RECEPTOR, IGG, LOW AFFINITY IIB -3.4225 0.001164 BC054112 RIKEN CDNA 5033414K04 GENE -3.42118 0.000256 AK017885 RAS HOMOLOG GENE FAMILY, MEMBER H -3.41664 0.00126 NM_172589 LIPOMA HMGIC FUSION PARTNER-LIKE 2 -3.41254 0.001044 AK079513 CD86 ANTIGEN -3.41072 0.002848 AK075888 CD83 ANTIGEN -3.4065 0.007132 AK129206 REGULATING SYNAPTIC MEMBRANE EXOCYTOSIS 2 -3.4003 0.000366 NM_133211 TOLL-LIKE RECEPTOR 7 -3.39602 0.000243 NM_008348 INTERLEUKIN 10 RECEPTOR, ALPHA -3.3939 0.005644 AK122347 RIKEN CDNA 9330153B10 GENE -3.3901 0.004106 SOLUTE CARRIER FAMILY 39 (IRON-REGULATED AK032732 TRANSPORTER), MEMBER 1 -3.38636 0.000448 NM_053214 MYOSIN IF -3.38092 0.002161 NM_009912 CHEMOKINE (C-C MOTIF) RECEPTOR 1 -3.3784 0.001216 NM_028773 RIKEN CDNA 1200013B08 GENE -3.37762 0.003342 AF323659 ATP-BINDING CASSETTE, SUB-FAMILY G (WHITE), MEMBER 1 -3.3741 9.42E-06 NM_027552 KYNURENINASE (L-KYNURENINE ) -3.37306 0.000103 NM_031159 APOLIPOPROTEIN B EDITING COMPLEX 1 -3.37282 0.002589 AK088398 -3.36558 0.000688 NM_008349 INTERLEUKIN 10 RECEPTOR, BETA -3.3631 0.000313 AK080845 ZINC FINGER, DHHC DOMAIN CONTAINING 14 -3.35494 0.000513 UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE S64760 A1 -3.34982 0.000142 NM_019455 PROSTAGLANDIN D2 SYNTHASE 2, HEMATOPOIETIC -3.3486 0.003115 NM_153505 NCK ASSOCIATED PROTEIN 1 LIKE -3.343 0.000395 NM_207246 RAS, GUANYL RELEASING PROTEIN 3 -3.33858 0.000599 AK028367 LEUCINE RICH REPEAT CONTAINING 33 -3.3374 0.001116 NM_178911 PHOSPHOLIPASE D FAMILY, MEMBER 4 -3.33712 0.003776 NM_00100394 8 RIKEN CDNA 5033414K04 GENE -3.33228 0.000911 AK077019 NCK ASSOCIATED PROTEIN 1 LIKE -3.32772 0.000318 NM_008327 INTERFERON ACTIVATED GENE 202 -3.32556 0.00062 SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, AK033539 MEMBER 2B1 -3.31752 0.001284 NM_011701 VIMENTIN -3.3154 7.46E-05 NM_031843 DIPEPTIDYLPEPTIDASE 7 -3.31358 0.001578 NM_020001 C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER N -3.31322 0.002712 AK129262 FERM DOMAIN CONTAINING 4B -3.30788 0.002942 AK017351 RIKEN CDNA 5430427O19 GENE -3.30518 0.002786 NM_009631 ADENOSINE A3 RECEPTOR -3.3048 0.000272 NM_023132 RENIN BINDING PROTEIN -3.30474 4.1E-05 SOLUTE CARRIER FAMILY 39 (IRON-REGULATED AK083288 TRANSPORTER), MEMBER 1 -3.3041 0.000784 NM_146069 LEUCINE RICH REPEAT CONTAINING 33 -3.30236 0.000664 PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, FAMILY O AK014374 MEMBER 1 -3.30072 0.003467 NM_011426 SIALIC ACID BINDING IG-LIKE LECTIN 1, SIALOADHESIN -3.29544 0.000468 AK042502 LEUCINE RICH REPEAT CONTAINING 33 -3.29524 0.000284 BC065783 LYMPHOCYTE ANTIGEN 86 -3.29472 0.00238 SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID NM_011405 TRANSPORTER, Y+ SYSTEM), MEMBER 7 -3.29236 0.000517 BC053392 BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE -3.28982 0.000316 BC019400 SYNDECAN BINDING PROTEIN -3.2886 0.00042 AK028480 MACROPHAGE SCAVENGER RECEPTOR 1 -3.28148 0.000322 NM_008511 LYMPHOID-RESTRICTED MEMBRANE PROTEIN -3.2814 0.00451 NM_010188 FC RECEPTOR, IGG, LOW AFFINITY III -3.28106 0.00308 M34897 ECOTROPIC VIRAL INTEGRATION SITE 2A -3.2782 0.000408 NM_134152 LEUPAXIN -3.2656 0.003645 WISKOTT-ALDRICH SYNDROME PROTEIN INTERACTING NM_153138 PROTEIN -3.2619 9.21E-06 SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, BC049251 MEMBER 2B1 -3.25744 0.001568 BC034893 C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER A3 -3.25704 0.002959 BC059047 GLUCOSAMINE (N-ACETYL)-6-SULFATASE -3.24632 0.001432 AK080884 G PROTEIN-COUPLED RECEPTOR 137B -3.2394 0.001928 AJ131395 PROCOLLAGEN, TYPE XIV, ALPHA 1 -3.23872 0.000324 NM_022964 LINKER FOR ACTIVATION OF T CELLS FAMILY, MEMBER 2 -3.23528 0.001622 NM_183168 PYRIMIDINERGIC RECEPTOR P2Y, G-PROTEIN COUPLED, 6 -3.23492 0.002909 BC044664 EXPRESSED SEQUENCE AI118514 -3.23482 0.000455 AK089998 PROSAPOSIN -3.2345 0.000822 AK089998 PROSAPOSIN -3.2345 0.000822 NM_026887 RIKEN CDNA 1500012A13 GENE -3.23386 0.002107 NM_019734 N-ACYLSPHINGOSINE AMIDOHYDROLASE 1 -3.23308 0.001089 PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE 4- DIOXYGENASE (PROLINE 4-HYDROXYLASE), ALPHA 1 NM_011030 POLYPEPTIDE -3.22344 0.001997 SQUAMOUS CELL CARCINOMA ANTIGEN RECOGNIZED BY T NM_172508 CELLS 2 -3.21822 0.000142 NM_181348 -3.2061 1.4E-05 UDP-GAL:BETAGLCNAC BETA 1,3-GALACTOSYLTRANSFERASE, NM_020026 POLYPEPTIDE 3 -3.20522 0.001635 NM_009924 CANNABINOID RECEPTOR 2 (MACROPHAGE) -3.20308 0.001111 RECOMBINING BINDING PROTEIN SUPPRESSOR OF HAIRLESS NM_009035 (DROSOPHILA) -3.203 0.000168 NM_008906 PROTECTIVE PROTEIN FOR BETA-GALACTOSIDASE -3.20268 0.000494 NM_145148 FERM DOMAIN CONTAINING 4B -3.2024 0.003164 NM_178611 LEUKOCYTE-ASSOCIATED IG-LIKE RECEPTOR 1 -3.19912 0.001843 AK050129 EXPRESSED SEQUENCE AI788969 -3.19894 0.000671 NM_009099 TRIPARTITE MOTIF PROTEIN 30 -3.19616 0.001084 NM_173014 ACYLTRANSFERASE LIKE 1 -3.1945 0.001385 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, AK004668 MEMBER 13B -3.1898 0.003865 NM_008885 PERIPHERAL MYELIN PROTEIN -3.18518 0.000123 BC025587 UNC-93 HOMOLOG B1 (C. ELEGANS) -3.18324 0.005178 ATP-BINDING CASSETTE, SUB-FAMILY B (MDR/TAP), NM_011075 MEMBER 1B -3.182 0.001077 NM_175437 RIKEN CDNA A530088I07 GENE -3.17324 0.001854 UDP-GAL:BETAGLCNAC BETA 1,3-GALACTOSYLTRANSFERASE, AK003837 POLYPEPTIDE 3 -3.16558 0.001935 NM_010876 NEUTROPHIL CYTOSOLIC FACTOR 1 -3.16304 0.002299 ATP-BINDING CASSETTE TRANSPORTER SUB-FAMILY A AK029256 MEMBER 9 -3.1575 0.004345 NM_026405 RAB32, MEMBER RAS ONCOGENE FAMILY -3.1548 0.000931 AK021181 MYOSIN IF -3.15442 0.002988 NM_029364 GLUCOSAMINE (N-ACETYL)-6-SULFATASE -3.15242 0.001589 AB041594 RIKEN CDNA 6330407G11 GENE -3.15088 0.000266 BC057650 MYOCYTE ENHANCER FACTOR 2C -3.14562 4.55E-05 NM_010745 LYMPHOCYTE ANTIGEN 86 -3.14552 0.003004 BC067006 MYOD FAMILY INHIBITOR DOMAIN CONTAINING -3.14516 0.001964 NM_009779 COMPLEMENT COMPONENT 3A RECEPTOR 1 -3.14432 0.000501 NM_013590 P LYSOZYME STRUCTURAL -3.14268 0.003778 BC029876 NEUROPILIN 2 -3.14116 9.47E-05 NM_175088 MYOD FAMILY INHIBITOR DOMAIN CONTAINING -3.14026 0.001634 SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN NM_177909 EXCHANGER), ISOFORM 9 -3.1399 0.001167 NM_008320 INTERFERON REGULATORY FACTOR 8 -3.13598 0.0044 NM_008360 INTERLEUKIN 18 -3.1355 0.000452 AK031491 FERM DOMAIN CONTAINING 4B -3.13076 0.003542 NM_177745 -3.12784 0.000655 BC021637 CD68 ANTIGEN -3.11896 0.000501 NM_008245 HEMATOPOIETICALLY EXPRESSED HOMEOBOX -3.11886 0.000222 AF061744 FYN BINDING PROTEIN -3.11262 0.001685 AK032609 HYPOTHETICAL PROTEIN 6430704N06 -3.11102 0.000333 NM_009848 ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1 -3.10538 0.002543 NM_027923 RIKEN CDNA 1110007C02 GENE -3.1033 0.002062 AK046286 CDNA SEQUENCE AF529169 -3.103 0.000946 NM_198895 ACTIVE BCR-RELATED GENE -3.1003 0.002564 NM_007645 CD37 ANTIGEN -3.09696 0.002474 A DISINTEGRIN AND METALLOPEPTIDASE DOMAIN 9 NM_007404 (MELTRIN GAMMA) -3.09304 0.000431 AF184912 INOSITOL POLYPHOSPHATE-5-PHOSPHATASE D -3.08686 0.002435 PHOSPHOINOSITIDE-3-KINASE, CATALYTIC, GAMMA AK077772 POLYPEPTIDE -3.0851 0.000735 AK007777 PHOSPHOINOSITIDE-3-KINASE ADAPTOR PROTEIN 1 -3.08214 0.001249 NM_011905 TOLL-LIKE RECEPTOR 2 -3.08188 0.00641 NM_00100436 3 ZNUAK FAMILY, SNF1-LIKE KINASE, 1 -3.0779 0.002211 AMYLOID BETA (A4) PRECURSOR PROTEIN-BINDING, FAMILY AF020313 B, MEMBER 1 INTERACTING PROTEIN -3.07166 0.001147 AK036167 SRC-LIKE ADAPTOR -3.0712 0.002973 NM_030682 TOLL-LIKE RECEPTOR 1 -3.07096 0.008829 NM_023423 RIKEN CDNA 6330407G11 GENE -3.06876 0.000301 A DISINTEGRIN AND METALLOPEPTIDASE DOMAIN 9 AK122188 (MELTRIN GAMMA) -3.06614 0.000365 AF542387 ZINC FINGER, DHHC DOMAIN CONTAINING 14 -3.06346 0.00158 BC031369 FERM DOMAIN CONTAINING 4B -3.05688 0.002833 NM_010902 NUCLEAR FACTOR, ERYTHROID DERIVED 2, LIKE 2 -3.05668 0.000281 NM_010330 EMBIGIN -3.05394 0.000322 BC048682 DYSTROBREVIN BINDING PROTEIN 1 -3.04724 0.00044 NM_025772 DYSTROBREVIN BINDING PROTEIN 1 -3.04612 0.000358 HYPOXANTHINE GUANINE PHOSPHORIBOSYL AY423851 1 -3.04462 0.000366 NM_028035 SORTING NEXIN 10 -3.04252 0.000273 NM_024465 RIKEN CDNA 6330583M11 GENE -3.04162 0.001514 NM_010566 INOSITOL POLYPHOSPHATE-5-PHOSPHATASE D -3.04126 0.004583 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE BC025886 SUBSTRATE 1 -3.03854 0.003289 NM_021281 CATHEPSIN S -3.03694 0.001774 NM_008509 LIPOPROTEIN LIPASE -3.0347 0.003171 AF043256 INTEGRIN BETA 5 -3.03442 0.004449 AK028366 CATHEPSIN S -3.03272 0.001934 N-ACYLSPHINGOSINE AMIDOHYDROLASE (ACID NM_025972 CERAMIDASE)-LIKE -3.03262 0.005978 NM_008587 C-MER PROTO-ONCOGENE TYROSINE KINASE -3.0267 0.004948 BC040467 ZNUAK FAMILY, SNF1-LIKE KINASE, 1 -3.02232 0.004301 AJ002386 CATHEPSIN S -3.01904 0.001581 NM_009139 CHEMOKINE (C-C MOTIF) LIGAND 6 -3.01752 0.006528 AY157834 INTERLEUKIN 18 -3.00244 0.00032 BC022136 STABILIN 1 -2.99974 0.000769 SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, NM_175316 MEMBER 2B1 -2.99644 0.001158 NM_026386 SORTING NEXIN 2 -2.99638 0.001327 BC057864 CD300 ANTIGEN LIKE FAMILY MEMBER F -2.99448 0.00103 NM_198018 ACTIVE BCR-RELATED GENE -2.99138 0.002785 BC002138 RIKEN CDNA 6330583M11 GENE -2.98972 0.00097 NM_022321 PARVIN, GAMMA -2.98738 0.000709 NM_145976 CDNA SEQUENCE BC027057 -2.98514 0.003315 AK041479 RIKEN CDNA A430107D22 GENE -2.98394 0.001353 NM_009673 ANNEXIN A5 -2.98392 0.000536 AB011812 PROTEIN KINASE C, DELTA -2.97898 0.005979 BC059064 ACTIVE BCR-RELATED GENE -2.97474 0.003114 NM_173394 TOLL-LIKE RECEPTOR ADAPTOR MOLECULE 2 -2.97298 0.000143 NM_008292 HYDROXYSTEROID (17-BETA) DEHYDROGENASE 4 -2.97242 0.001045 X05837 HEAT SHOCK PROTEIN 8 -2.9716 0.000202 NM_016797 SYNTAXIN 7 -2.97114 0.0007 NM_008737 NEUROPILIN 1 -2.9706 0.001189 NM_012057 INTERFERON REGULATORY FACTOR 5 -2.97024 0.008675 BC043066 RAS RELATED PROTEIN 2A -2.9606 0.000985 BC026506 MICRORCHIDIA 3 -2.95826 0.002106 BC055044 ERYTHROCYTE PROTEIN BAND 4.1-LIKE 2 -2.95348 0.000978 AK011423 GLUCOSAMINE (N-ACETYL)-6-SULFATASE -2.94334 0.001482 PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE, TYPE II, NM_008845 ALPHA -2.9405 0.001979 NM_177337 ADP-RIBOSYLATION FACTOR-LIKE 11 -2.93716 0.000547 BC026585 CDNA SEQUENCE BC026585 -2.93544 0.001232 NM_198894 ACTIVE BCR-RELATED GENE -2.927 0.002602 AK129429 HYPOTHETICAL PROTEIN LOC243772 -2.92134 0.000782 NM_010511 INTERFERON GAMMA RECEPTOR 1 -2.9166 0.003114 COMPLEMENT COMPONENT 1, Q SUBCOMPONENT, NM_010740 RECEPTOR 1 -2.91106 0.002236 NM_144846 RIKEN CDNA 0910001A06 GENE -2.90944 0.000784 NM_007644 SCAVENGER RECEPTOR CLASS B, MEMBER 2 -2.90886 0.001675 AK129090 ER DEGRADATION ENHANCER, MANNOSIDASE ALPHA-LIKE 1 -2.9012 0.001189 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AY243585 GAMMA -2.901 0.000461 NM_177305 ADP-RIBOSYLATION FACTOR-LIKE 4C -2.89934 0.001804 NM_009145 STROMAL CELL DERIVED FACTOR RECEPTOR 1 -2.89882 0.002271 X05837 HEAT SHOCK PROTEIN 8 -2.89722 0.000226 BC057300 RAS P21 PROTEIN ACTIVATOR 3 -2.89338 0.002327 X05837 HEAT SHOCK PROTEIN 8 -2.89196 0.000246 BC057027 TBC1 DOMAIN FAMILY, MEMBER 9 -2.88796 0.000318 NM_133648 SOLUTE CARRIER FAMILY 12, MEMBER 6 -2.88434 0.003157 NM_026640 RIKEN CDNA 4632417K18 GENE -2.8838 0.000408 NM_027758 TBC1 DOMAIN FAMILY, MEMBER 9 -2.87694 0.000434 NM_177000 RIKEN CDNA C130050O18 GENE -2.87668 0.000933 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR U01841 GAMMA -2.87442 0.000487 NM_022011 GENERAL TRANSCRIPTION FACTOR II H, POLYPEPTIDE 2 -2.86808 0.001368 X95521 PHOSPHODIESTERASE 3B, CGMP-INHIBITED -2.86748 0.001839 NM_028608 GLI PATHOGENESIS-RELATED 1 (GLIOMA) -2.86468 0.002891 NM_009025 RAS P21 PROTEIN ACTIVATOR 3 -2.86156 0.003406 BC005417 RAS-RELATED GTP BINDING C -2.86058 0.001682 NM_133649 SOLUTE CARRIER FAMILY 12, MEMBER 6 -2.85324 0.004965 NM_007535 B-CELL LEUKEMIA/LYMPHOMA 2 RELATED PROTEIN A1C -2.84998 0.004168 PROTEIN KINASE, CAMP DEPENDENT REGULATORY, TYPE I NM_008923 BETA -2.84938 0.001139 AK030757 ERYTHROCYTE PROTEIN BAND 4.1-LIKE 2 -2.84524 0.000633 AK086714 RIKEN CDNA 2310079N02 GENE -2.83922 0.00054 NM_00100550 8 RHO GTPASE ACTIVATING PROTEIN 30 -2.83604 0.004302 M92933 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, C -2.83592 0.00095 NM_028712 RAP2B, MEMBER OF RAS ONCOGENE FAMILY -2.8316 2E-05 S70108 CD86 ANTIGEN -2.8283 0.002666 NM_030710 SLAM FAMILY MEMBER 6 -2.82824 0.003082 NM_00100586 0 DENDRITIC CELL INHIBITORY RECEPTOR 2 -2.81858 0.003541 NM_007798 CATHEPSIN B -2.81422 0.001371 NM_010442 HEME OXYGENASE (DECYCLING) 1 -2.8132 0.00263 NM_172603 PHD FINGER PROTEIN 11 -2.81148 0.0085 NM_021507 SULFIDE QUINONE REDUCTASE-LIKE (YEAST) -2.8065 0.006177 BC025502 RIKEN CDNA 0610025G21 GENE -2.80552 0.004633 AK029009 C-MER PROTO-ONCOGENE TYROSINE KINASE -2.80214 0.003264 AK029512 ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1 -2.79634 0.007045 NM_029519 RAS RELATED PROTEIN 2A -2.7914 0.000581 BC031984 HISTOCOMPATIBILITY 2, M REGION 3 -2.7895 0.003 PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) NM_177741 SUBUNIT 3B -2.78542 0.000388 BC037732 RAS-RELATED GTP BINDING C -2.78232 0.001696 ATPASE, H+ TRANSPORTING, LYSOSOMAL (VACUOLAR U13839 PROTON PUMP) 42KD -2.78008 0.00072 NM_175116 PURINERGIC RECEPTOR P2Y, G-PROTEIN COUPLED, 5 -2.77512 0.00053 AK028875 CHEMOKINE (C-X-C MOTIF) LIGAND 16 -2.76806 0.001104 AK052299 STEROL O-ACYLTRANSFERASE 1 -2.76732 4.99E-05 BC006737 CASPASE 8 -2.76634 0.000363 BC021472 INTERLEUKIN 13 RECEPTOR, ALPHA 1 -2.763 0.001045 NM_133685 RIKEN CDNA 1700093E07 GENE -2.76204 0.001921 NM_007534 B-CELL LEUKEMIA/LYMPHOMA 2 RELATED PROTEIN A1A -2.76106 0.001301 NM_007534 B-CELL LEUKEMIA/LYMPHOMA 2 RELATED PROTEIN A1A -2.75728 0.0016 NM_007534 B-CELL LEUKEMIA/LYMPHOMA 2 RELATED PROTEIN A1B -2.75728 0.0016 ATPASE, H+ TRANSPORTING, LYSOSOMAL (VACUOLAR AY033882 PROTON PUMP), SUBUNIT 1 -2.75304 0.001156 U55060 LECTIN, GALACTOSE BINDING, SOLUBLE 9 -2.74844 0.000955 BC026382 G PROTEIN-COUPLED RECEPTOR 155 -2.7483 0.002539 NM_011673 UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE -2.73874 0.000149 NM_019821 GLYCOLIPID TRANSFER PROTEIN -2.73858 0.001079 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, NM_011706 SUBFAMILY V, MEMBER 2 -2.73562 0.004535 NM_028732 RIKEN CDNA 4632428N05 GENE -2.72854 0.004695 CYTOPLASMIC TYROSINE KINASE, DSCR28C RELATED NM_013689 (DROSOPHILA) -2.72848 0.002344 BC049097 LYSOSOMAL MEMBRANE GLYCOPROTEIN 1 -2.72398 0.002478 NM_008720 NIEMANN PICK TYPE C1 -2.71978 0.002625 AK079252 C-MER PROTO-ONCOGENE TYROSINE KINASE -2.71596 0.00184 AK087960 PROTEOGLYCAN 1, SECRETORY GRANULE -2.71394 0.000936 NM_153510 EXPRESSED SEQUENCE AV021745 -2.71114 0.010139 AK028625 ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1 -2.70922 0.002705 YAMAGUCHI SARCOMA VIRAL (V-YES-1) ONCOGENE NM_010747 HOMOLOG -2.70642 0.001419 NM_144830 TRANSMEMBRANE PROTEIN 106A -2.70242 0.001487 NM_007535 B-CELL LEUKEMIA/LYMPHOMA 2 RELATED PROTEIN A1C -2.6973 0.007095 AK051270 RIKEN CDNA 1700093E07 GENE -2.6939 0.002739 PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) BC060261 SUBUNIT 3B -2.69378 0.000518 NM_133721 RIKEN CDNA 2610002H11 GENE -2.69106 0.000449 NM_010129 EPITHELIAL MEMBRANE PROTEIN 3 -2.69096 0.000371 NM_134131 TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 8 -2.69072 0.0014 NM_145158 ELASTIN MICROFIBRIL INTERFACER 2 -2.68654 0.007068 NM_009163 SPHINGOSINE PHOSPHATE LYASE 1 -2.68646 7.02E-05 NM_022320 G PROTEIN-COUPLED RECEPTOR 35 -2.68402 0.001853 NM_198617 TSPY-LIKE 3 -2.6835 0.00079 NM_008505 LIM DOMAIN ONLY 2 -2.68336 0.001613 HYPOXANTHINE GUANINE PHOSPHORIBOSYL TRANSFERASE NM_013556 1 -2.68098 0.000454 AK036232 DNA SEGMENT, CHR 12, ERATO DOI 553, EXPRESSED -2.67846 0.002168 AK007716 ALDO-KETO REDUCTASE FAMILY 1, MEMBER C12 -2.67704 0.001528 NM_007486 RHO, GDP DISSOCIATION INHIBITOR (GDI) BETA -2.67698 0.003685 AK083987 RIKEN CDNA 2610002H11 GENE -2.67666 0.000335 NM_00100149 1 TROPOMYOSIN 4 -2.6729 0.000119 NM_023735 ARP3 ACTIN-RELATED PROTEIN 3 HOMOLOG (YEAST) -2.67098 0.000257 BC036146 TISSUE FACTOR PATHWAY INHIBITOR -2.65906 0.000882 RECOMBINING BINDING PROTEIN SUPPRESSOR OF HAIRLESS BC051387 (DROSOPHILA) -2.65464 4.14E-05 AK044121 CD34 ANTIGEN -2.65294 0.005091 NM_007388 ACID PHOSPHATASE 5, TARTRATE RESISTANT -2.64776 0.000247 NM_008225 HEMATOPOIETIC CELL SPECIFIC LYN SUBSTRATE 1 -2.64734 0.003726 BC019682 CATHEPSIN D -2.64676 0.001379 NM_008035 FOLATE RECEPTOR 2 (FETAL) -2.6458 0.003514 BC066212 LYMPHOCYTE ANTIGEN 9 -2.64232 0.004466 AK008543 ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 4 -2.64218 0.001117 NM_009790 CALMODULIN 1 -2.64082 0.001741 NM_011303 DEHYDROGENASE/REDUCTASE (SDR FAMILY) MEMBER 3 -2.63944 1.44E-05 NM_011338 CHEMOKINE (C-C MOTIF) LIGAND 9 -2.63446 0.000983 AK087634 STABILIN 1 -2.63382 0.001815 AJ222814 B-CELL LINKER -2.63078 0.001093 NM_134250 HEPATITIS A VIRUS CELLULAR RECEPTOR 2 -2.62862 0.001866 NM_010242 FUCOSYLTRANSFERASE 4 -2.62842 5.8E-05 NM_011303 DEHYDROGENASE/REDUCTASE (SDR FAMILY) MEMBER 3 -2.62596 6.69E-05 BC054824 SIGNAL-INDUCED PROLIFERATION ASSOCIATED GENE 1 -2.62098 0.003622 NM_028836 CHITOBIASE, DI-N-ACETYL- -2.61974 0.001356 NM_013837 PROTEIN-TYROSINE SULFOTRANSFERASE 1 -2.61746 0.000712 U20314 HISTOCOMPATIBILITY 2, CLASS II, LOCUS MB1 -2.6139 0.007119 AF114437 PHOSPHATIDYLCHOLINE TRANSFER PROTEIN -2.61318 0.000184 AF114437 PHOSPHATIDYLCHOLINE TRANSFER PROTEIN -2.61318 0.000184 AF146516 PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL 4 -2.60952 0.007675 BC049939 RIKEN CDNA 2610002H11 GENE -2.6068 0.000207 M29009 COMPLEMENT COMPONENT FACTOR H -2.60258 0.004108 AK088815 LYMPHOCYTE ANTIGEN 9 -2.60246 0.00402 V-RAL SIMIAN LEUKEMIA VIRAL ONCOGENE HOMOLOG A NM_019491 (RAS RELATED) -2.60008 0.000508 NM_133825 DNA SEGMENT, CHR 1, ERATO DOI 622, EXPRESSED -2.59382 0.001116 ENDOTHELIAL DIFFERENTIATION SPHINGOLIPID G-PROTEIN- NM_007901 COUPLED RECEPTOR 1 -2.5907 0.002032 NM_028243 RIKEN CDNA 2610104A14 GENE -2.58916 0.000637 AF251704 CD300A ANTIGEN -2.58874 0.00556 PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, ALPHA BC019368 TYPE, 8 -2.5862 0.000237 NM_007853 DEGENERATIVE SPERMATOCYTE HOMOLOG 1 (DROSOPHILA) -2.5837 0.000222 BC028755 PROTEIN C RECEPTOR, ENDOTHELIAL -2.5762 0.000833 NM_022325 CATHEPSIN Z -2.57568 0.000652 BC023348 COPINE II -2.57428 0.002543 SOLUTE CARRIER FAMILY 4, SODIUM BICARBONATE AK088400 COTRANSPORTER, MEMBER 7 -2.57134 0.001087 BC047135 CYTOPLASMIC FMR1 INTERACTING PROTEIN 1 -2.57128 0.002711 AK036591 RING FINGER PROTEIN 13 -2.57124 0.001379 NM_145541 RAS-RELATED PROTEIN-1A -2.56916 0.000156 BC004852 RIKEN CDNA 1700093E07 GENE -2.56882 0.004841 BC052529 IBR DOMAIN CONTAINING 3 -2.56608 0.006028 NM_008133 GLUTAMATE DEHYDROGENASE 1 -2.55912 0.001705 NM_027100 RWD DOMAIN CONTAINING 2 -2.55524 0.001186 NM_009658 ALDO-KETO REDUCTASE FAMILY 1, MEMBER B3 (ALDOSE -2.55124 0.003177 REDUCTASE) AK006330 G PROTEIN-COUPLED RECEPTOR 160 -2.55028 0.000297 NM_181277 PROCOLLAGEN, TYPE XIV, ALPHA 1 -2.54878 0.000357 AK008904 RIKEN CDNA 1110002B05 GENE -2.54676 0.000514 BC006865 PROTEIN DISULFIDE ASSOCIATED 6 -2.54114 0.000417 CYTOPLASMIC TYROSINE KINASE, DSCR28C RELATED S53716 (DROSOPHILA) -2.54084 0.003787 NM_008131 GLUTAMATE-AMMONIA LIGASE (GLUTAMINE SYNTHETASE) -2.54024 2.06E-07 NM_022018 NIBAN PROTEIN -2.53896 0.004625 SOLUTE CARRIER FAMILY 8 (SODIUM/CALCIUM NM_011406 EXCHANGER), MEMBER 1 -2.53608 8.91E-05 NM_009663 ARACHIDONATE 5-LIPOXYGENASE ACTIVATING PROTEIN -2.53448 0.000625 BC026424 RIKEN CDNA 2610104A14 GENE -2.5313 0.000604 NM_008328 INTERFERON ACTIVATED GENE 203 -2.5297 0.001705 AF490347 DEVELOPMENTAL PLURIPOTENCY-ASSOCIATED 3 -2.52306 0.000147 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22 NM_008979 (LYMPHOID) -2.51898 0.003645 NM_018773 SRC FAMILY ASSOCIATED PHOSPHOPROTEIN 2 -2.51492 0.001529 NM_008917 PALMITOYL-PROTEIN THIOESTERASE 1 -2.5122 0.000983 NM_009794 CALPAIN 2 -2.51172 0.000913 NM_175254 RIKEN CDNA 9330180L21 GENE -2.50476 0.000486 AK129359 CTTNBP2 N-TERMINAL LIKE -2.50426 0.001084 AK053527 HYPOTHETICAL PROTEIN, MNCB-5555 -2.50152 0.000266 NM_172442 DELTEX 4 HOMOLOG (DROSOPHILA) -2.50132 0.00153 NM_144843 MYOTUBULARIN RELATED PROTEIN 6 -2.50066 0.002575 AK040959 RIKEN CDNA 9330153B10 GENE -2.50062 0.003708 AK012103 HYDROXYSTEROID (17-BETA) DEHYDROGENASE 12 -2.50058 6.57E-05 FASCICULATION AND ELONGATION PROTEIN ZETA 2 (ZYGIN BC064130 II) -2.50048 0.000111 NM_181397 RIKEN CDNA 2310015N21 GENE -2.49924 0.00085 NM_008534 LYMPHOCYTE ANTIGEN 9 -2.49798 0.007554 NM_177171 HYPOTHETICAL PROTEIN LOC268546 -2.49676 0.000756 NM_009760 BCL2/ADENOVIRUS E1B INTERACTING PROTEIN 1, NIP3 -2.49102 0.002643 NM_008879 LYMPHOCYTE CYTOSOLIC PROTEIN 1 -2.48712 0.001343 BC006785 LYSOSOMAL MEMBRANE GLYCOPROTEIN 1 -2.48512 0.00067 NM_138677 ER DEGRADATION ENHANCER, MANNOSIDASE ALPHA-LIKE 1 -2.47818 0.00047 AK017908 TORSIN FAMILY 3, MEMBER A -2.47414 0.002091 AK122515 RIKEN CDNA 1110067B02 GENE -2.4729 0.006587 AF434663 IMMUNOGLOBULIN SUPERFAMILY, MEMBER 4A -2.472 0.0002 NM_172537 RIKEN CDNA 1110067B02 GENE -2.47122 0.006608 AF121118 SOLUTE CARRIER FAMILY 12, MEMBER 4 -2.47076 0.003955 NM_008548 MANNOSIDASE 1, ALPHA -2.47024 0.000656 NM_008663 MYOSIN VIIA -2.46864 0.00094 NM_011461 SPI-C TRANSCRIPTION FACTOR (SPI-1/PU.1 RELATED) -2.4671 0.003518 COLONY STIMULATING FACTOR 2 RECEPTOR, BETA 2, LOW- NM_007781 AFFINITY (GRANULOCYTE-MACROPHAGE) -2.46422 0.000991 NM_024454 RAB21, MEMBER RAS ONCOGENE FAMILY -2.4632 0.00048 U89400 ACTIN, BETA, CYTOPLASMIC -2.46224 0.000791 NM_172475 FERM DOMAIN CONTAINING 4A -2.46204 0.002521 NM_027288 RIKEN CDNA 2410030O07 GENE -2.46066 0.000972 AK076519 ADP-RIBOSYLATION FACTOR-LIKE 6 INTERACTING PROTEIN 5 -2.45946 0.010135 BC049626 SYCP3 LIKE Y-LINKED -2.45922 0.001422 NM_008828 PHOSPHOGLYCERATE KINASE 1 -2.45626 9.03E-05 NM_007598 CAP, ADENYLATE CYCLASE-ASSOCIATED PROTEIN 1 (YEAST) -2.4486 0.003417 AK122493 HYPOTHETICAL PROTEIN LOC268546 -2.4478 0.001344 NM_018750 RAS ASSOCIATION (RALGDS/AF-6) DOMAIN FAMILY 5 -2.44334 0.002643 NM_011045 PROLIFERATING CELL NUCLEAR ANTIGEN -2.44064 0.000347 NM_021460 LYSOSOMAL ACID LIPASE 1 -2.43842 0.007394 NM_013610 NINJURIN 1 -2.43678 0.001528 AK076109 BETA-GLUCURONIDASE STRUCTURAL -2.43024 0.001211 BC060718 RIKEN CDNA 2310050N11 GENE -2.42974 0.00235 NM_025813 MAJOR FACILITATOR SUPERFAMILY DOMAIN CONTAINING 1 -2.4287 0.001751 NM_008466 KARYOPHERIN (IMPORTIN) ALPHA 3 -2.42784 0.00046 NM_013820 HEXOKINASE 2 -2.42744 0.001794 BC058236 VACUOLAR PROTEIN SORTING 26 (YEAST) -2.42346 0.00316 BC054521 YEAST SPS1/STE20-RELATED KINASE 3 (S. CEREVISIAE) -2.42168 0.000598 BC058234 NIBAN PROTEIN -2.41992 0.006899 NM_008528 B-CELL LINKER -2.41912 0.002901 BC014802 ADENYLATE KINASE 1 -2.41702 0.001985 NM_011379 SIGNAL-INDUCED PROLIFERATION ASSOCIATED GENE 1 -2.41662 0.005823 AK122406 HUNTINGTIN INTERACTING PROTEIN 14 -2.41586 0.003927 NM_027109 DEOXYRIBONUCLEASE 1-LIKE 1 -2.41244 0.004342 AK088090 CDC42 SMALL EFFECTOR 2 -2.41176 0.000288 U36758 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, E -2.4097 0.000403 NM_021524 PRE-B-CELL COLONY-ENHANCING FACTOR 1 -2.4078 0.001098 NM_009955 DIHYDROPYRIMIDINASE-LIKE 2 -2.40554 0.003243 NM_010304 GUANINE NUCLEOTIDE BINDING PROTEIN, ALPHA 15 -2.40472 0.001933 AK028811 CYTOPLASMIC FMR1 INTERACTING PROTEIN 1 -2.40268 0.000833 AB093292 FERM DOMAIN CONTAINING 4A -2.40206 0.003269 NM_175534 MAS-RELATED GPR, MEMBER E -2.3969 0.000747 BC003786 FC RECEPTOR, IGG, ALPHA CHAIN TRANSPORTER -2.39636 0.00271 NM_011212 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, E -2.3936 0.001592 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE D87968 SUBSTRATE 1 -2.39328 0.000431 BC021393 CUG TRIPLET REPEAT, RNA BINDING PROTEIN 1 -2.38948 0.001134 CAPPING PROTEIN (ACTIN FILAMENT) MUSCLE Z-LINE, NM_007604 ALPHA 2 -2.38816 0.002078 NM_009007 RAS-RELATED C3 BOTULINUM SUBSTRATE 1 -2.38254 0.001401 BC019491 ANGIOPOIETIN-LIKE 3 -2.37852 0.002674 NM_016802 RAS HOMOLOG GENE FAMILY, MEMBER A -2.37312 0.000759 BC043679 SIGNAL-INDUCED PROLIFERATION ASSOCIATED GENE 1 -2.36954 0.002404 SERINE PALMITOYLTRANSFERASE, LONG CHAIN BASE AK080181 SUBUNIT 2 -2.36834 3.22E-05 AK008777 ACTIN RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 2 -2.36768 0.000371 NM_024225 SORTING NEXIN 5 -2.35968 0.000167 NM_013885 CHLORIDE INTRACELLULAR CHANNEL 4 (MITOCHONDRIAL) -2.3512 0.000345 NM_177366 G PROTEIN-COUPLED RECEPTOR 157 -2.3502 0.000243 AK081613 RAS-RELATED C3 BOTULINUM SUBSTRATE 1 -2.34548 0.001501 SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID AK005699 TRANSPORTERS), MEMBER 13 -2.34504 0.000349 M23109 COAGULATION FACTOR IX -2.34194 0.002291 AK029118 RIKEN CDNA B430108F07 GENE -2.33948 1.86E-05 AK088751 RAS ASSOCIATION (RALGDS/AF-6) DOMAIN FAMILY 5 -2.33548 0.004069 AK034298 TRANSMEMBRANE PROTEIN 19 -2.33536 0.000238 BC050110 SPINDLE ASSEMBLY 6 HOMOLOG (C. ELEGANS) -2.33518 8.24E-05 AK010947 CELLULAR REPRESSOR OF E1A-STIMULATED GENES 1 -2.33496 0.006304 AK028096 VACUOLAR PROTEIN SORTING 26 (YEAST) -2.32554 0.003249 NM_009178 ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 4 -2.32186 0.002068 AK085844 CELLULAR REPRESSOR OF E1A-STIMULATED GENES 1 -2.32116 0.006416 BC049105 TRIPARTITE MOTIF-CONTAINING 35 -2.32 0.000279 AK041179 RIKEN CDNA A430107D22 GENE -2.31972 0.003559 NM_018821 SUPPRESSOR OF CYTOKINE SIGNALING 6 -2.3181 0.002 NM_007502 ATPASE, NA+/K+ TRANSPORTING, BETA 3 POLYPEPTIDE -2.3167 0.000178 NM_011604 TOLL-LIKE RECEPTOR 6 -2.31656 0.003942 BC027370 RIKEN CDNA B430108F07 GENE -2.31656 0.000842 BC063265 HYPOTHETICAL PROTEIN LOC268546 -2.31226 0.000449 BC023924 PHYTOCERAMIDASE, ALKALINE -2.31168 0.000208 AK040554 RIKEN CDNA B430108F07 GENE -2.30904 0.000329 NM_133672 VACUOLAR PROTEIN SORTING 26 (YEAST) -2.30258 0.004021 EUKARYOTIC TRANSLATION INITIATION FACTOR 4E MEMBER NM_025829 3 -2.29862 0.004935 NM_027285 RIKEN CDNA 1700029I01 GENE -2.29456 0.004082 BC043324 RIKEN CDNA 2310015N21 GENE -2.2939 9.62E-05 SERINE PALMITOYLTRANSFERASE, LONG CHAIN BASE NM_011479 SUBUNIT 2 -2.28874 2.37E-05 NM_198295 THIOREDOXIN DOMAIN CONTAINING 10 -2.2844 0.000914 TRANSMEMBRANE EMP24-LIKE TRAFFICKING PROTEIN 10 BC006774 (YEAST) -2.28416 0.001081 AK129051 HYPOTHETICAL PROTEIN LOC216023 -2.28018 0.001329 SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID NM_172371 TRANSPORTERS), MEMBER 13 -2.27728 0.000598 AK084199 RIKEN CDNA D230007K08 GENE -2.27436 0.000678 SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE B, NM_023647 MEMBER 9C -2.27238 0.000104 AK014153 ARACHIDONATE 5-LIPOXYGENASE ACTIVATING PROTEIN -2.27226 0.000149 SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE B, BC011415 MEMBER 9C -2.2713 0.001016 NM_007952 PROTEIN DISULFIDE ISOMERASE ASSOCIATED 3 -2.26786 0.00153 BC002000 OPIOID RECEPTOR, SIGMA 1 -2.26732 0.000316 NM_008608 MATRIX METALLOPEPTIDASE 14 (MEMBRANE-INSERTED) -2.26632 0.000523 NM_027935 TRANSMEMBRANE PROTEIN 50A -2.26524 0.004399 BC060143 ACTIN RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 5 -2.26294 0.000259 NM_00100416 N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE, 4 ALPHA AND BETA SUBUNITS -2.25854 0.000789 AK129097 PHD FINGER PROTEIN 15 -2.2579 0.001038 BC019840 FERRITIN LIGHT CHAIN 1 -2.25454 0.003565 TRANSFORMING, ACIDIC COILED-COIL CONTAINING PROTEIN NM_177089 1 -2.25238 0.000756 NM_021876 EMBRYONIC ECTODERM DEVELOPMENT -2.25236 0.003605 TUMOR NECROSIS FACTOR (LIGAND) SUPERFAMILY, AK034121 MEMBER 13B -2.2475 0.000989 NM_022324 STROMAL CELL-DERIVED FACTOR 2-LIKE 1 -2.24724 0.00025 NM_177372 HYPOTHETICAL PROTEIN LOC216023 -2.24488 0.000859 NM_011937 GLUCOSAMINE-6-PHOSPHATE DEAMINASE 1 -2.24226 0.000257 NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC, NM_198429 CALCINEURIN-DEPENDENT 1 -2.24036 0.001618 AY147002 BACULOVIRAL IAP REPEAT-CONTAINING 1B -2.2341 0.004618 NM_030691 IMMUNOGLOBULIN SUPERFAMILY, MEMBER 6 -2.23354 0.005536 NM_009976 CYSTATIN C -2.23302 0.000378 AK077625 GLUCOSAMINE-6-PHOSPHATE DEAMINASE 1 -2.2315 0.00044 BC013468 ARSENIC (+3 OXIDATION STATE) METHYLTRANSFERASE -2.23144 4.71E-05 NM_023141 TORSIN FAMILY 3, MEMBER A -2.23136 0.000262 BC051517 COMM DOMAIN CONTAINING 8 -2.23106 0.000863 NM_010160 CUG TRIPLET REPEAT, RNA BINDING PROTEIN 2 -2.23076 0.000477 NM_134133 RIKEN CDNA 2010002N04 GENE -2.22966 0.002049 NM_176860 RIKEN CDNA 2810457I06 GENE -2.22546 0.001818 NM_181547 NITRIC OXIDE SYNTHASE TRAFFICKER -2.22474 0.003486 AK042426 TRANSMEMBRANE PROTEIN 19 -2.22058 0.000335 NM_012054 ACYLOXYACYL HYDROLASE -2.2168 0.001237 NM_031165 HEAT SHOCK PROTEIN 8 -2.20514 0.000652 BC049262 ATPASE, CA++ TRANSPORTING, PLASMA MEMBRANE 1 -2.2026 0.000933 NM_175382 RIKEN CDNA 2700049P18 GENE -2.19928 0.005401 NM_008875 PHOSPHOLIPASE D1 -2.199 0.005622 AF145374 TRIPARTITE MOTIF-CONTAINING 35 -2.19548 0.000518 NM_007806 CYTOCHROME B-245, ALPHA POLYPEPTIDE -2.19468 7.66E-05 HEAT SHOCK 70KD PROTEIN 5 (GLUCOSE-REGULATED NM_022310 PROTEIN) -2.19386 0.000595 BC019962 ZINC FINGER PROTEIN 275 -2.19028 5.24E-05 NM_00100188 1 RIKEN CDNA 2510009E07 GENE -2.1892 0.001751 BC057606 KELCH-LIKE 5 (DROSOPHILA) -2.18002 0.000735 MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, NM_027209 MEMBER 6B -2.17296 0.002659 NM_011816 RIKEN CDNA E430034L04 GENE -2.1726 0.001732 AF090696 CUG TRIPLET REPEAT, RNA BINDING PROTEIN 2 -2.17206 0.000379 AK052824 TRANSMEMBRANE PROTEIN 77 -2.16548 0.000618 NM_019955 RECEPTOR-INTERACTING SERINE-THREONINE KINASE 3 -2.16398 0.000653 AK034772 NMD3 HOMOLOG (S. CEREVISIAE) -2.15962 0.000421 NM_020577 ARSENIC (+3 OXIDATION STATE) METHYLTRANSFERASE -2.15798 0.000462 M28684 HISTOCOMPATIBILITY 2, D REGION LOCUS 1 -2.15692 0.002778 NM_010240 FERRITIN LIGHT CHAIN 1 -2.15644 0.003404 NM_019553 DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 21 -2.155 0.001928 DNA SEGMENT, CHR 6, WAYNE STATE UNIVERSITY 163, NM_138594 EXPRESSED -2.14912 0.000132 NM_010191 FARNESYL DIPHOSPHATE FARNESYL TRANSFERASE 1 -2.14356 0.001164 NM_026437 RIKEN CDNA 1810055E12 GENE -2.14076 0.001375 BC054791 CARNITINE PALMITOYLTRANSFERASE 1A, LIVER -2.13702 6.29E-05 AF290973 INTERFERON GAMMA INDUCIBLE PROTEIN 30 -2.1363 0.002477 AK028220 CD63 ANTIGEN -2.13592 8.54E-05 M28684 HISTOCOMPATIBILITY 2, Q REGION LOCUS 2 -2.13112 0.00332 NM_010557 INTERLEUKIN 4 RECEPTOR, ALPHA -2.12968 0.009188 NM_026609 LEPTIN RECEPTOR OVERLAPPING TRANSCRIPT-LIKE 1 -2.12498 0.00138 AK078062 INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 2 -2.12364 0.001337 CORE-BINDING FACTOR, RUNT DOMAIN, ALPHA SUBUNIT 2, AK033680 TRANSLOCATED TO, 3 HOMOLOG (HUMAN) -2.12274 0.003377 BC025182 HYPOTHETICAL PROTEIN LOC216023 -2.11794 0.002158 NM_016787 BCL2/ADENOVIRUS E1B INTERACTING PROTEIN 1, NIP2 -2.11636 0.000872 BC040460 DENN/MADD DOMAIN CONTAINING 4B -2.11088 0.008594 K01446 HISTOCOMPATIBILITY 2, D REGION LOCUS 1 -2.10804 0.003278 UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N- NM_144908 ACETYLGALACTOSAMINYLTRANSFERASE 11 -2.10612 0.000109 NM_178610 HIV-1 REV BINDING PROTEIN 2 -2.1041 0.001055 NM_010392 HISTOCOMPATIBILITY 2, D REGION LOCUS 1 -2.10194 0.004361 NM_022314 TROPOMYOSIN 5 -2.09706 0.001345 NM_176840 OXYSTEROL BINDING PROTEIN-LIKE 11 -2.09544 0.001936 AK034348 PROSTAGLANDIN E RECEPTOR 4 (SUBTYPE EP4) -2.09224 0.000225 NM_053090 DOWN-REGULATED BY CTNNB1, A -2.09114 0.005219 NM_007801 CATHEPSIN H -2.08998 0.00113 NM_007653 CD63 ANTIGEN -2.08998 0.000117 NM_009735 BETA-2 MICROGLOBULIN -2.08814 0.000569 BC012309 INTERLEUKIN 4 RECEPTOR, ALPHA -2.08362 0.008336 AMYLOID BETA (A4) PRECURSOR PROTEIN-BINDING, FAMILY U70210 B, MEMBER 2 -2.08198 0.000735 AK008143 PURINE-NUCLEOSIDE PHOSPHORYLASE -2.08 0.000858 AK078123 DNA SEGMENT, CHR 5, ERATO DOI 371, EXPRESSED -2.07758 0.001501 TUMOR NECROSIS FACTOR (LIGAND) SUPERFAMILY, AK079180 MEMBER 13B -2.07296 0.010408 NM_008163 GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 -2.06796 0.000253 NM_175188 MEMBRANE-ASSOCIATED RING FINGER (C3HC4) 1 -2.06742 0.002866 BC058161 CCAAT/ENHANCER BINDING PROTEIN (C/EBP), ALPHA -2.064 0.005245 BC023427 PLATELET DERIVED GROWTH FACTOR, B POLYPEPTIDE -2.0635 0.003031 AK046079 RIKEN CDNA 2900035H07 GENE -2.06222 0.002584 AB033615 -LIKE 2 -2.05846 0.000113 AK009229 N-ACETYLTRANSFERASE 5 (ARD1 HOMOLOG, S. CEREVISIAE) -2.05716 0.000878 BC066809 RIKEN CDNA 2900035H07 GENE -2.05604 0.00228 AF017175 CARNITINE PALMITOYLTRANSFERASE 1A, LIVER -2.05426 8.37E-05 NM_013477 ATPASE, H+ TRANSPORTING, LYSOSOMAL V0 SUBUNIT D1 -2.0515 0.000424 BC060253 RIKEN CDNA 5730494M16 GENE -2.05034 0.008149 MYRISTOYLATED ALANINE RICH PROTEIN KINASE C NM_008538 SUBSTRATE -2.0491 0.001056 NM_009861 CELL DIVISION CYCLE 42 HOMOLOG (S. CEREVISIAE) -2.04528 0.000313 NM_023409 NIEMANN PICK TYPE C2 -2.04514 0.001054 BC056473 NANOS HOMOLOG 1 (DROSOPHILA) -2.04422 0.001548 AK041324 RIKEN CDNA A630001G21 GENE -2.04196 0.001335 NM_007393 ACTIN, BETA, CYTOPLASMIC -2.03716 0.000873 BC050939 ATPASE, H+ TRANSPORTING, LYSOSOMAL V0 SUBUNIT C -2.03222 9.19E-05 NM_00100390 8 CLATHRIN, HEAVY POLYPEPTIDE (HC) -2.0322 0.003331 AMYLOID BETA (A4) PRECURSOR PROTEIN-BINDING, FAMILY AF133665 B, MEMBER 2 -2.02912 0.001998 AK036489 MEMBRANE-ASSOCIATED RING FINGER (C3HC4) 1 -2.02714 0.003135 NM_009729 ATPASE, H+ TRANSPORTING, LYSOSOMAL V0 SUBUNIT C -2.02522 0.000249 BC058274 WD REPEAT AND FYVE DOMAIN CONTAINING 3 -2.02484 0.003456 GROWTH FACTOR RECEPTOR BOUND PROTEIN 2- NM_181584 ASSOCIATED PROTEIN 3 -2.0204 0.003853 NM_133869 CHOLINE/ETHANOLAMINEPHOSPHOTRANSFERASE 1 -2.01166 0.00235 AF089751 PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL 4 -2.01146 0.001926 NM_133787 NMD3 HOMOLOG (S. CEREVISIAE) -2.0097 0.001272 BC033382 RAS RELATED PROTEIN 1B -2.00742 0.002117 BC031464 TRAFFICKING PROTEIN PARTICLE COMPLEX 6B -2.00568 0.001187 AF172088 ADP-RIBOSYLATION FACTOR-LIKE 6 INTERACTING PROTEIN 1 -2.0034 0.000649 AK090001 ADP-RIBOSYLATION FACTOR-LIKE 6 INTERACTING PROTEIN 1 -2.00014 0.000161 AK088577 CDNA SEQUENCE X99384 -1.99866 0.001756 U49950 YEAST SPS1/STE20-RELATED KINASE 3 (S. CEREVISIAE) -1.99322 0.000636 NM_134100 DNA SEGMENT, CHR 15, MOUSE GENOME INFORMATICS 27 -1.99172 0.003255 NM_194344 SH3 DOMAIN AND TETRATRICOPEPTIDE REPEATS 1 -1.99154 0.002031 NM_011633 TNF RECEPTOR-ASSOCIATED FACTOR 5 -1.9907 0.002863 NM_021389 SH3-DOMAIN KINASE BINDING PROTEIN 1 -1.98976 0.006181 ATP-BINDING CASSETTE, SUB-FAMILY C (CFTR/MRP), AK052291 MEMBER 9 -1.98894 0.001474 NM_008199 HISTOCOMPATIBILITY 2, BLASTOCYST -1.97768 0.005795 NM_175675 RIKEN CDNA 4930471M23 GENE -1.97678 0.000663 NM_019909 HISTOCOMPATIBILITY 2, Q REGION LOCUS 1 -1.97256 0.005435 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, AF279672 SUBFAMILY V, MEMBER 4 -1.97184 0.000897 AB093277 WD REPEAT AND FYVE DOMAIN CONTAINING 3 -1.97138 0.00384 GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), NM_025277 GAMMA 10 -1.96804 0.000417 NM_172714 EXPRESSED SEQUENCE AI461788 -1.96778 0.004956 NM_021540 RING FINGER PROTEIN 130 -1.9655 0.000727 NM_008633 MICROTUBULE-ASSOCIATED PROTEIN 4 -1.96258 0.000787 AK013963 LYSOSOMAL-ASSOCIATED PROTEIN TRANSMEMBRANE 4A -1.95876 0.000946 NM_178593 RCSD DOMAIN CONTAINING 1 -1.95448 0.001924 AK078662 RIKEN CDNA E330016A19 GENE -1.95412 0.001263 NM_053075 RAS-HOMOLOG ENRICHED IN BRAIN -1.95354 0.000547 AF061260 IMMUNOGLOBULIN SUPERFAMILY, MEMBER 4A -1.95214 0.000674 NM_010508 INTERFERON (ALPHA AND BETA) RECEPTOR 1 -1.95082 0.004015 V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA NM_010658 ONCOGENE FAMILY, PROTEIN B (AVIAN) -1.9428 0.004715 SOLUTE CARRIER FAMILY 37 (GLYCEROL-3-PHOSPHATE NM_020258 TRANSPORTER), MEMBER 2 -1.93636 0.000783 V-KI-RAS2 KIRSTEN RAT SARCOMA VIRAL ONCOGENE NM_021284 HOMOLOG -1.93266 0.000345 NM_175181 RIKEN CDNA 2600010E01 GENE -1.931 0.003016 BC019448 NUCLEAR RECEPTOR BINDING FACTOR 2 PSEUDOGENE -1.92812 0.00129 NM_033617 ATPASE, H+ TRANSPORTING, LYSOSOMAL V0 SUBUNIT C'' -1.927 0.000574 BC019374 GLUTAMATE-CYSTEINE LIGASE, CATALYTIC SUBUNIT -1.92234 0.002409 AK031291 DPY-19-LIKE 1 (C. ELEGANS) -1.92146 0.000178 UBIQUITIN-CONJUGATING E2E 1, UBC4/5 NM_009455 HOMOLOG (YEAST) -1.91836 0.0047 BC049274 UBIQUITIN SPECIFIC PEPTIDASE 12 -1.9173 0.002696 BC067412 PHOSPHOGLYCERATE MUTASE 1 -1.91166 0.000624 NM_011779 CORONIN, ACTIN BINDING PROTEIN 1C -1.90488 0.001233 AK046516 HYPOTHETICAL PROTEIN B330003H21 -1.9048 0.001362 BC049972 DENN/MADD DOMAIN CONTAINING 4B -1.90388 0.008707 BC046440 HYPOTHETICAL PROTEIN LOC269471 -1.9019 0.001898 NM_145554 LOW DENSITY LIPOPROTEIN RECEPTOR ADAPTOR PROTEIN 1 -1.89886 0.003689 NM_021884 TUMOR SUSCEPTIBILITY GENE 101 -1.89852 0.004132 NM_172498 PTK2 PROTEIN TYROSINE KINASE 2 BETA -1.89504 0.003991 AK079611 HYPOTHETICAL PROTEIN MGC30586 -1.89484 0.000241 NM_019566 RAS HOMOLOG GENE FAMILY, MEMBER G -1.893 0.001112 SOLUTE CARRIER FAMILY 4, SODIUM BICARBONATE AK049322 COTRANSPORTER, MEMBER 7 -1.88932 0.003919 AK079062 RIKEN CDNA 2310057D15 GENE -1.88832 0.000554 NM_019661 RIKEN CDNA 0610042I15 GENE -1.8814 0.003083 BC055398 UBIQUITIN SPECIFIC PEPTIDASE 12 -1.8749 0.001555 NM_172839 CYCLIN J -1.87442 4.58E-05 NM_153509 CDNA SEQUENCE AF529169 -1.87434 0.001022 UDP-GAL:BETAGAL BETA 1,3-GALACTOSYLTRANSFERASE NM_146184 POLYPEPTIDE 7 -1.87336 0.008659 NM_030717 LACTAMASE, BETA -1.8712 0.00025 AK009391 DIHYDROURIDINE SYNTHASE 2-LIKE (SMM1, S. CEREVISIAE) -1.86748 3.24E-05 NM_026998 SORTING NEXIN 6 -1.84644 0.002091 NM_026738 RIKEN CDNA 1110007C09 GENE -1.8457 0.002457 AY048852 TUMOR PROTEIN D52 -1.84562 0.00134 BC024909 SH3 DOMAIN AND TETRATRICOPEPTIDE REPEATS 1 -1.84368 0.000281 NM_145376 RIKEN CDNA 2900035H07 GENE -1.83898 0.000679 AK047427 BROMODOMAIN ADJACENT TO ZINC FINGER DOMAIN 1A -1.83018 0.000422 AK011178 RIKEN CDNA 2600010E01 GENE -1.82972 0.006992 NM_011669 UBIQUITIN SPECIFIC PEPTIDASE 12 -1.82804 0.00464 NM_019460 SCM-LIKE WITH FOUR MBT DOMAINS 1 -1.82436 0.000779 NM_023065 INTERFERON GAMMA INDUCIBLE PROTEIN 30 -1.82188 0.00045 MACROPHAGE GALACTOSE N-ACETYL-GALACTOSAMINE NM_010796 SPECIFIC LECTIN 1 -1.81994 0.002685 COLONY STIMULATING FACTOR 2 RECEPTOR, ALPHA, LOW- NM_009970 AFFINITY (GRANULOCYTE-MACROPHAGE) -1.81316 0.001274 BC046424 DNAJ (HSP40) HOMOLOG, SUBFAMILY C, MEMBER 16 -1.81112 0.002373 NM_177617 -1.80658 0.005954 NM_026697 RAB14, MEMBER RAS ONCOGENE FAMILY -1.80478 0.000318 NM_025547 MTERF DOMAIN CONTAINING 1 -1.79064 0.002448 AK075744 TRANSMEMBRANE PROTEIN 66 -1.78712 0.000156 BC019448 NUCLEAR RECEPTOR BINDING FACTOR 2 PSEUDOGENE -1.77786 0.001462 PANTOTHENATE KINASE 2 (HALLERVORDEN-SPATZ NM_153501 SYNDROME) -1.7776 0.003304 BC003996 RIKEN CDNA 1810021C21 GENE -1.77754 0.000388 NM_178719 EXPRESSED SEQUENCE AI452372 -1.77522 0.00255 NM_017375 OSTEOCLAST STIMULATING FACTOR 1 -1.76986 0.001554 BC019809 LEUCINE RICH REPEAT CONTAINING 8 FAMILY, MEMBER C -1.76658 0.002055 AB093293 TBC1 DOMAIN FAMILY, MEMBER 14 -1.76484 0.001943 NM_012051 ETS VARIANT GENE 3 -1.76436 0.005006 AK003446 ATPASE, H+ TRANSPORTING, LYSOSOMAL V1 SUBUNIT D -1.7625 0.000607 BC055295 DEDICATOR OF CYTOKINESIS 8 -1.75738 0.002063 NM_175562 RAB39, MEMBER RAS ONCOGENE FAMILY -1.7478 0.003481 MOB1, MPS ONE BINDER KINASE ACTIVATOR-LIKE 1B BC011285 (YEAST) -1.74672 0.002081 NM_130796 SORTING NEXIN ASSOCIATED GOLGI PROTEIN 1 -1.74642 0.000449 NM_012060 B-CELL RECEPTOR-ASSOCIATED PROTEIN 31 -1.73386 0.002236 AF038994 Y BOX PROTEIN 1 -1.72516 0.004844 AB028847 ACTIN, BETA, CYTOPLASMIC -1.71674 0.003323 AK089021 TRANSMEMBRANE PROTEIN 14C -1.71366 0.003458 AK122407 DNAJ (HSP40) HOMOLOG, SUBFAMILY C, MEMBER 16 -1.71346 0.000859 NM_011034 PEROXIREDOXIN 1 -1.71144 0.009309 NM_008163 GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 -1.7098 0.002415 1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 1 NM_026644 (LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE, DELTA) -1.7089 0.000384 NM_021278 THYMOSIN, BETA 4, X -1.70874 0.002182 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, M59378 MEMBER 1B -1.7075 0.005338 NM_007548 PR DOMAIN CONTAINING 1, WITH ZNF DOMAIN -1.70724 0.006762 PROTEIN KINASE INHIBITOR BETA, CAMP DEPENDENT, NM_008863 TESTIS SPECIFIC -1.70498 0.000168 NM_138584 SPASTIC PARAPLEGIA 21 HOMOLOG (HUMAN) -1.70398 7.54E-05 AK004298 LECTIN, GALACTOSE BINDING, SOLUBLE 1 -1.70226 0.001421 NM_011787 AUTOCRINE MOTILITY FACTOR RECEPTOR -1.70222 0.008018 AF016313 TISSUE FACTOR PATHWAY INHIBITOR -1.70218 0.004357 NM_172768 RIKEN CDNA A930008A22 GENE -1.69804 0.003513 SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN NM_177353 EXCHANGER), ISOFORM 7 -1.69748 0.005781 AK079115 MORTALITY FACTOR 4 LIKE 1 -1.69708 0.000268 NM_173405 RIKEN CDNA 6530401C20 GENE -1.6957 0.003993 BC021754 RHO GTPASE ACTIVATING PROTEIN 9 -1.6954 0.002364 NM_009418 TRIPEPTIDYL PEPTIDASE II -1.6881 0.006952 BC058722 SOLUTE CARRIER FAMILY 45, MEMBER 4 -1.68786 0.001967 AK004298 LECTIN, GALACTOSE BINDING, SOLUBLE 1 -1.68696 0.000685 AK004298 LECTIN, GALACTOSE BINDING, SOLUBLE 1 -1.68696 0.000685 AK010424 MYELOID CELL LEUKEMIA SEQUENCE 1 -1.68486 0.001751 AK050695 RIKEN CDNA 6030405P19 GENE -1.68376 0.002415 AK079115 MORTALITY FACTOR 4 LIKE 1 -1.68104 7.16E-05 X56603 CALRETICULIN -1.68074 0.002786 M12185 HISTOCOMPATIBILITY 2, D REGION LOCUS 1 -1.67786 0.002802 NM_026400 DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 11 -1.67784 0.001512 BC022740 RIKEN CDNA 4930583H14 GENE -1.67622 0.001457 AK010924 DYSTROBREVIN BINDING PROTEIN 1 -1.67342 0.00042 MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 NM_019920 INTERACTING PROTEIN 1 -1.6729 0.001879 AK044728 RIKEN CDNA A930037G23 GENE -1.67228 0.002591 NM_145514 WD REPEAT DOMAIN 26 -1.6702 0.000389 BC057601 RIKEN CDNA A930037G23 GENE -1.66748 0.005102 NM_133838 EH-DOMAIN CONTAINING 4 -1.66646 0.000152 NM_026381 SCOTIN GENE -1.66484 0.00282 AK129087 PLEIOMORPHIC ADENOMA GENE-LIKE 2 -1.6636 0.000872 NM_008668 NGFI-A BINDING PROTEIN 2 -1.66204 0.00133 TRANSCRIPTION ELONGATION FACTOR B (SIII), POLYPEPTIDE NM_013736 3 -1.6612 0.000915 NM_017472 SORTING NEXIN 3 -1.65764 0.006298 NM_011908 UBIQUITIN-LIKE 3 -1.6565 0.00302 BC053524 IMPORTIN 7 -1.6526 0.001604 NM_172827 LEUCYL/CYSTINYL -1.65136 0.000108 NM_009615 A DISINTEGRIN AND METALLOPEPTIDASE DOMAIN 17 -1.64756 0.000651 AK077305 ODD OZ/TEN-M HOMOLOG 4 (DROSOPHILA) -1.6467 8.38E-05 NM_018804 SYNAPTOTAGMIN 11 -1.6427 0.006975 NM_025968 LEUKOTRIENE B4 12-HYDROXYDEHYDROGENASE -1.63622 0.000434 AF038994 Y BOX PROTEIN 1 -1.63616 0.00525 SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER NM_009579 1 -1.6267 0.010695 U60969 FORMIN 1 -1.61774 0.003648 U47325 HISTOCOMPATIBILITY 2, D REGION LOCUS 1 -1.61734 0.004008 AK129123 RAL GUANINE NUCLEOTIDE EXCHANGE FACTOR RALGPS1A -1.61606 0.000957 BC023409 HISTOCOMPATIBILITY 2, D REGION LOCUS 1 -1.60926 0.003396 SPLICING FACTOR PROLINE/GLUTAMINE RICH BC049227 (POLYPYRIMIDINE TRACT BINDING PROTEIN ASSOCIATED) -1.60906 0.001693 AK077081 TBC1 DOMAIN FAMILY, MEMBER 9 -1.60884 0.004319 AF024519 TSC22 DOMAIN FAMILY 3 -1.60742 0.002037 NM_007387 ACID PHOSPHATASE 2, LYSOSOMAL -1.60688 0.001732 AK129229 RIKEN CDNA 1700126I16 GENE -1.6049 0.003898 NM_181732 RIKEN CDNA 2610208M17 GENE -1.6044 0.000272 NM_016681 CHK2 CHECKPOINT HOMOLOG (S. POMBE) -1.60132 0.003352 AK014561 PALMITOYL-PROTEIN THIOESTERASE 1 -1.60128 0.003114 U27014 SORBITOL DEHYDROGENASE -1.59776 0.001181 UBIQUITIN-CONJUGATING ENZYME E2D 3 (UBC4/5 NM_025356 HOMOLOG, YEAST) -1.59266 0.002215 NM_178787 RIKEN CDNA A930037G23 GENE -1.57734 0.001792 AK086624 DELTEX 4 HOMOLOG (DROSOPHILA) -1.57032 8.4E-06 NM_022813 SECRETORY CARRIER MEMBRANE PROTEIN 2 -1.56066 0.000628 MICROTUBULE ASSOCIATED MONOXYGENASE, CALPONIN NM_138315 AND LIM DOMAIN CONTAINING 1 -1.56016 0.001073 LIM DOMAIN CONTAINING PREFERRED TRANSLOCATION AK079115 PARTNER IN LIPOMA -1.55512 0.000208 NM_011695 VOLTAGE-DEPENDENT ANION CHANNEL 2 -1.54952 0.001071 BC027342 CDNA SEQUENCE BC027342 -1.54792 0.001492 AK015255 TUBULIN, BETA 6 -1.54672 0.004659 SPLICING FACTOR PROLINE/GLUTAMINE RICH BC055468 (POLYPYRIMIDINE TRACT BINDING PROTEIN ASSOCIATED) -1.54464 0.001487 AK033089 NUCLEAR RECEPTOR COACTIVATOR 6 INTERACTING PROTEIN -1.53864 0.00361 CEROID LIPOFUSCINOSIS, NEURONAL 3, JUVENILE (BATTEN, NM_009907 SPIELMEYER-VOGT DISEASE) -1.52786 0.003305 BC006897 EXPRESSED SEQUENCE AI606441 -1.52676 0.003264 AK050665 TROPOMYOSIN 5 -1.5229 0.000192 SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, NM_133668 PHOSPHATE CARRIER), MEMBER 3 -1.51882 0.000992 NM_146258 SEROLOGICALLY DEFINED COLON CANCER ANTIGEN 13 -1.51782 0.002131 AK090139 HYPOTHETICAL PROTEIN 4932422C22 -1.51474 0.001855 AY062008 3-PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE-1 -1.50406 0.006303 AK009340 RIKEN CDNA 2310014H01 GENE -1.50132 0.000327 AK037889 ER DEGRADATION ENHANCER, MANNOSIDASE ALPHA-LIKE 1 -1.5004 0.003431 NM_146126 SORBITOL DEHYDROGENASE -1.4992 0.000917 BC032282 FLIGHTLESS I HOMOLOG (DROSOPHILA) -1.49248 0.000447 AK088560 ROD1 REGULATOR OF DIFFERENTIATION 1 (S. POMBE) -1.4861 0.000636 BC058078 EXPRESSED SEQUENCE AI606441 -1.48478 0.002784 NM_008556 MAMMARY TRANSFORMING GENE 1 -1.48304 0.002255 NM_026635 RIKEN CDNA 5730536A07 GENE -1.4816 0.002761 AK004601 INOSITOL POLYPHOSPHATE-5-PHOSPHATASE B -1.47566 0.002695 BC028872 RAB24, MEMBER RAS ONCOGENE FAMILY -1.4728 0.002724 BC057180 ATPASE, CA++ TRANSPORTING, PLASMA MEMBRANE 1 -1.47118 0.001553 BC025099 TUDOR DOMAIN CONTAINING 7 -1.47074 0.000856 UDP-N-ACTEYLGLUCOSAMINE PYROPHOSPHORYLASE 1-LIKE BC068207 1 -1.46426 0.001117 NM_027113 WD REPEAT DOMAIN 5B -1.46226 0.001617 ALDO-KETO REDUCTASE FAMILY 1, MEMBER A4 (ALDEHYDE NM_021473 REDUCTASE) -1.45708 0.000393 NM_145624 ZINC FINGER PROTEIN 709 -1.44694 0.00216 NM_026998 SORTING NEXIN 6 -1.44256 0.003196 AK089070 MAMMARY TRANSFORMING GENE 1 -1.44222 0.0004 AK004722 INOSITOL POLYPHOSPHATE-5-PHOSPHATASE B -1.4406 0.001316 NM_178376 RAS-RELATED GTP BINDING A -1.4389 0.002826 SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTERS), NM_023596 MEMBER 3 -1.43644 0.001192 BC050039 WD REPEAT DOMAIN 67 -1.43408 0.003546 AK005004 RAB7, MEMBER RAS ONCOGENE FAMILY -1.43018 0.000966 GUANOSINE DIPHOSPHATE (GDP) DISSOCIATION INHIBITOR NM_008112 2 -1.42894 0.006117 NM_026446 REGULATOR OF G-PROTEIN SIGNALING 19 -1.42696 0.003103 AK011719 RIKEN CDNA 2610039C10 GENE -1.42672 0.000722 NM_009288 SERINE/THREONINE KINASE 10 -1.42588 0.003233 NM_027769 COPINE III -1.42116 0.004857 AK042787 THIOREDOXIN DOMAIN CONTAINING 10 -1.41616 0.000199 X64070 MANNOSE-6-PHOSPHATE RECEPTOR, CATION DEPENDENT -1.41218 0.003681 NM_144915 RIKEN CDNA E330036I19 GENE -1.41216 0.00216 BC052027 DNAJ (HSP40) HOMOLOG, SUBFAMILY C, MEMBER 2 -1.40856 0.003455 NM_018788 EXOSTOSES (MULTIPLE)-LIKE 3 -1.40768 0.001554 SEMA DOMAIN, IMMUNOGLOBULIN DOMAIN (IG), TRANSMEMBRANE DOMAIN (TM) AND SHORT NM_013660 CYTOPLASMIC DOMAIN, (SEMAPHORIN) 4D -1.4047 0.002668 NM_175185 HYDROXYSTEROID DEHYDROGENASE LIKE 1 -1.40206 0.003613 AK075982 RNA BINDING MOTIF PROTEIN 13 -1.39788 0.001148 NM_181470 LTV1 HOMOLOG (S. CEREVISIAE) -1.39114 0.001313 NM_025991 KELCH REPEAT AND BTB (POZ) DOMAIN CONTAINING 4 -1.38778 6.8E-06 NM_175509 RIKEN CDNA 9430067K14 GENE -1.38348 0.002019 AK129486 VACUOLAR PROTEIN SORTING 13C (YEAST) -1.38346 0.005141 BC030869 PHOSPHOGLUCOMUTASE 1 -1.37816 0.002196 NM_145933 BETA GALACTOSIDE ALPHA 2,6 SIALYLTRANSFERASE 1 -1.37522 0.004835 MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, BC052405 MEMBER 1 -1.37356 0.002724 AK077791 ROD1 REGULATOR OF DIFFERENTIATION 1 (S. POMBE) -1.37018 0.009559 NM_009222 SYNAPTOSOMAL-ASSOCIATED PROTEIN 23 -1.36166 0.00219 NM_146115 RIKEN CDNA A830007P12 GENE -1.3578 0.000614 BC013450 Y BOX PROTEIN 1 -1.35676 0.007665 NM_029565 TRANSMEMBRANE PROTEIN 59 -1.34682 0.000636 NM_027569 SPERM ASSOCIATED ANTIGEN 9 -1.34242 5.23E-05 BC060100 SPERM ASSOCIATED ANTIGEN 9 -1.33998 0.000622 AK012307 PRENYL (SOLANESYL) DIPHOSPHATE SYNTHASE, SUBUNIT 1 -1.33872 0.005128 NM_020611 STEROID 5 ALPHA-REDUCTASE 2-LIKE -1.32922 0.001122 NM_146243 ARP2 ACTIN-RELATED PROTEIN 2 HOMOLOG (YEAST) -1.3214 0.00277 BC037615 RAS-RELATED GTP BINDING A -1.32104 0.000551 NM_145221 RIKEN CDNA 2900057D21 GENE -1.31588 0.004392 AK085828 INTEGRIN BETA 1 (FIBRONECTIN RECEPTOR BETA) -1.31378 0.004475 NM_010758 MYELIN-ASSOCIATED GLYCOPROTEIN -1.29296 0.003229 GOLGI ASSOCIATED PDZ AND COILED-COIL MOTIF AK030427 CONTAINING -1.28794 0.004231 NM_016809 RNA BINDING MOTIF PROTEIN 3 -1.28688 0.001777 NM_027274 RIKEN CDNA 2810025M15 GENE -1.28066 0.001189 BC047530 ARP2 ACTIN-RELATED PROTEIN 2 HOMOLOG (YEAST) -1.27776 0.002782 AK014534 RIKEN CDNA 4631424J17 GENE -1.27692 0.00356 NM_183258 RIKEN CDNA 2610001J05 GENE -1.27316 0.007312 AK032037 RIKEN CDNA 2310014G06 GENE -1.26032 0.006221 INTEGRIN-LINKED KINASE-ASSOCIATED SERINE/THREONINE NM_023343 PHOSPHATASE 2C -1.25756 0.001813 NM_025418 RIKEN CDNA 1110059P08 GENE -1.25298 0.006557 MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, NM_153058 MEMBER 2 -1.24758 0.00567 NM_019484 RNA AND EXPORT FACTOR BINDING PROTEIN 2 -1.2356 0.000994 BC052165 ZINC FINGER PROTEIN 105 -1.23434 0.00152 NM_011696 VOLTAGE-DEPENDENT ANION CHANNEL 3 -1.22546 0.001757 NM_025888 RIKEN CDNA 2410004N11 GENE -1.2235 0.000953 NM_026764 S-TRANSFERASE, MU 4 -1.22162 0.001583 AK088462 HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K -1.20958 0.000439 AK014737 RIKEN CDNA 3110001A18 GENE -1.20386 0.002676 NM_009507 VON HIPPEL-LINDAU SYNDROME HOMOLOG -1.2003 0.0008 NM_009914 CHEMOKINE (C-C MOTIF) RECEPTOR 3 -1.18216 0.001239 AK013254 RIKEN CDNA 2410004N11 GENE -1.17994 0.001506 NM_177235 RIKEN CDNA B230209C24 GENE -1.17128 0.000818 AK004324 RIKEN CDNA 1200015A19 GENE -1.16426 0.001225 AK085534 RIKEN CDNA 2310009E04 GENE -1.16108 0.000478 NM_133854 SNAP-ASSOCIATED PROTEIN -1.15098 0.003553 RECEPTOR (TNFRSF)-INTERACTING SERINE-THREONINE NM_009068 KINASE 1 -1.14776 0.002255 NM_023173 RIKEN CDNA 1190004O14 GENE -1.14228 0.000282 AK012533 RIKEN CDNA 2610039C10 GENE -1.14124 0.000987 BC018353 HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U -1.13892 0.000812 AK004324 RIKEN CDNA 1200015A19 GENE -1.12772 0.002138 NM_178613 RIKEN CDNA 4933433P14 GENE -1.1251 0.001137 TRANSFORMATION RELATED PROTEIN 53 BINDING PROTEIN AK036324 1 -1.12506 0.000104 ADULT MALE LIVER TUMOR CDNA, RIKEN FULL-LENGTH ENRICHED LIBRARY, CLONE:C730031A08 PRODUCT:GAMMA AK050250 TUBULIN RING COMPLEX PROTEIN HOMOLOG -1.12032 0.000661 BC061692 ANKYRIN REPEAT DOMAIN 13A -1.11184 0.00265 NM_007834 DOWN SYNDROME CRITICAL REGION GENE 3 -1.062 0.002464 NM_175096 DNA SEGMENT, CHR 5, ERATO DOI 593, EXPRESSED -1.04986 0.000536 AK007666 STROMAL MEMBRANE-ASSOCIATED PROTEIN 1-LIKE -1.04954 0.001946 BC007173 TRIPEPTIDYL PEPTIDASE II -1.0488 0.004192 BC043449 RIKEN CDNA 1600012H06 GENE -1.04256 0.000102 BC024986 SPASTIC PARAPLEGIA 7 HOMOLOG (HUMAN) -1.03722 0.001968 NM_133716 STROMAL MEMBRANE-ASSOCIATED PROTEIN 1-LIKE -1.02646 0.001942 AK087821 RIKEN CDNA 2610528K11 GENE -1.02026 0.003458 AK009216 RIKEN CDNA 4933440H19 GENE -1.01564 0.000759 AK003154 ANKYRIN REPEAT DOMAIN 13A -1.00802 0.002971 NM_133726 SUPPRESSION OF TUMORIGENICITY 13 -0.9637 0.002049 AK012250 NUCLEOSOME ASSEMBLY PROTEIN-1 -0.95794 0.002543 PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), BC023062 ALPHA ISOFORM -0.95516 0.004982 NM_172400 DNAJ (HSP40) HOMOLOG, SUBFAMILY C, MEMBER 8 -0.95068 0.002365 AK051753 HISTONE DEACETYLASE 2 -0.92224 0.002313 NM_172758 CDNA SEQUENCE BC031853 -0.90978 0.000146 NM_026184 ERO1-LIKE BETA (S. CEREVISIAE) -0.9097 0.007155 SMALL NUCLEAR RNA ACTIVATING COMPLEX, POLYPEPTIDE NM_178392 1 -0.90572 0.005169 NM_027886 SERINE/THREONINE KINASE 11 INTERACTING PROTEIN -0.87056 0.000575 BC051487 UBIQUITIN-CONJUGATING ENZYME E2Q (PUTATIVE) -0.84054 0.003975 TANKYRASE, TRF1-INTERACTING ANKYRIN-RELATED ADP- BC057370 RIBOSE POLYMERASE -0.83756 0.007117 NM_145955 RIKEN CDNA 1110007A13 GENE -0.83494 0.001358 PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), NM_144880 ALPHA ISOFORM -0.82446 0.002278 X76850 MAP KINASE-ACTIVATED PROTEIN KINASE 2 -0.79862 0.002171 SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE B, BC062169 MEMBER 6C -0.76894 0.00177 NM_007438 ALDOLASE 1, A ISOFORM -0.75164 0.003298 BC002212 RIKEN CDNA F830020C16 GENE -0.74896 0.009179 AK088308 HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1 -0.7144 0.003939 NM_134046 RIKEN CDNA 2810429O05 GENE -0.69302 0.001352 PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), NM_144880 ALPHA ISOFORM -0.65794 0.003523 CLEAVAGE STIMULATION FACTOR, 3' PRE-RNA SUBUNIT 2, AK082910 TAU -0.6489 0.001782 NM_080446 HELICASE (DNA) B -0.48842 0.000587 LECITHIN-RETINOL ACYLTRANSFERASE AF255061 (PHOSPHATIDYLCHOLINE-RETINOL-O-ACYLTRANSFERASE) 0.49708 0.000304 NM_178071 NON-METASTATIC CELLS 7, PROTEIN EXPRESSED IN 0.59372 2.75E-06 NM_172863 ZINC FINGER PROTEIN 697 0.59836 0.002125 NM_008966 PROSTAGLANDIN F RECEPTOR 0.59904 0.00369 NM_145837 INTERLEUKIN 17D 0.67888 0.003477 AK003805 RIKEN CDNA 1110019B22 GENE 0.69132 0.001655 AK053178 SIMILAR TO AXONEMAL HEAVY CHAIN DYNEIN TYPE 3 0.73204 2.28E-05 AK006923 RIKEN CDNA 1700069L16 GENE 0.7525 0.000577 AK053150 NUCLEAR FACTOR I/A 0.89038 0.003178 BC044789 VACUOLAR PROTEIN SORTING 37D (YEAST) 0.89836 0.000824 AK008577 RIKEN CDNA 2010317E24 GENE 0.89866 0.000652 POTASSIUM VOLTAGE GATED CHANNEL, SHAB-RELATED NM_008420 SUBFAMILY, MEMBER 1 0.9048 0.000927 NM_134164 SYNAPTOTAGMIN XII 0.91278 0.000596 NM_178757 INTERFERON REGULATORY FACTOR 2 BINDING PROTEIN 1 0.9657 0.000916 NM_133194 SEX COMB ON MIDLEG-LIKE 2 (DROSOPHILA) 0.9686 0.008217 GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE, AK049951 SPERMATOGENIC 1.00074 0.001737 NM_145577 CDNA SEQUENCE BC023179 1.0215 0.001628 BC016891 BILIARY GLYCOPROTEIN 1 1.05726 0.000207 BC025887 OPEN READING FRAME 34 1.05922 0.000808 BC002294 TRANSMEMBRANE PROTEIN 16K 1.06524 0.000622 BC058674 PROLINE RICH 12 1.07382 0.001348 BC030392 T-CELL RECEPTOR ALPHA CHAIN 1.08052 0.000505 NM_173778 RIKEN CDNA 4933412E14 GENE 1.08444 7.59E-05 NM_016707 B-CELL CLL/LYMPHOMA 11A (ZINC FINGER PROTEIN) 1.10588 0.000823 ATPASE, AMINOPHOSPHOLIPID TRANSPORTER-LIKE, CLASS I, NM_015803 TYPE 8A, MEMBER 2 1.117 0.000372 NM_027804 UBIQUITIN SPECIFIC PEPTIDASE 19 1.11954 0.00345 NM_175168 PTK7 PROTEIN TYROSINE KINASE 7 1.15888 0.001518 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, NM_028075 MEMBER 13C 1.16512 0.003371 BC046400 PHOSPHOLIPASE A2, GROUP IVF 1.18858 0.000485 GENERAL TRANSCRIPTION FACTOR II I REPEAT DOMAIN- AY149690 CONTAINING 1 1.1908 0.001329 NM_023663 RECEPTOR-INTERACTING SERINE-THREONINE KINASE 4 1.19928 0.003017 NM_172795 RIKEN CDNA A830091I15 GENE 1.20694 0.00515 AK044739 RIKEN CDNA C030011O14 GENE 1.21428 0.003434 BC042604 SYNAPTIC NUCLEAR ENVELOPE 2 1.2149 0.000759 M97957 PYRUVATE CARBOXYLASE 1.22024 0.000666 NM_00100188 2 REGULATOR OF TELOMERE ELONGATION HELICASE 1 1.22416 8.77E-05 NM_133731 PROTEASE, SERINE, 22 1.22548 0.000274 BC055912 RIKEN CDNA 1700025G04 GENE 1.22746 0.001445 NM_145635 CDNA SEQUENCE BC054059 1.2282 0.000654 NM_00100574 0 PHOSPHATASE AND ACTIN REGULATOR 1 1.24306 0.000818 NM_019956 KERATIN COMPLEX 2, BASIC, GENE 6G 1.24656 3.14E-06 AK010670 HLA-B-ASSOCIATED TRANSCRIPT 3 1.24712 0.00289 G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 5, BC008228 MEMBER C 1.25208 0.006317 NM_008797 PYRUVATE CARBOXYLASE 1.26746 0.001114 AK083524 POL POLYPROTEIN 1.2695 0.004942 NM_145392 BCL2-ASSOCIATED ATHANOGENE 2 1.26994 0.005599 NM_213729 EXPRESSED SEQUENCE AI842396 1.2768 0.001533 BC059850 FATTY ACID SYNTHASE 1.29168 0.000499 NM_134437 INTERLEUKIN 17 RECEPTOR D 1.2978 0.003817 NM_029794 DNA SEGMENT, CHR 11, ERATO DOI 636, EXPRESSED 1.30484 3.95E-06 AK035271 VILLIN 2 1.3119 0.00071 AJ272170 SH3-BINDING DOMAIN GLUTAMIC ACID-RICH PROTEIN 1.31388 0.000582 NM_00100160 DISABLED HOMOLOG 2 (DROSOPHILA) INTERACTING 2 PROTEIN 1.31738 0.000259 U96752 HISTOCOMPATIBILITY 2, Q REGION LOCUS 1 1.32642 0.001476 PROTEIN KINASE, AMP-ACTIVATED, ALPHA 2 CATALYTIC AK044030 SUBUNIT 1.32668 0.000819 BC046513 FATTY ACID SYNTHASE 1.33696 0.00275 AK077665 PYRUVATE CARBOXYLASE 1.33814 0.000544 TRANSDUCIN-LIKE ENHANCER OF SPLIT 6, HOMOLOG OF NM_053254 DROSOPHILA E(SPL) 1.34354 0.003312 NM_133743 LY6/PLAUR DOMAIN CONTAINING 3 1.34618 0.002628 DISABLED HOMOLOG 2 (DROSOPHILA) INTERACTING AY178784 PROTEIN 1.3617 0.000359 AK006430 CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 5 1.36724 0.00166 AF193435 SRY-BOX CONTAINING GENE 14 1.3738 0.002003 NM_139306 RIKEN CDNA 2410116I05 GENE 1.37914 0.004545 AK122487 SORBIN AND SH3 DOMAIN CONTAINING 1 1.38392 0.001794 AK021342 RIKEN CDNA D730045B01 GENE 1.39778 0.001841 AK010945 UNC-5 HOMOLOG C (C. ELEGANS)-LIKE 1.4002 0.000729 NM_178413 CDNA SEQUENCE BC051244 1.40926 0.000554 AK075634 RIKEN CDNA 1110025H02 GENE 1.41 0.005356 AK006314 SPERMATID PERINUCLEAR RNA BINDING PROTEIN 1.41362 0.000333 NM_019429 PROTEASE, SERINE, 16 (THYMUS) 1.4179 0.000779 U58494 GAG 1.43068 0.004781 NM_00100446 TRANSFORMING, ACIDIC COILED-COIL CONTAINING PROTEIN 8 2 1.43202 0.000487 U58494 GAG 1.43956 0.000304 TRANSFORMING, ACIDIC COILED-COIL CONTAINING PROTEIN NM_021314 2 1.44628 0.000777 NM_177667 TETRATRICOPEPTIDE REPEAT DOMAIN 22 1.44768 0.001873 AK078209 DIFFERENTIALLY EXPRESSED IN B16F10 1 1.4477 0.000585 BC005674 ZINC FINGER, CCHC DOMAIN CONTAINING 14 1.4496 0.002167 SIRTUIN 5 (SILENT MATING TYPE INFORMATION NM_178848 REGULATION 2 HOMOLOG) 5 (S. CEREVISIAE) 1.45154 0.000772 AK030513 FAS APOPTOTIC INHIBITORY MOLECULE 2 1.45358 0.000948 NM_054043 MUSASHI HOMOLOG 2 (DROSOPHILA) 1.4592 0.001791 AK049903 TWEETY HOMOLOG 1 (DROSOPHILA) 1.4601 0.000723 2 DAYS NEONATE THYMUS THYMIC CELLS CDNA, RIKEN FULL-LENGTH ENRICHED LIBRARY, CLONE:E430033N13 PRODUCT:RETROVIRUS-RELATED POL POLYPROTEIN AK088963 HOMOLOG, FULL INSERT SEQUENCE 1.47326 0.004214 BC048855 RIKEN CDNA 2300006M17 GENE 1.47702 0.001755 BC050137 EXPRESSED SEQUENCE AA409659 1.48208 0.000729 BC058398 WINGLESS-RELATED MMTV INTEGRATION SITE 7B 1.48524 0.00184 BC028765 RIKEN CDNA 0610010O12 GENE 1.48528 0.000106 DISABLED HOMOLOG 2 (DROSOPHILA) INTERACTING AK122548 PROTEIN 1.48864 0.000244 NM_009528 WINGLESS-RELATED MMTV INTEGRATION SITE 7B 1.4918 0.001191 NM_020006 CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 4 1.49794 0.001928 BC024883 WD REPEAT DOMAIN, PHOSPHOINOSITIDE INTERACTING 1 1.50714 0.000155 NM_145919 ABHYDROLASE DOMAIN CONTAINING 14A 1.51838 0.000636 U58494 GAG 1.52854 0.000217 NM_133816 SH3-DOMAIN BINDING PROTEIN 4 1.53604 0.00242 S74315 ANTIGEN LEC-A 1.54876 0.003068 AK014390 BETA-SITE APP CLEAVING ENZYME 1 1.55518 0.001701 NM_011858 ODD OZ/TEN-M HOMOLOG 4 (DROSOPHILA) 1.55534 0.008638 NM_145601 CDNA SEQUENCE BC016201 1.56214 3.61E-05 NM_026125 C1Q DOMAIN CONTAINING 2 1.5646 7.15E-05 NM_172383 RIKEN CDNA 6330530A05 GENE 1.58148 0.006031 NM_021534 PEROXISOMAL MEMBRANE PROTEIN 4 1.59092 0.002103 BC066175 UBIQUITIN SPECIFIC PEPTIDASE 54 1.59274 0.000686 S74315 ANTIGEN LEC-A 1.5941 0.003241 NM_144534 TRANSMEMBRANE PROTEIN 38A 1.59536 0.003156 BC025943 TANKYRASE 1 BINDING PROTEIN 1 1.59698 0.001044 AK004054 PHOSPHATE CYTIDYLYLTRANSFERASE 2, ETHANOLAMINE 1.5984 0.003774 AF019086 KALLIKREIN 1-RELATED PEPTIDASE B24 1.60568 0.001504 NM_133995 UREIDOPROPIONASE, BETA 1.61446 0.003331 NM_133776 G PROTEIN-COUPLED RECEPTOR 110 1.6202 0.003701 AK050496 DYNEIN, AXONEMAL, INTERMEDIATE CHAIN 1 1.63282 0.001067 AF521593 SORBIN AND SH3 DOMAIN CONTAINING 1 1.6367 0.001874 AK129436 TANKYRASE 1 BINDING PROTEIN 1 1.6447 0.000962 AK050490 OXYSTEROL BINDING PROTEIN-LIKE 10 1.64544 0.004003 NM_011061 PEPTIDYL ARGININE DEIMINASE, TYPE IV 1.6456 0.001483 NM_178149 RIKEN CDNA 1500004A08 GENE 1.6457 7.9E-05 NM_133667 PYRUVATE DEHYDROGENASE KINASE, ISOENZYME 2 1.6518 0.002368 NM_175289 RIKEN CDNA D930048N14 GENE 1.6523 0.00071 NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED MOIETY X)-TYPE AK019109 MOTIF 17 1.66416 0.000439 BC023356 SRY-BOX CONTAINING GENE 10 1.6678 0.000893 NM_018826 IROQUOIS RELATED HOMEOBOX 5 (DROSOPHILA) 1.67458 0.000745 U37501 LAMININ, ALPHA 5 1.67644 0.000815 AK042747 EXPRESSED SEQUENCE C85492 1.67952 0.002895 TRANSDUCIN-LIKE ENHANCER OF SPLIT 6, HOMOLOG OF BC048832 DROSOPHILA E(SPL) 1.68456 0.002819 U58494 GAG 1.70372 0.003929 AK004534 RAS-LIKE, FAMILY 11, MEMBER B 1.70648 0.000194 M10062 INTRACISTERNAL A PARTICLES 1.70758 0.004568 AK048708 NEUREGULIN 1 1.72086 0.003926 AF017182 SRY-BOX CONTAINING GENE 10 1.72086 0.000805 AK052439 NEOGENIN 1.72152 0.008255 NM_146013 SEC14-LIKE 4 (S. CEREVISIAE) 1.73372 5.41E-05 M10062 INTRACISTERNAL A PARTICLES 1.74496 0.002295 AK045783 RAB3A INTERACTING PROTEIN 1.75262 0.000494 BC057211 MITOGEN-ACTIVATED PROTEIN KINASE 11 1.76236 0.000795 S74315 ANTIGEN LEC-A 1.76886 0.003378 AF461092 CHONDROITIN SULFATE PROTEOGLYCAN 5 1.78558 0.004244 S74315 ANTIGEN LEC-A 1.78734 0.002167 NM_172739 GLUCOCORTICOID RECEPTOR DNA BINDING FACTOR 1 1.80576 0.00101 NM_054071 FIBROBLAST GROWTH FACTOR RECEPTOR-LIKE 1 1.80732 2.93E-05 AK014261 RIKEN CDNA 3110079O15 GENE 1.8136 0.001634 BC021842 SUSHI DOMAIN CONTAINING 4 1.83408 0.001904 NM_144549 TRIBBLES HOMOLOG 1 (DROSOPHILA) 1.83512 0.000517 NM_130887 PAPILIN, PROTEOGLYCAN-LIKE SULFATED GLYCOPROTEIN 1.85044 3.33E-05 AK006174 RIKEN CDNA 1700020L24 GENE 1.85506 0.00331 NM_183037 HYPOTHETICAL PROTEIN LOC54129 1.86672 0.00095 BC029233 VALYL-TRNA SYNTHETASE 2-LIKE 1.8751 0.001629 NM_177679 RIKEN CDNA 9130230L23 GENE 1.88 0.001849 NM_031874 RAB3D, MEMBER RAS ONCOGENE FAMILY 1.8844 0.001181 DNA SEGMENT, CHR 10, BRIGHAM & WOMEN'S GENETICS AK122475 1379 EXPRESSED 1.88814 0.001884 NM_009567 ZINC FINGER PROTEIN 93 1.9144 0.002393 NEURAL PROLIFERATION, DIFFERENTIATION AND CONTROL NM_008721 GENE 1 1.91504 0.005242 BC005747 PAPILIN, PROTEOGLYCAN-LIKE SULFATED GLYCOPROTEIN 1.92894 0.000327 BC043478 LAMININ, ALPHA 5 1.92954 0.000925 NM_181681 CDNA SEQUENCE BC005764 1.9333 0.004137 ELOVL FAMILY MEMBER 7, ELONGATION OF LONG CHAIN NM_029001 FATTY ACIDS (YEAST) 1.96438 8.65E-06 NM_010723 LIM DOMAIN ONLY 4 1.97128 0.003667 AK033507 GLUCOSAMINE 1.97132 0.003115 NM_145973 RIKEN CDNA A930015D22 GENE 1.97484 0.000288 NM_027984 EPSIN 3 1.98072 0.000634 NM_007929 EPITHELIAL MEMBRANE PROTEIN 2 1.98896 6.92E-05 NM_133243 1.99124 0.005683 V-ERB-B2 ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE BC029028 HOMOLOG 3 (AVIAN) 1.99686 0.000181 AK017419 DUAL SPECIFICITY PHOSPHATASE 8 2.0108 0.002343 NM_027419 RIKEN CDNA 2810408A11 GENE 2.01564 0.000475 SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN NM_023055 EXCHANGER), ISOFORM 3 REGULATOR 2 2.01672 0.000246 ST6 (ALPHA-N-ACETYL-NEURAMINYL-2,3-BETA-GALACTOSYL- 1,3)-N-ACETYLGALACTOSAMINIDE ALPHA-2,6- NM_009180 SIALYLTRANSFERASE 2 2.02154 3.63E-05 BC026599 RIKEN CDNA 4732435N03 GENE 2.0221 0.002741 BC016106 ASPARAGINASE LIKE 1 2.03332 0.002847 NM_029341 CALCYPHOSINE-LIKE 2.0338 0.000516 SOLUTE CARRIER FAMILY 1 (NEURONAL/EPITHELIAL HIGH AFFINITY GLUTAMATE TRANSPORTER, SYSTEM XAG), U75214 MEMBER 1 2.0349 0.004702 BC065049 HYPOTHETICAL PROTEIN LOC54129 2.04568 0.000792 NM_153412 RIKEN CDNA C820004H04 GENE 2.05574 0.003516 AK076656 RIKEN CDNA 4732415M23 GENE 2.05782 0.001499 NM_026837 TRANSMEMBRANE PROTEIN 53 2.06218 0.002346 BC043727 DENN/MADD DOMAIN CONTAINING 2D 2.06736 0.000152 BC010843 TRANSMEMBRANE PROTEASE, SERINE 13 2.06748 0.000365 AK003974 RIKEN CDNA 1110030G05 GENE 2.06876 0.000744 NM_130878 PROTOCADHERIN 21 2.07482 0.003192 BC024501 LIGATIN 2.0772 0.000708 BC006733 CDNA SEQUENCE BC037006 2.08028 0.007231 AK122250 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 17 2.08246 0.000843 NM_017403 HYPOTHETICAL PROTEIN LOC54129 2.08718 0.000817 MITOGEN ACTIVATED PROTEIN KINASE 8 INTERACTING NM_011162 PROTEIN 1 2.089 0.00016 NM_026728 ENOYL COENZYME A HYDRATASE DOMAIN CONTAINING 2 2.09754 1.26E-05 NM_010423 HAIRY/ENHANCER-OF-SPLIT RELATED WITH YRPW MOTIF 1 2.10312 0.004148 BC046827 CHEMOKINE (C-X-C MOTIF) LIGAND 12 2.12226 0.001181 BC046827 CHEMOKINE (C-X-C MOTIF) LIGAND 12 2.12226 0.001181 NM_009854 CD7 ANTIGEN 2.13208 0.002358 RHO/RAC GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) BC009156 18 2.13838 0.000568 BC032275 RECEPTOR-LIKE TYROSINE KINASE 2.13948 0.000331 BC008266 DENN/MADD DOMAIN CONTAINING 2D 2.14518 0.000479 BC049240 LIGASE III, DNA, ATP-DEPENDENT 2.146 0.001278 NM_011414 SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR 2.15266 0.001033 0 DAY NEONATE CEREBELLUM CDNA, RIKEN FULL-LENGTH ENRICHED LIBRARY, CLONE:C230080E09 AK082664 PRODUCT:HYPOTHETICAL PROTEIN, FULL INSERT SEQUENCE 2.15316 0.002313 NM_008609 MATRIX METALLOPEPTIDASE 15 2.1533 0.000431 AK129371 SHROOM 2.15506 0.001298 NM_029413 MICRORCHIDIA 4 2.1603 0.002412 BC003951 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5 2.1679 0.001984 AK078970 LAMININ, BETA 3 2.16876 0.001252 AK017530 RIKEN CDNA 5730409E15 GENE 2.17046 0.005586 NM_023564 PHOSPHOLIPID SCRAMBLASE 3 2.17958 0.004595 NM_009985 CATHEPSIN W 2.18526 0.001349 NM_020578 EH-DOMAIN CONTAINING 3 2.19738 0.000931 AK078901 RIKEN CDNA 9130006H11 GENE 2.19768 0.000205 AK031946 RIKEN CDNA 6330505N24 GENE 2.20192 1.29E-05 BC019731 CDNA SEQUENCE BC019731 2.20858 0.003272 NM_172753 RIKEN CDNA 4732435N03 GENE 2.20958 0.000255 NM_013649 RECEPTOR-LIKE TYROSINE KINASE 2.21036 9.24E-05 MICROTUBULE-ASSOCIATED PROTEIN 1 LIGHT CHAIN 3 AK003122 ALPHA 2.2106 0.000478 BC026392 EH-DOMAIN CONTAINING 3 2.21582 0.000976 NM_008860 PROTEIN KINASE C, ZETA 2.21784 0.001466 BC054465 MYOSIN, HEAVY POLYPEPTIDE 14 2.22624 0.004975 AB093231 TALIN 2 2.23074 0.000594 M12312 ENVELOPE POLYPROTEIN 2.24556 0.002847 AY363100 MYOSIN, HEAVY POLYPEPTIDE 14 2.24844 0.005942 BC063753 TROPONIN T2, CARDIAC 2.25028 0.000494 WILLIAMS BEUREN SYNDROME CHROMOSOME REGION 27 NM_024479 (HUMAN) 2.25588 0.001214 AK129182 HUNTINGTIN INTERACTING PROTEIN 1 RELATED 2.26706 0.001583 BC003909 SHROOM 2.27146 0.00081 BC022680 NEURONAL GUANINE NUCLEOTIDE EXCHANGE FACTOR 2.2765 0.000871 NM_080595 EXPRESSED SEQUENCE AW122071 2.27974 0.003189 AK005166 INOSITOL HEXAPHOSPHATE KINASE 2 2.28024 0.00319 BC060270 RIKEN CDNA 5133400C09 GENE 2.29756 0.005386 NM_198001 RIKEN CDNA 1110008P14 GENE 2.29814 0.002949 BC058110 RIKEN CDNA 2700063G02 GENE 2.29822 0.00208 AK008111 PROTOCADHERIN 1 2.30536 0.002749 NM_026097 RING FINGER AND FYVE LIKE DOMAIN CONTAINING PROTEIN 2.3186 0.003871 BC041796 MYOSIN, HEAVY POLYPEPTIDE 14 2.32616 0.001727 AK078167 MICROTUBULE-ASSOCIATED PROTEIN TAU 2.32728 0.001194 NM_172520 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 19 2.32774 0.00087 NM_177784 KELCH-LIKE 23 (DROSOPHILA) 2.32934 0.003509 AK017597 TALIN 2 2.3304 0.000421 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, BC046472 SUBFAMILY M, MEMBER 4 2.33352 0.000213 NM_145890 GRAINYHEAD-LIKE 1 (DROSOPHILA) 2.34008 0.002962 BC029027 CALSYNTENIN 1 2.3455 0.000363 BC026370 TRANSMEMBRANE PROTEIN 63B 2.3567 0.000614 AK044784 TRANSCRIPTION FACTOR DP 2 2.35704 0.002621 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, BC058632 SUBFAMILY M, MEMBER 4 2.36164 0.000292 BC053843 CALSYNTENIN 1 2.36272 0.000198 NM_021542 POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 5 2.36426 0.001285 PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, FAMILY F AK007489 (WITH FYVE DOMAIN) MEMBER 1 2.36968 0.00889 NM_008150 GLYPICAN 4 2.38092 0.000284 AK002723 BCL2-ANTAGONIST/KILLER 1 2.39562 0.003826 NM_133191 EPS8-LIKE 2 2.3967 0.000636 NM_010593 JUNCTION PLAKOGLOBIN 2.4056 0.000512 AB110830 PROTEIN KINASE C, ZETA 2.40682 0.000705 NM_134253 BCL2/ADENOVIRUS E1B 19KD INTERACTING PROTEIN LIKE 2.40872 0.000722 BC026771 DISCOIDIN, CUB AND LCCL DOMAIN CONTAINING 1 2.40928 0.002881 BC062270 MYOSIN VC 2.4102 0.002186 ADULT MALE OLFACTORY BRAIN CDNA, RIKEN FULL-LENGTH ENRICHED LIBRARY, CLONE:6430505H07 PRODUCT:EPH AK032223 RECEPTOR A4, FULL INSERT SEQUENCE. 2.41374 0.005669 AK032154 RIKEN CDNA 3110015B12 GENE 2.41722 0.003091 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, BC046537 SUBFAMILY M, MEMBER 4 2.41736 0.000218 NM_030704 HEAT SHOCK PROTEIN 8 2.4207 0.002858 AK005104 TRANSMEMBRANE PROTEIN 53 2.42102 0.001014 BC010306 RIKEN CDNA 3110043J09 GENE 2.42228 0.004343 AK087163 SARCOSINE DEHYDROGENASE 2.42316 0.000278 NM_178667 TRANSCRIPTION FACTOR DP 2 2.42324 0.001508 AK012195 EPHRIN A4 2.42984 0.00267 NM_175682 RIKEN CDNA 9930021D14 GENE 2.449 0.000628 BC059856 TALIN 2 2.45154 0.000963 BC055303 TYROSINE KINASE, NON-RECEPTOR, 1 2.4556 0.003205 NM_019935 OVO HOMOLOG-LIKE 1 (DROSOPHILA) 2.45774 0.000435 NM_008484 LAMININ, BETA 3 2.45944 0.000417 NM_172205 SUPRABASIN 2.46742 0.001863 BC013080 GRAINYHEAD-LIKE 1 (DROSOPHILA) 2.47112 0.001685 NM_008113 RHO GDP DISSOCIATION INHIBITOR (GDI) GAMMA 2.47332 0.002718 NM_031368 BONE GAMMA-CARBOXYGLUTAMATE PROTEIN 2 2.48278 0.000313 AK029271 RIKEN CDNA 1110036O03 GENE 2.49186 0.001444 NM_013614 ORNITHINE DECARBOXYLASE, STRUCTURAL 1 2.49236 0.000685 NM_008536 TRANSMEMBRANE 4 SUPERFAMILY MEMBER 1 2.49398 0.001855 AK029828 TALIN 2 2.50316 0.000396 BC048704 GLYCINE/ARGININE RICH PROTEIN 1 2.50838 0.000194 NM_013709 SH3 DOMAIN YSC-LIKE 1 2.51686 0.000766 AK077839 ACTININ ALPHA 4 2.51842 5.27E-05 AY046077 NOTCH-REGULATED ANKYRIN REPEAT PROTEIN 2.51954 0.002233 AK076386 RIKEN CDNA 9930021J17 GENE 2.5215 0.002899 AK020578 RNA BINDING MOTIF PROTEIN 35B 2.52304 0.000641 NM_133784 WW DOMAIN CONTAINING TRANSCRIPTION REGULATOR 1 2.52596 8.03E-07 NM_198190 NEUROTROPHIN 5 2.54118 0.005162 SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID NM_009197 TRANSPORTERS), MEMBER 2 2.54286 8.69E-05 AK077268 INAD-LIKE (DROSOPHILA) 2.54286 0.001249 NM_011792 BETA-SITE APP CLEAVING ENZYME 1 2.54568 0.000991 AK012385 RIKEN CDNA 2700046G09 GENE 2.54624 0.000403 NM_008056 FRIZZLED HOMOLOG 6 (DROSOPHILA) 2.55856 0.00348 AK008223 RIKEN CDNA 4432405B04 GENE 2.55996 0.001028 BC034069 RIKEN CDNA A830073O21 GENE 2.57022 0.000144 THYROID HORMONE RESPONSIVE SPOT14 HOMOLOG NM_009381 (RATTUS) 2.5758 0.001427 PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY A, MEMBER NM_009344 1 2.5821 0.000466 BC024687 VANG, VAN GOGH-LIKE 1 (DROSOPHILA) 2.5875 0.002512 AK013564 RIKEN CDNA 1520402A15 GENE 2.5965 0.000272 POTASSIUM CHANNEL TETRAMERISATION DOMAIN BC022615 CONTAINING 1 2.59688 0.000131 NM_145403 TRANSMEMBRANE PROTEASE, SERINE 4 2.59972 0.004283 NM_009897 CREATINE KINASE, MITOCHONDRIAL 1, UBIQUITOUS 2.60696 0.004704 AK050989 EPHRIN A5 2.60736 0.000708 NM_008939 PROTEASE, SERINE, 12 NEUROTRYPSIN (MOTOPSIN) 2.61968 0.000761 NM_010112 EMBRYONAL FYN-ASSOCIATED SUBSTRATE 2.62556 0.000535 AF026489 SPECTRIN BETA 3 2.63016 0.000496 NM_175279 RIKEN CDNA 4632411J06 GENE 2.63692 0.000336 SUPPRESSION OF TUMORIGENICITY 14 (COLON NM_011176 CARCINOMA) 2.64102 0.005298 AK037015 DNA SEGMENT, CHR 8, ERATO DOI 580, EXPRESSED 2.64272 0.000193 NM_007969 EXTRACELLULAR PROTEINASE INHIBITOR 2.64288 0.000468 NM_021895 ACTININ ALPHA 4 2.64478 0.000402 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.65092 0.004464 NM_053115 ACYL-COENZYME A OXIDASE 2, BRANCHED CHAIN 2.65328 0.000151 NM_172682 RIKEN CDNA 9930021J17 GENE 2.65394 0.00199 NM_029823 RIKEN CDNA 6530401D17 GENE 2.65988 0.000839 AK032782 RING FINGER PROTEIN 43 2.66608 0.000335 NM_134050 RAB15, MEMBER RAS ONCOGENE FAMILY 2.67164 0.000194 AK035818 RIKEN CDNA 2700063G02 GENE 2.7011 0.00087 NM_178763 RIKEN CDNA A030007D23 GENE 2.70136 0.000125 BC044668 RIKEN CDNA 2610305J24 GENE 2.70362 0.002261 DUAL-SPECIFICITY TYROSINE-(Y)-PHOSPHORYLATION AK035114 REGULATED KINASE 3 2.717 0.003042 NM_172613 ATPASE TYPE 13A4 2.72496 0.001893 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, BC049993 SUBFAMILY M, MEMBER 4 2.73106 0.001873 AF068748 SPHINGOSINE KINASE 1 2.73756 0.000968 AF051150 BETA-SITE APP-CLEAVING ENZYME 2 2.7376 0.002287 NM_010664 KERATIN COMPLEX 1, ACIDIC, GENE 18 2.74148 0.003013 NM_013670 SMALL NUCLEAR RIBONUCLEOPROTEIN N 2.74374 0.000732 AK053563 DNA SEGMENT, CHR 8, ERATO DOI 580, EXPRESSED 2.74572 0.000945 NM_177638 CRUMBS HOMOLOG 3 (DROSOPHILA) 2.74948 0.002525 NM_009525 WINGLESS-RELATED MMTV INTEGRATION SITE 5B 2.76258 0.000773 AK088204 SPECIAL AT-RICH SEQUENCE BINDING PROTEIN 1 2.76616 0.000146 AK019183 PRP40 PRE-MRNA PROCESSING FACTOR 40 HOMOLOG A 2.76934 0.000308 (YEAST) ANTIGEN P97 (MELANOMA ASSOCIATED) IDENTIFIED BY NM_013900 MONOCLONAL ANTIBODIES 133.2 AND 96.5 2.77148 0.004743 AK032057 ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 3 2.77312 0.000887 NM_021344 TESCALCIN 2.77948 0.002868 NM_178928 EXPRESSED SEQUENCE AI173486 2.77974 0.002186 NM_145394 SOLUTE CARRIER FAMILY 44, MEMBER 3 2.78472 0.001777 BC051406 WINGLESS-RELATED MMTV INTEGRATION SITE 5B 2.78496 0.001378 NM_182930 HYPOTHETICAL PROTEIN BC031133 2.78562 0.00027 NM_007741 PROCOLLAGEN, TYPE IX, ALPHA 2 2.78654 0.00176 AK009513 RAS HOMOLOG GENE FAMILY, MEMBER U 2.79122 0.002764 D87966 TEA DOMAIN FAMILY MEMBER 4 2.80758 3.29E-05 NM_010271 GLYCEROL-3-PHOSPHATE DEHYDROGENASE 1 (SOLUBLE) 2.81284 0.000579 AK005885 TRANSMEMBRANE PROTEIN 53 2.81396 0.003421 NM_144919 HISTONE DEACETYLASE 11 2.81434 0.001058 T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN NM_134249 CONTAINING 2 2.81972 0.001103 AK028848 RIKEN CDNA 2700063G02 GENE 2.82618 0.000524 AK053704 TRANSCRIPTION FACTOR AP-2, ALPHA 2.8319 0.003518 NM_023805 SOLUTE CARRIER FAMILY 38, MEMBER 3 2.83448 0.000513 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.83462 0.005528 NM_025367 SPHINGOSINE KINASE 1 2.84494 0.001306 AK046433 RIKEN CDNA 4632411J06 GENE 2.84612 0.00023 NM_133955 RAS HOMOLOG GENE FAMILY, MEMBER U 2.84648 0.002215 NM_013738 PLECKSTRIN 2 2.8473 0.001703 BC043322 PLEXIN B1 2.85284 0.000227 NM_008036 FBJ OSTEOSARCOMA ONCOGENE B 2.85308 0.002116 BC029089 RIKEN CDNA 2010300C02 GENE 2.85624 0.000433 BC010337 KERATIN COMPLEX 2, BASIC, GENE 7 2.85726 0.000278 NM_153784 CDNA SEQUENCE BC038613 2.85844 0.003051 AK050531 RIKEN CDNA C630004H02 GENE 2.86602 0.000239 AK012553 METALLOPHOSPHOESTERASE DOMAIN CONTAINING 2 2.86638 0.002034 S42570 DYSTROPHIN 2.86676 0.000901 NM_172528 LEUCINE RICH REPEAT CONTAINING 1 2.8704 0.003551 NM_207654 EPHRIN A5 2.87358 0.000879 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.875 0.003962 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.882 0.003713 AK014292 PROCOLLAGEN, TYPE XVIII, ALPHA 1 2.90196 0.001021 A DISINTEGRIN-LIKE AND METALLOPEPTIDASE (REPROLYSIN BC005780 TYPE) WITH THROMBOSPONDIN TYPE 1 MOTIF, 8 2.9057 0.003791 NM_010125 E74-LIKE FACTOR 5 2.91018 0.001399 AF047377 HEAT SHOCK PROTEIN 1 2.9127 0.000968 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.91424 0.005291 BC042459 CINGULIN 2.91598 0.000636 NM_145826 INTERLEUKIN 17 RECEPTOR E 2.9181 0.001423 NM_175454 RIKEN CDNA C630004H02 GENE 2.91818 0.000195 NM_144795 PYRROLINE-5-CARBOXYLATE REDUCTASE 1 2.9217 0.000191 NM_016887 CLAUDIN 7 2.92242 0.001324 NM_026708 TLC DOMAIN CONTAINING 1 2.92742 0.000579 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.92858 0.003976 BC003962 NCK-ASSOCIATED PROTEIN 1 2.92866 0.001109 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.9349 0.004848 AK015784 STEAROYL-COENZYME A DESATURASE 3 2.93854 0.00138 NM_010800 BASIC HELIX-LOOP-HELIX DOMAIN CONTAINING, CLASS B, 8 2.94426 0.002954 NM_181820 TRANSMEMBRANE CHANNEL-LIKE GENE FAMILY 4 2.94726 0.002255 BC022613 LEUCINE RICH REPEAT CONTAINING 1 2.94962 0.004509 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.95268 0.006256 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.9558 0.008682 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.96564 0.006762 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 2.96916 0.003606 BC051512 RIKEN CDNA 2310026E23 GENE 2.98264 0.000485 NM_025519 RIKEN CDNA 2310010I16 GENE 2.98924 0.000421 BC004016 URIDINE-CYTIDINE KINASE 2 3.0028 0.000771 BC064474 CINGULIN 3.00294 0.000628 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 3.00534 0.007061 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 3.01068 0.005922 NM_008034 FOLATE RECEPTOR 1 (ADULT) 3.01104 0.000171 NM_153577 EXPRESSED SEQUENCE AI428936 3.01232 0.000509 FERMRHOGEF (ARHGEF) AND PLECKSTRIN DOMAIN PROTEIN BC030329 1 (CHONDROCYTE-DERIVED) 3.02084 0.001234 NM_025865 RIKEN CDNA 2310030G06 GENE 3.0221 0.002595 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 3.02338 0.006001 NM_027292 BENZODIAZAPINE RECEPTOR, PERIPHERAL-LIKE 1 3.0237 0.000379 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 3.02826 0.007584 BC062194 INAD-LIKE (DROSOPHILA) 3.02934 0.000863 NM_008125 GAP JUNCTION MEMBRANE CHANNEL PROTEIN BETA 2 3.0315 0.001341 BC027812 KERATINOCYTE ASSOCIATED PROTEIN 3 3.03554 0.002345 BC056636 ATPASE, H+ TRANSPORTING, LYSOSOMAL V1 SUBUNIT C2 3.03746 0.002787 NM_017405 LIPOLYSIS STIMULATED LIPOPROTEIN RECEPTOR 3.04094 0.003101 SOLUTE CARRIER FAMILY 5 (IODIDE TRANSPORTER), AK039927 MEMBER 8 3.0425 0.000966 NM_022032 PERP, TP53 APOPTOSIS EFFECTOR 3.04352 0.001569 NM_026323 WAP FOUR-DISULFIDE CORE DOMAIN 2 3.04488 0.00459 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 3.04544 0.006174 NM_133664 LADININ 3.04646 0.000151 AK045941 L1 REPEAT, TF SUBFAMILY, MEMBER 29 3.0575 0.007811 FERMRHOGEF (ARHGEF) AND PLECKSTRIN DOMAIN PROTEIN BC043327 1 (CHONDROCYTE-DERIVED) 3.0841 0.001128 NM_145562 RIKEN CDNA 9130213B05 GENE 3.08442 0.000278 BC044668 RIKEN CDNA 2610305J24 GENE 3.08604 0.001718 NM_016966 3-PHOSPHOGLYCERATE DEHYDROGENASE 3.09796 0.00091 BC018257 HEAT SHOCK PROTEIN 1 3.1026 0.000503 NM_172775 PLEXIN B1 3.11116 0.000299 NM_009334 TRANSCRIPTION FACTOR AP-2 BETA 3.11286 0.000278 AK078614 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, K 3.11624 0.001578 BC009815 MELANOMA INHIBITORY ACTIVITY 1 3.11638 0.000527 AK010355 ENDOTHELIAL PRECURSOR PROTEIN B9 3.1177 0.001306 NM_027402 FIBRONECTIN TYPE III DOMAIN CONTAINING 5 3.13372 0.000238 NM_009902 CLAUDIN 3 3.138 0.003528 FERMRHOGEF (ARHGEF) AND PLECKSTRIN DOMAIN PROTEIN AK034903 1 (CHONDROCYTE-DERIVED) 3.15282 0.00108 NM_029796 LEUCINE-RICH ALPHA-2-GLYCOPROTEIN 1 3.1535 0.002316 NM_053015 MELANOPHILIN 3.1567 0.000909 NM_015789 DICKKOPF-LIKE 1 3.15764 0.001475 FERMRHOGEF (ARHGEF) AND PLECKSTRIN DOMAIN PROTEIN BC027077 1 (CHONDROCYTE-DERIVED) 3.16718 0.001064 NM_013593 MYOGLOBIN 3.16896 0.002127 AF033274 A KINASE (PRKA) ANCHOR PROTEIN 2 3.16914 9.64E-05 BC037633 RIKEN CDNA 2310026E23 GENE 3.16964 0.00209 NM_007759 CELLULAR RETINOIC ACID BINDING PROTEIN II 3.17328 0.001041 BC054113 RIBOSOMAL PROTEIN S6 KINASE POLYPEPTIDE 6 3.18842 0.002764 AK009888 D164 SIALOMUCIN-LIKE 2 3.1931 0.00011 NM_009335 TRANSCRIPTION FACTOR AP-2, GAMMA 3.19336 0.00024 NM_021300 REPRODUCTIVE HOMEOBOX 4B 3.19738 0.000867 FERMRHOGEF (ARHGEF) AND PLECKSTRIN DOMAIN PROTEIN BC004009 1 (CHONDROCYTE-DERIVED) 3.20036 0.001639 NM_007563 2,3-BISPHOSPHOGLYCERATE MUTASE 3.20262 0.000733 V-ERB-B2 ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2, NEURO/GLIOBLASTOMA DERIVED ONCOGENE NM_010152 HOMOLOG (AVIAN) 3.21606 0.000514 CBP/P300-INTERACTING TRANSACTIVATOR, WITH GLU/ASP- AK012136 RICH CARBOXY-TERMINAL DOMAIN, 4 3.2177 0.001056 AK048658 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, K 3.21976 0.000643 AK004470 RIKEN CDNA 1190003J15 GENE 3.22718 2.96E-05 NM_026416 S100 CALCIUM BINDING PROTEIN A16 3.23322 6E-05 AK010151 FRUCTOSAMINE 3 KINASE 3.23668 0.001827 AK008189 GLUTATHIONE S-TRANSFERASE, ALPHA 4 3.23678 0.000557 M19436 MYOSIN, LIGHT POLYPEPTIDE 4 3.2396 0.000378 BC022608 SYNAPTOTAGMIN-LIKE 3 3.2424 0.000342 NM_024223 CYSTEINE RICH PROTEIN 2 3.25174 0.002079 NM_009697 NUCLEAR RECEPTOR SUBFAMILY 2, GROUP F, MEMBER 2 3.25636 0.001578 BC031863 LEUCINE RICH REPEAT CONTAINING 8 FAMILY, MEMBER E 3.26346 6.69E-05 NM_133351 PROTEASE, SERINE, 8 (PROSTASIN) 3.26392 0.001374 NM_025778 RIKEN CDNA 4933405K19 GENE 3.26504 2.72E-05 NM_178049 EXPRESSED SEQUENCE AI839049 3.28602 0.000126 NM_011935 ESTROGEN-RELATED RECEPTOR GAMMA 3.29866 0.000959 U16669 SIMILAR TO HYPOTHETICAL PROTEIN ORF-1137 3.29954 0.004148 POTASSIUM CHANNEL TETRAMERISATION DOMAIN NM_146188 CONTAINING 15 3.32314 0.005422 CYSTEINE-RICH SECRETORY PROTEIN LCCL DOMAIN NM_030209 CONTAINING 2 3.33002 0.000274 BC058773 START DOMAIN CONTAINING 10 3.3356 0.000612 BC008156 UBIQUITIN SPECIFIC PEPTIDASE 43 3.33896 0.002517 U16669 SIMILAR TO HYPOTHETICAL PROTEIN ORF-1137 3.3397 0.003892 BC044668 RIKEN CDNA 2610305J24 GENE 3.34728 0.004912 EXCISION REPAIR CROSS-COMPLEMENTING RODENT REPAIR AK004652 DEFICIENCY, COMPLEMENTATION GROUP 2 3.34776 3.78E-05 NM_008597 MATRIX GLA PROTEIN 3.3598 0.003896 BC044668 RIKEN CDNA 2610305J24 GENE 3.36002 0.005011 NM_011254 RETINOL BINDING PROTEIN 1, CELLULAR 3.36002 0.000383 EXCISION REPAIR CROSS-COMPLEMENTING RODENT REPAIR NM_007949 DEFICIENCY, COMPLEMENTATION GROUP 2 3.39034 5.47E-05 BC060266 DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1 3.40006 0.00106 BC049954 EXPRESSED SEQUENCE AI839049 3.40826 0.001071 AF331640 LECTIN, GALACTOSE BINDING, SOLUBLE 7 3.40916 0.000597 NM_144953 RIKEN CDNA 1700019D03 GENE 3.41752 0.002878 AK003632 HOMER HOMOLOG 2 (DROSOPHILA) 3.41866 2.42E-05 BC044668 RIKEN CDNA 2610305J24 GENE 3.43698 0.003162 NM_019990 START DOMAIN CONTAINING 10 3.43794 0.000215 NM_026163 PLAKOPHILIN 2 3.45644 0.001429 AK078864 TRANSMEMBRANE PROTEIN 40 3.45808 0.000842 BC057166 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, F 3.46396 0.000565 NM_028078 JUNCTION ADHESION MOLECULE 4 3.46396 5.71E-05 NM_145395 CDNA SEQUENCE BC019755 3.46974 0.000281 AF363723 FRIZZLED HOMOLOG 2 (DROSOPHILA) 3.48606 0.002789 AK009235 PROTEIN PHOSPHATASE 1J 3.50378 5.29E-05 NM_009413 TUMOR PROTEIN D52-LIKE 1 3.51358 8.37E-05 KH DOMAIN CONTAINING, RNA BINDING, SIGNAL NM_010158 TRANSDUCTION ASSOCIATED 3 3.51822 0.000129 NM_153392 RIKEN CDNA 4922503N01 GENE 3.52352 5.02E-05 AF237721 PROCOLLAGEN, TYPE IX, ALPHA 3 3.53072 0.001217 AF143541 DECAY ACCELERATING FACTOR 1 3.53788 0.000295 SOLUTE CARRIER FAMILY 15 (H+/PEPTIDE TRANSPORTER), BC018335 MEMBER 2 3.54524 0.001694 NM_146230 ACETYL-COENZYME A ACYLTRANSFERASE 1A 3.55342 0.001089 NM_010516 CYSTEINE RICH PROTEIN 61 3.55754 0.001292 M25944 CARBONIC ANHYDRASE 2 3.56518 0.001041 AK053576 DNA SEGMENT, CHR 8, ERATO DOI 580, EXPRESSED 3.57444 0.000765 NM_007675 CEA-RELATED CELL ADHESION MOLECULE 10 3.58462 0.000623 BC024606 SERUM AMYLOID A 2 3.60458 0.000849 NM_177130 GLYCOSYLTRANSFERASE 28 DOMAIN CONTAINING 2 3.60756 7.52E-05 BC057925 RIKEN CDNA 5430432L21 GENE 3.61048 0.001252 NM_172563 HEPATIC LEUKEMIA FACTOR 3.61484 0.000501 BC019563 TRANSMEMBRANE PROTEIN 54 3.6182 0.000578 AK003258 PROCOLLAGEN, TYPE IX, ALPHA 3 3.62276 0.000457 BC025454 ENOYL COENZYME A HYDRATASE DOMAIN CONTAINING 2 3.6239 0.00067 NM_009936 PROCOLLAGEN, TYPE IX, ALPHA 3 3.62404 0.001838 BC002195 RIKEN CDNA C430003P19 GENE 3.6384 6.69E-05 SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, AK009434 MEMBER 2A1 3.64328 0.001496 NM_009931 PROCOLLAGEN, TYPE IV, ALPHA 1 3.64434 0.000223 NM_011314 SERUM AMYLOID A 2 3.64766 0.000924 BC024529 CUE DOMAIN CONTAINING 1 3.64996 1.49E-05 AK020842 NETRIN G1 3.65774 0.000954 NM_008738 NEURTURIN 3.6776 0.000161 NM_201236 RIKEN CDNA 5430432L21 GENE 3.73218 0.000697 BC027668 GENE MODEL 566, (NCBI) 3.73438 3.46E-05 NM_008059 G0/G1 SWITCH GENE 2 3.74494 2.59E-05 BC056176 LAMININ, ALPHA 4 3.74706 0.001018 NM_212457 BRAIN EXPRESSED GENE 4 3.76912 0.000267 M21800 RIKEN CDNA 9130020O15 GENE 3.78748 0.003176 BC018338 MATRIX GLA PROTEIN 3.80754 0.002582 U43525 PROTEINASE 3 3.81598 0.000788 BC048564 RIKEN CDNA 4930415O20 GENE 3.82288 4.65E-05 THYROID HORMONE RESPONSIVE SPOT14 HOMOLOG AK077300 (RATTUS) 3.82874 0.000325 NM_011178 PROTEINASE 3 3.85708 0.000532 BIREGIONAL CELL ADHESION MOLECULE-RELATED/DOWN- NM_172506 REGULATED BY ONCOGENES (CDON) BINDING PROTEIN 3.86494 0.000497 M21800 RIKEN CDNA 9130020O15 GENE 3.90512 0.003295 BC011055 TRANSFORMING GROWTH FACTOR, BETA 2 3.90578 1.12E-05 BIREGIONAL CELL ADHESION MOLECULE-RELATED/DOWN- BC026443 REGULATED BY ONCOGENES (CDON) BINDING PROTEIN 3.91216 0.000548 AK053689 NETRIN G1 3.9222 0.000701 BC021849 EXPRESSED SEQUENCE AW122071 3.93438 0.000294 BC055439 MYOSIN, LIGHT POLYPEPTIDE 9, REGULATORY 3.99758 0.000554 BC055439 MYOSIN, LIGHT POLYPEPTIDE 9, REGULATORY 4.02434 0.000128 BC054421 DYSFERLIN 4.05954 0.000197 AK007353 ENVOPLAKIN 4.08962 1.68E-05 V00856 WHEY ACIDIC PROTEIN 4.23336 0.001358 BC005582 PEPTIDOGLYCAN RECOGNITION PROTEIN 1 4.31988 0.000623 NM_175000 HEMOGLOBIN, THETA 1 4.52328 0.001103 AK011075 HEMOGLOBIN BETA CHAIN COMPLEX 4.5902 0.001378 AK008047 WNK LYSINE DEFICIENT PROTEIN KINASE 4 4.87404 9.41E-06 BC024575 AMINOLEVULINIC ACID SYNTHASE 2, ERYTHROID 5.05172 0.000813